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Coeliac disease or gluten-sensitive enteropathy is a chronic multi-system disease caused 
by intolerance to gluten protein. A key feature is an abnormal small bowel mucosa, 
which more or less normalises after instigation of a gluten-free diet. Coeliac disease has 
a genetic background since patients have either an HLA-DQ2 or an HLA-DQ8 
haplotype, but, since 25% of the ‘normal’ European population carries the HLA-DQ2 
haplotype, other factors must be involved.  Coeliac disease affects all ages and, although 
the primary event takes place in the gut, many related symptoms such as weight loss, 
anemia, osteoporosis etc., are symptoms of malabsorption. The symptoms strongly 
varying from almost no complaints to severe illness requiring hospitalization. 
 
Because many of the affected persons are not detected, symptomatic disease is often 
referred to as the tip of the coeliac iceberg3, 4, due to many individuals with so-called 
‘silent’ or ‘latent’ coeliac disease.  
Silent coeliacs are persons who do have coeliac sprue but no clinical symptoms. The 
reason for this is unknown, although the length of small intestine involved may play a 
role.  Patients with latent coeliac disease have no histological abnormalities but they 
might have exhibited signs and symptoms of coeliac disease in the past or they might do 
so in the future.  
Classical coeliac disease refers to patients with symptoms of intestinal malabsorption in 
combination with fully developed villous atrophy, crypthyperplasia and intraepithelial 
lymphocytosis. 
However, one of the most common forms of celiac disease is atypical coeliac disease: 
patients with few or no gastrointestinal symptoms but with iron deficiency, 
osteoporosis, short stature or infertility. These patients are difficult to separate from 
silent coeliacs. 
Refractory coeliac disease is used to define patients with coeliac disease and villous 
atrophy who do not or no longer respond to a gluten-free diet. This can be due to hidden 
dietary errors but often it means a gluten-independent coeliac-like reaction and these 
patients are at risk for serious complications such as ulcerative jejunitis and malignant 
lymphoma. 
 
It was previously estimated that coeliac disease affects 1:1500 persons in Europe, North 
America and Australia. The prevalence among non-Caucasians is much lower. Due to 
improved diagnostic approaches the prevalence is nowadays considered much higher 
than formerly stated and is roughly estimated at 1: 3001 or  1:1002  
 
The immunological process that results in coeliac disease is now quite well known. In 
patients with gluten sensitivity there is an immunological reaction in the gut in which 
specific T-cells react with glutine peptides that have been transformed by 
transglutamase. These peptides are presented by antigen presenting cells in association 
with HLA haplotypes DQ2 (or (DQ8) (see figure 1). 
 
 
 
 
 
Histopathological aspects of coeliac disease 
 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I: Supposed immunological pathway of coeliac disease (van de Wal et al. Gut 
2000; 46:734-737) 
 
 
This leads to a T-cell activation, proliferation and intraepithelial lymphocytosis as the 
primary histological feature accompanied by progressive histological abnormalities in 
the small intestinal mucosa ranging from no architectural abnormalities to full-blown 
villous atrophy.  
 
The diagnosis of celiac disease can be substantiated by serological tests. Serologic 
markers such as antibodies to reticulin, gliadine, endomysium and tissue 
transglutaminase are often present in coeliac patients. Anti-reticulin antibodies are 
specific but not very sensitive. Anti-gliadin antibodies can be of class IgG or IgA. IgA 
antibodies seem more specific and IgG antibodies more sensitive. Anti-endomysium 
and anti-tTG antibodies reach high levels of sensitivity and specificity. Furthermore, a 
combination of tests gives very high figures for sensitivity and specificity1.  It seems, 
however, that in earlier stages of the disease, in which a lesser degree of epithelial 
damage is present, there is less sensitivity and especially less specificity (this thesis). 
 
The inflammatory response is not limited to the small bowel but may be present in other 
parts of the digestive system such as the esophagus, stomach and large bowel 
(lymphocytic gastritis and colitis). Remote organs such as the skin and the upper 
aerodigestive tract may also be involved.  Dermatitis herpetiformis, a blistering skin 
lesion, is part of the spectrum of coeliac disease as well. 
 
Another morphological complication in addition to osteomalacia is ulcerative enteritis 
in patients in whom the disease inexplicably deteriorates, resulting in ulcerations and 
strictures, mostly of the small bowel and sometimes of the stomach. This is or could 
herald the development of an aggressive T-cell lymphoma in the bowel or elsewhere in 
the body. Other types of malignancies, mostly carcinomas in the bowel, are more 
prevalent than in a control population. 
Other diseases associated with coeliac disease include atopic dermatitis, epilepsy, 
diabetes mellitus, primary biliary cirrhosis, sarcoidosis, Sjögren’s syndrome and thyroid 
disease1 
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In our studies we wished to improve the diagnostic process for coeliac disease and 
especially we wished to develop early markers for the development of malignant 
lymphomas with are very aggressive and leads to the death of the patient. 
 

 
 
 
 
 
 
  
 
 
  
 
 
 
Outline of the thesis
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Chapter I: 
 
In an introduction we describe the epidemiology, signs, symptoms and diagnosis of 
coeliac disease. 
 
Chapter II 
 
The keystone of the diagnosis of coeliac disease is a small bowel biopsy. In this chapter 
criteria for reporting are defined, based on our experience in many patients. We 
presented a modified Marsh classification. This classification was used to assess the 
efficiency of serological testing of anti-endomysium and anti-gliadin. The sensitivity 
and specificity of both tests are related to the histological findings. The value of both 
antibody tests is described and discussed in screening programs. 
 
Chapter III: 
 
In order to refine diagnostic criteria we studied patients with unclear diagnostic features.  
This chapter describes the clinical and histopathological follow-up of patients with 
initial borderline histopathological abnormalities who are challenged by gluten intake. 
The diagnosis of coeliac disease in these patients is not straightforward. The value of 
provocation with gluten was tested in a group of 38 patients. Before and after the gluten 
challenge small intestinal biopsies were taken. Moreover, signs and symptoms of 
malabsorption were scored. 
 
Chapter IV: 
 
In the past the histopathological confirmation of the diagnosis of coeliac disease was 
established on a jejunal biopsy.  Perhaps this can be replaced by biopsies from the distal 
duodenum? 
In this chapter the value of Crosby suction capsule jejunal biopsies are compared with 
endoscopic guided distal duodenal forceps biopsies in order to reach a reliable 
histopathological diagnosis of coeliac disease. Until the recent past, only jejunal 
biopsies were supposed to be sufficiently representative to make a reliable diagnosis of 
coeliac disease.  Histologic interpretation was done by the modified Marsh criteria.
Histopathological aspects of coeliac disease 
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Chapter V:  
 
In this chapter we investigate the histopathological follow-up in patients with confirmed 
coeliac disease. 
We describe the histological recovery in 158 patients with coeliac disease who are 
followed for up to 15 years. These patients underwent multiple small intestinal biopsies 
during follow-up. The study investigates the occurrence of histologic remission in adult 
and pediatric patients. The results should have implications for the intensity and timing 
of systematic follow-up in order to prevent complications. 
 
 
Chapter VI:  
 
The histological interpretation of a small bowel biopsy is one of the cornerstones of the 
diagnosis of coeliac disease. How reliable is the histopathological diagnosis of a small 
biopsy? 
In this chapter we presents the results of tests on the reliability of diagnosis as tested in 
a series of biopsies of 495 patients diagnosed from 1985 up to 2002.   
Because the histological diagnosis is the still the gold standard of diagnosis reliability of 
this diagnosis is of utmost importance. The biopsies were classified according to the 
modified Marsh criteria, and possible reasons for false positive and false negative 
histopathological diagnosis are discussed together with histological pitfalls in the 
differential diagnoses of coeliac disease. 
 
Chapter VII:  
 
More than 5 % of adult patients diagnosed with coeliac disease do not respond to a 
gluten-free diet or they relapse after an initially good response. This leads to a condition 
of so-called refractory coeliac disease with potentially serious complications such as 
ulcerative jejunitis and malignant lymphoma.   
There is a form of refractory coeliac disease with circulating phenotypically abnormal 
lymphoid cells. How these patients are found in a practical manner is subject of this 
study.  Methods to detect phenotypically abnormal T-cells are immunohistology and 
flowcytometry. Both techniques are compared in a subgroup of coeliacs and the results 
are related to the final outcome of the patients. Moreover, the value of T-cell receptor 
rearrangement is tested and is related to the final outcome.  
 
Chapter VIII and IX: 
 
Coeliac disease gives rise to many complications. In a minor subgroup of patients these 
are neoplasms. The eighth and ninth chapter reviews the relation between coeliac 
disease and the development of T-cell lymphoma and other malignant complications. 
The histological types of lymphomas and other tumours with a supposed relation to 
coeliac disease are discussed. Also a review is given of refractory coeliac disease. 
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Chapter X: 
 
The final chapter gives an overview of the general aspects of the histopathology of 
coeliac disease together with a summary of this thesis. 
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Coeliac Disease: Changing Views on Gluten-Sensitive Enteropathy 
 
P. J. Wahab, J. W. R. Meijer, M. S. Goerres & C. J. J. Mulder 
Depts. of Gastroenterology and Pathology, Rijnstate Hospital, Arnhem, The 
Netherlands 
Scand J Gastroenterol 2002; 37 Suppl 236:60–65. 
Departments of Gastroenterology and Pathology Rijnstate hospital Arnhem 
 
Background: The continuing growth of scientific development in coeliac disease in the 
past decade points to the need for the formulation of a new concept of pathophysiology 
and clinical approach to the coeliac condition. Immunogenetic studies have shown a 
correlation of the disease to the HLA region on the short arm of chromosome 6; 
immunological research has led to the concept of a T-cell-driven immunologic response 
of the small intestine, with the identification of highly sensitive and specific antibodies; 
and our understanding of the histopathology of coeliac disease has changed 
dramatically, initiated by the proposition of a spectrum of gluten-sensitive enteropathy 
by Marsh in 1992. Clinical studies report a significant change in patient characteristics 
and epidemiology. The incidence of the disease has shifted to a majority of adult 
coeliacs and it may present with less severe symptoms of malabsorption. Screening 
studies suggest an overall prevalence of up to 1 in 200–300.  
Methods: Update on histopathology concentrating on the work of our research group.  
Results: We specifically describe the work of our group in Arnhem concerning the 
identification and validation of the spectrum of intestinal histopathology in gluten-
sensitive enteropathy, i.e. lymphocytic enteritis (Marsh I lesion), lymphocytic enteritis 
with crypt hyperplasia (Marsh II lesion), and villous atrophy, subdivided into partial 
villous atrophy (Marsh IIIA), subtotal villous atrophy (Marsh IIIB) and total villous 
atrophy (Marsh IIIC). Special attention is given to a subgroup of ‘refractory coeliacs ’, 
including the identification of (pre-) malignant aberrant T cells in the intestinal mucosa 
of these patients. Conclusion: New data on immunogenetics, epidemiology, 
histopathology and patient characteristics point to a significant change of view on 
coeliac disease.  
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In the past decade, the understanding of the histopathology, immunogenetics and 
clinical aspects of coeliac disease has changed dramatically. Traditionally, the coeliac 
condition was known as a disease of childhood, managed by pediatricians and 
characterized by malabsorption due to villous atrophy, with a fast and clear histological 
and clinical response to gluten withdrawal from the diet 1, 2. In the 1990s, intensified 
scientific interest led to an impressive step forward in the understanding of the disease. 
Through in vitro gluten challenge studies, Marsh 3 demonstrated a spectrum of 
consecutive stages of mucosal abnormalities that can be seen in gluten sensitivity, 
which was in contrast to the on/off phenomenon of total villous atrophy that was 
previously believed to be present in the ‘allergic’ reaction of the intestinal mucosa to 
gluten. Immunological studies demonstrated that in active coeliac disease antibodies to 
reticulin, gliadin, endomysium and tissue transglutaminase can be detected, which 
opened the way for new diagnostic strategies and population screening 4–7. 
Immunogenetic research located coeliac-related patterns on the immunology related 
HLA region on the short arm of chromosome 6 8–10, giving way to the formation of new 
concepts of the etiology of the inflammatory response that is seen in coeliac disease. 
Clinical studies, including population screening with antibodies to gliadin and 
endomysium, suggested that the disease can present with milder symptoms than severe 
malabsorption, and that the diagnosis was most often missed in routine medical 
practice. Catassi 11 even proposed the analogy of a ‘coeliac iceberg’, when in screening 
studies in a population of Italian school children he found an incidence of coeliac 
disease of up to 1 in 200, implicating a prevalence of more than 10-fold higher than 
previously found.  Mearin confirmed this ‘iceberg’ of coeliac disease in a screening 
study among a population of Dutch school children 29. The publication of Marsh in 1992 
formed the basis of the clinical and histopathological studies on coeliac disease 
performed by our group in Arnhem in the past decade. We focused on the clinical and 
histopathological presentation, diagnosis and follow-up of the coeliac condition, 
exploring the in vitro spectrum of gluten-sensitive enteropathy in clinical practice.  
 
The Coeliac Spectrum According to Marsh 
 
The spectrum of gluten-sensitive enteropathy as described by Marsh consists of 
consecutive stages of progressive abnormalities of the small intestinal mucosa, 
comprising infiltration of the epithelium with lymphocytes, hyperplasia of crypts, 
progressive loss of surface epithelial cells and, ultimately, villous atrophy. In the Marsh 
I lesion (lymphocytic enteritis), the architecture of the mucosa appears normal and the 
mucosal epithelium is invaded by lymphocytes. Marsh II (lymphocytic enteritis with 
crypt hyperplasia) is characterized by intraepithelial lymphocytosis accompanied by 
hyperplasia of the crypts. Marsh III (flat lesion) consists of intraepithelial 
lymphocytosis, crypt hyperplasia and villous atrophy. Marsh also recognized a type 4 
lesion (irreversible hypoplastic/ atrophic lesion) in which malignant (lymphomatous) 
transformation can develop.   
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Intestinal Biopsies from the Distal Duodenum  
 
Traditionally, the diagnosis of coeliac disease is made by the recognition of villous 
atrophy in mucosal specimens from the jejunum. The biopsies are taken by suction 
capsule (Crosby), requiring patient sedation, radiographic guidance and, preferably, 
endoscopy 12, 13. This procedure is strenuous for patients, time-consuming and 
expensive. If reliable mucosal specimens could be taken from the distal duodenum, this 
would allow us to take biopsies in patients with less obvious symptoms and signs of 
coeliac disease and facilitate our search of the coeliac spectrum of mucosal pathology. 
We compared 171 paired biopsies taken from the distal duodenum by endoscopic jumbo 
forceps and the jejunum by endoscopic guided Crosby capsule 14. Fourteen Crosby 
capsule biopsies were of insufficient quality for adequate interpretation. Of the 
remaining 157 paired biopsies, clinically significant differences were seen in only 6%. 
The discrepancies in proximal and distal biopsies were equally divided: half showed 
more severe lesions proximal and half more severe in the distal biopsies. This validated 
the taking of biopsies from the duodenal mucosa.  
 
 
 
The Marsh Spectrum of Gluten-Sensitive Enteropathy in vivo. 
 
In the past decade, we have taken intestinal biopsies with low threshold in patients with 
possible gluten sensitivity. This included patients with mild symptoms, e.g. fatigue, 
abdominal complaints, iron- and/or folic acid deficiency and high-risk populations, 
including first-degree relatives of coeliac patients and patients with other autoimmune-
related diseases such as Sjögren’s disease, rheumatoid arthritis, diabetes mellitus and 
autoimmune thyroiditis. When looking more carefully at the intestinal specimens we 
indeed recognized the consecutive stages of intraepithelial lymphocytosis, crypt 
hyperplasia and villous destruction. For scientific standardization of mucosal 
interpretation we introduced additional criteria for the distinct stages. In Marsh I 
(lymphocytic enteritis) we assume intraepithelial lymphocytosis is present when more 
than 30 lymphocytes per 100 epithelial cells are counted. In Marsh II (lymphocytic 
enteritis with crypt hyperplasia) we recognize intraepithelial lymphocytosis and crypt 
hyperplasia, with elongation and branching of crypts in which there is a much higher 
proliferation rate. Considering Marsh III we recognize three distinct stages of villous 
atrophy. In Marsh IIIA lesions (partial villous atrophy) villi are shortened and blunt. 
Arbitrarily, we classify as Marsh IIIA if the villous/crypt ratio is below 1:1. In Marsh 
IIIB (subtotal villous atrophy) the villi are clearly atrophic, but still recognizable. 
Finally, in Marsh IIIC, total villous atrophy, the villi are absent or rudimentary, the 
mucosa resembling colonic mucosa (Fig. 1). Furthermore, in refractory coeliac disease 
patients, i.e. patients with persisting villous atrophy or with a relapse to villous atrophy 
despite strict adherence to a gluten-free diet, we recognize two immunohistological 
subgroups. When performing T-cell immunophenotyping of the intraepithelial 
population of lymphocytes, one group is characterized by the absence of the surface 
expression of cytoplasmic CD3 and surface expression of CD2, CD7, CD103 (mucosa-
associated) and CD95 (FAS-receptor). The transition to enteropathy associated T-cell 
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lymphoma is high in these patients with a premature population of intraepithelial 
lymphocytes (refractory coeliac disease type II). In the other refractory coeliacs (type I), 
villous atrophy is seen without aberrant T-cell populations, and the incidence of 
lymphoma is low in this group. Interestingly, when revising intestinal specimens of 
patients who were referred for a second opinion, we often recognized these mucosal 
abnormalities of the glutensensitive spectrum, particularly Marsh II and IIIA, although 
the biopsies were initially interpreted by pathologists as being normal or showing a-
specific abnormalities.  
 
 
Validation of Marsh I, II, IIIA-B-C, IV 
 
The criteria for the diagnosis of coeliac disease were formulated in 1974 and revised in 
1979 and 1990 by the European Society of Pediatric Gastroenterology and Nutrition 
(ESPGAN) 15, 16. A specific definition of adulthood coeliac disease was not formulated. 
Coeliac disease is defined as malabsorption due to villous atrophy, responding both 
clinically and histologically to withdrawal of gluten from the diet. Clearly, the patients 
that we identified with intermediate mucosal pathology do not meet these diagnostic 
criteria. Therefore we performed clinical and histological studies in these patient groups 
in an attempt to validate their gluten sensitivity. First, in all patients other causes of 
malabsorption were excluded, including a/hypo-gammaglobulinaemia, AIDS 
enteropathy, autoimmune enteropathy, amyloidosis, bacterial overgrowth, collagenous 
sprue, eosinophilic enteritis, giardiasis, intestinal lymphangiectasia, intestinal 
lymphoma, Whipple’s disease, tropical sprue, pancreas insufficiency, hyperthyroidism 
and radiation enteritis. 
 
 
Marsh I: Gluten Challenge (17) 
 
Thirty-eight patients presenting with either mild or severe signs and symptoms of 
malabsorption in whom we recognized lymphocytic enteritis (Marsh I lesion) in the 
small-bowel mucosa were subjected to a gluten challenge consisting of 30 g of gluten 
per day for 2 months while maintaining their normal gluten-containing diet. In 12 
patients we demonstrated a significant change in mucosal histopathology, i.e. crypt 
hyperplasia and partial or subtotal villous atrophy. After installment of a gluten-free 
diet, symptom relief and improvement of malabsorption parameters were seen in all 
patients. Furthermore, follow-up intestinal biopsies in all 12 patients showed 
normalization or improvement to Marsh I or Marsh II lesions. We therefore concluded 
that these patients were indeed gluten-sensitive.  
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Marsh II: HLA-DQ Typing and Gluten-free Diet 18 
 
In 21 patients referred to our hospital for analysis of symptoms of malabsorption, we 
found Marsh II, lymphocytic enteritis with crypt hyperplasia in their small intestinal 
mucosa. Coeliac-related HLA-DQ2 or DQ8 markers were present in 21 of 27 patients 
(78% vs. 45% in the general population), supporting their gluten sensitivity. Twenty-
five patients were motivated to adhere to a gluten free diet. During follow-up, clinical 
and histological parameters improved, c.q. normalized in all patients. Two (control) 
patients refused a gluten free diet; both deteriorated to partial villous atrophy (Marsh 
IIIA) during follow-up. These findings confirm the suggestion that these individuals are 
gluten sensitive and support the assumption that coeliac disease may present with a 
Marsh II enteropathy.  
 
Marsh III A, B, and C: Clinical Studies 
 
The ESPGAN criteria for the diagnosis of coeliac disease speak of villous atrophy and 
in clinical practice it is generally accepted that this includes mucosal images less severe 
than total villous atrophy. While looking at the broad spectrum of gluten-sensitive 
enteropathy we recognized distinct stages of villous atrophy and classified them as 
partial villous atrophy (Marsh IIIA), subtotal villous atrophy (Marsh IIIB) and total 
villous atrophy (Marsh IIIC). When revising mucosal specimens for a second opinion 
we regularly experience that Marsh IIIA lesions are initially overlooked and the 
diagnosis missed. We performed several pathophysiological and immunogenetic studies 
with respect to the arbitrary stages of villous atrophy to investigate whether this 
histological distinction has any clinical significance. 
 
Histological Follow-up 19 
 
According to the diagnostic criteria, mucosal pathology in coeliacs should normalise in 
response to a gluten-free diet. However, scientific reports on histological recovery, 
including time schemes and end-stage histology are lacking. We investigated 
histological follow-up profiles of 158 coeliac patients diagnosed in our hospital in the 
past 15 years. Histological remission, defined as Marsh 0, I or II, was seen in 65% 
within 2 years, 85% within 5 years and 91% after 5 years of adhering to a gluten-free 
diet. When dividing the patients into subgroups (Marsh IIIA, IIIB and IIIC), we found a 
slower and ultimately less complete recovery in patients with more severe villous 
atrophy. In conclusion, we found that histological recovery in coeliacs after starting a 
gluten-free diet takes time, is incomplete in a substantial subgroup of patients and 
recovery is correlated to the degree of initial mucosal pathology. 
 
Serological Studies 
 
Coeliac-related serological tests have had great attention in the past decade. Formerly, 
antibodies to reticulin and gliadine were introduced, but their sensitivity proved to be 
fairly low. The introduction of antibodies to endomysium and recently tissue 
glutaminase was welcomed with great enthusiasm. 
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Reports suggested a sensitivity and specificity of up to nearly 100%, implying that the 
taking of small intestinal biopsies was to become obsolete. We performed sensitivity 
studies of endomysial antibodies in our cohort of Marsh IIIA, IIIB and IIIC coeliac 
patients and found antibodies in all patients with Marsh IIIC lesions, but in only in 80% 
of Marsh IIIB patients and even 60% in Marsh IIIA (20). Seronegative coeliac disease 
therefore seems a reality and the presence of anti-endomysial antibodies was found to 
be correlated with the degree of villous atrophy. These findings have been reproduced 
in other European countries21,22 and suggest a limited value of antibody testing in 
coeliac disease. Recently, a remarkable correlation between seronegative coeliac disease 
and smoking was reported23, which may partly explain seronegativity in coeliacs.  
 
Glutathione S-Transferase 
 
The glutathione/glutathione S-transferase biotransformation system is known to be 
decreased in various diseases of the gut. This decrease is associated with the increase in 
incidence of malignancy due to the impairment of detoxification of carcinogenic 
substances in the gut. We investigated the mucosal enzyme activity of the GSH/GST 
biotransformation system in patients with untreated coeliac disease and found a 
decrease strongly correlated to the degree of villous atrophy 24. 
 
 
Refractory Coeliac Disease 
 
Probably because our hospital is considered a tertiary referral centre for coeliac disease, 
the prevalence of refractory coeliac disease in our cohort of patients is high (9%). 
Although reports on the prevalence are scarce, it is assumed to be 0%–5%. Also, a clear 
definition of the refractory condition is lacking. We consider coeliacs to be refractory, 
when symptoms of malabsorption due to villous atrophy are seen, persisting or 
regressing after a former good response despite a strict adherence to a gluten-free diet. 
All other possible causes of the state of malabsorption must be excluded and additional 
features supporting the diagnosis of coeliac disease must be looked for, including the 
presence of antibodies in the untreated state and the presence of coeliac-related HLA-
DQ markers. Recently, we suggested dividing refractory patients into two categories; 
type I without aberrant T cells and type II with aberrant T cells detected by T-cell 
immunophenotyping by flowcytometric analysis or immunohistology of the intestinal 
mucosa. We recognize these refractory lesions in all subgroups of villous atrophy, 
including Marsh IIIA. In particular, the type II lesion is considered to be a premalignant 
condition and indeed the incidence of lymphoma in this group is high. In an attempt to 
treat refractory coeliac disease we performed several therapeutic trials. Cyclosporin was 
effective in 40% of patients, but considering the possible adverse effects of the drug we 
remain to be reserved about this treatment25. IL-10 was not effective in treating 
refractory patients26, but the preliminary results of a combination of prednisone/ 
azathioprine are promising (60% response), particularly in the type I refractory 
patients27. Recently, we started an open trial in which the effect and safety of the 
chemotherapeutical agent cladribine in type II refractory patients are investigated. The 
first experiences are promising.  
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Epidemiology 
 
The clinical presentation of coeliac disease has been shown to be diverse, varying from 
severe, debilitating malabsorption states to mild symptoms such as fatigue, abdominal 
complaints and isolated iron deficiency. At present, more than 60% of newly diagnosed 
patients in The Netherlands are adults; 15%–20% are over 60 years of age28. In society, 
and even among general practitioners and internists, it is still generally considered a 
disease of childhood. Owing to intensified scientific research and publications and 
increasing attention in postgraduate teachings and in general publicity, the growing 
knowledge of coeliac disease has had its repercussions on incidence and prevalence of 
the disease. This probably reflects a better recognition of patients rather than a real 
increment of prevalence of the disease. The prevalence in The Netherlands has almost 
doubled in the past decade to 24 per 100,000 inhabitants (Fig. 2), although striking 
differences in prevalence are seen, reaching from 8 per 100,000 in Amsterdam and 
Rotterdam to 32 per 100,000 in Arnhem, Leiden and Nijmegen. Screening studies in the 
general population throughout Europe and recently also in the USA suggest that the true 
prevalence of coeliac disease may estimate even 1 in 200–400 inhabitants29, 30.  
 
Conclusion 
 
The strong impulses of scientific studies on pathophysiology, immunogenetics and 
clinical aspects of coeliac disease have had a great impact on the understanding of the 
disease. One of the great breakthroughs has been the recognition of a spectrum of 
mucosal pathology concerning gluten-sensitive enteropathy, suggested by Marsh in the 
early 1990s. After recognizing this spectrum in our patients, we have been able to 
validate these findings to be a true clinical reality. Furthermore, the identification of a 
subgroup of refractory patients in which the incidence of malignancy is high has placed 
us for a great clinical challenge. As our understanding of the coeliac condition is 
growing and publicity on the subject is increasing, the prevalence rates are continually 
rising. The ‘coeliac iceberg’ is steadily being brought to the surface. Still, considering 
the surprisingly low prevalence rates in some parts of the country and the frequently 
missed diagnoses we see in second opinion, coeliac disease and the spectrum of gluten-
sensitive enteropathy must continue to be the subject of attention. Clinical pathologists 
in particular should be alert to recognizing the less severe histopathological 
abnormalities within the gluten sensitivity spectrum. Furthermore, the demonstration of 
seronegative coeliac disease, especially anti-endomysium negativity, may explain the 
missing of diagnoses, because at present these antibodies are often unjustly considered 
almost 100% sensitive for detecting coeliac disease. The present understanding of 
pathophysiology, clinical presentation and epidemiology of the disease challenges the 
ESPGAN definition of (childhood) coeliac disease: ‘When is a coeliac a coeliac?’ In 
fact, recently, a working group of the United European Gastroenterology Week UEGW) 
formulated new guidelines for (adult) coeliac disease published and discussed at the 
UEGW meeting in October 2001 in Amsterdam 31. 
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Fig. 2: Prevalence of coeliac disease in The Netherlands (1990– 
2000) (source: Dutch Coeliac Society). 
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Abstract: 
 
OBJECTIVE: We have undertaken a study to assess the efficiency of serological tests in 
the diagnosis of celiac disease (CD) during the period January 1, 1994 to January 7, 
1997. Our aim was to evaluate the sensitivity of IgA antiendomysium (EMA) and IgA 
antigliadin (AGA) with regard to the degree of histological abnormality in biopsy 
specimens of small intestine in untreated celiac disease patients and first-degree 
relatives. 
METHODS: The study population comprised 101 cases: 85 untreated celiac patients 
and 16 first-degree relatives with a mean age of 42 yr (range, 2–76 yrs). Sixteen of 85 
were excluded from study because they did not satisfy the study or diagnostic criteria of 
CD. EMA and AGA have been compared with the degree of villous atrophy (VA) in 69 
celiac patients and 16 relatives according to the Marsh criteria of 1992. We divided the 
Marsh III histology into three subgroups as follows: Marsh IIIa (partial VA), Marsh IIIb 
(subtotal VA), and Marsh IIIc (total villous atrophy). 
RESULTS: The specificity and positive predictive value of EMA for CD was excellent, 
because all EMA-positive patients (n = 42) were diagnosed with CD. The sensitivity of 
EMA, however, differed between CD subgroups; in patients with total VA, the 
sensitivity of EMA was 100% (17/17). However, in patients with partial VA (Marsh 
IIIa), the sensitivity of EMA was disappointing, only 9/29 (31%). Three of 72 coeliacs 
with Marsh IIIb and Marsh IIIc had IgA deficiency and were excluded from the study. 
Elevated AGA has been detected in the sera of 39 of 69 (62%) patients. A combination 
of EMA and AGA tests showed a sensitivity of 76% (53/69). None of 16 first-degree 
relatives with Marsh I-II had positive EMA. 
CONCLUSIONS: Interpretation of negative serology needs great awareness. Although 
EMA sensitivity in total villous atrophy is excellent, in partial villous atrophy the 
sensitivity of EMA appears to be disappointing. Our experience shows that EMA and 
AGA have only limited value in screening programs for CD. 
 
 
 
INTRODUCTION 
 
During the last decade better knowledge of celiac disease (CD) has permitted the 
identification not only of the typical forms characterized by gastrointestinal symptoms, 
but also of the atypical forms. CD has non-specific features and may in general be a sub 
clinical condition. For instance, it has been reported that CD is common in patients with 
neurological diseases of unknown cause (1, 2). A gluten-free diet (GFD) has been 
shown to reduce the risk of gastrointestinal malignancies and other complications of 
untreated CD (3–7). A considerable number of coeliacs do not show demonstrable 
clinical or functional alterations while using a gluten- containing diet, despite 
significant histological abnormalities (8 –10). The extent of mucosal damage is perhaps 
smaller in silent than in symptomatic CD (11, 12). Sub clinical individuals have a high 
threshold before undergoing small intestinal biopsy. The use of antigliadin (AGA) and 
antiendomysium (EMA) antibodies has simplified the diagnostic procedure, but only in 
coeliacs with severe proximal mucosal change. Diagnostic difficulties emerge in the 
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presence of discrete mucosal abnormalities with increased density of intraepithelial 
lymphocytes in otherwise normal mucosa (13). The development of EMA seems to 
depend on the severity of the intestinal histopathology of CD (14, 15). 
Thus small intestinal biopsy is the gold standard against which the accuracy of antibody 
tests should be compared 
(16). Several studies have shown that the sensitivity of EMA correlates with the degree 
of villous atrophy (VA) in untreated CD (14, 16–20), but the problem of negative 
serology in untreated celiac patients is not discussed in their interpretations. In our 
opinion, the presence of EMA- or AGA-negative CD is underestimated in the literature 
and a subgroup of CD will be under diagnosed using only serology (13). The purpose of 
this study was to investigate the diagnostic value of serology (EMA/AGA) with regard 
to the histopathological features of CD. The lack of information concerning this 
procedure was the reason for this study.  
 
 
 
MATERIALS AND METHODS 
 
The study was designed to evaluate the diagnostic value of IgA EMA and IgA AGA 
with regard to the degree of histological abnormality in untreated celiac disease patients. 
One hundred one cases were investigated, including 85 untreated celiac patients and 16 
first-degree relatives with histological abnormalities (Marsh I–III). Sixteen of 85 
patients were excluded from study; four of them did not satisfy the diagnostic criteria of 
CD, three were IgA deficient, and nine of them underwent serological tests during 
gluten-free diet for .1 wk. Sera from 69 untreated CD patients (median age, 41; range, 
2–76 yr; 25 men and 44 women) and 16 first-degree relatives admitted to our 
department for small intestinal biopsy or for diagnostic re-evaluation were analyzed. 
Sixteen first-degree relatives with minor histological abnormalities (Marsh I, II) in their 
small intestine biopsy specimens were selected as controls. Diagnosis of CD was based 
on small intestinal biopsy specimens showing the appropriate histopathological features 
and clinical improvement on a GFD, according to the recently revised diagnostic criteria 
(9, 21). The serum samples and intestinal biopsies were analyzed in a blinded fashion. 
All sera were tested for IgA EMA, IgA AGA, and serum IgA levels. IgA EMA has been 
studied by indirect immunofluorescence on frozen sections of commercial slides of 
primate ileum (Euro immune). 
To avoid false negative results EMA was evaluated at two dilutions (1:10 and 1:50). In 
addition, the absence of EMA was verified in two laboratories by using monkey 
esophagus as substrate in the immunofluorescence assay. 
IgA AGA was measured by enzyme-linked immunosorbent assay (ELISA) (22, 23). 
Serum was diluted 1:100 and the results were expressed in terms of arbitrary units 
(AU/ml) (CLB Amsterdam). An IgA AGA level. 25 AU/ml was considered elevated. 
Total IgA was measured in all patients. Small intestinal biopsy sampling was done in 
which minimal requirements were four distal duodenal or jejunal biopsies (9, 24). 
Biopsy specimens were evaluated according to Marsh 1992 (9), revised in 1997 (25, 26) 
(Marsh IIIa, Marsh IIIb, and Marsh IIIc). Marsh I comprise normal mucosal architecture 
in which the villous epithelium is markedly infiltrated by lymphocytes only when the 
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lymphocytosis score is. 30 per 100 enterocytes (Fig.1). A hyperplastic lesion 
comprising enlarged crypts in which immature epithelial cells are being generated at an 
increased rate, accompanied by an influx of inflammatory cells, characterizes Marsh II 
(Fig. 2). In the original classification, Marsh III consists of the destructive lesion, which 
is synonymous with the typical flat mucosa originally associated with CD (9). However, 
in our study Marsh III comprised a large spectrum ranging from minor to severe VA. 
We classified the Marsh III into three subgroups as follows: Marsh IIIa (partial VA), in 
which shortened blunt villi are associated with a mild infiltration of lymphocytes in 
epithelial cells, accompanied by enlarged and hyperplastic crypts (Fig. 3); Marsh IIIb 
(subtotal VA), clearly atrophic villi but as such still recognizable, with the addition of 
enlarged crypts whose immature epithelial cells are being generated at an more 
increased rate, accompanied by an influx of inflammatory cells (Fig. 4); and Marsh IIIc 
(total VA), nearly total absence of villi, with severe atrophic, hyperplastic, and 
infiltrative lesion (Fig. 5). 
Our study was in accordance with the ethical standards of the human experimentation 
approved by the Ethical Review Committee of Rijnstate Hospital. 
 
 
Statistics 
 
Data were analyzed with PRISMA: 0, GRAPHPAD. Statistical analysis evaluated 
whether the differences for EMA/AGA sensitivity between Marsh IIIa (partial VA), IIIb 
(subtotal VA), and IIIc (total VA) were significant using the Fisher exact test. 
 
RESULTS 
 
Histological evaluation showed partial VA (Marsh IIIa) in 29/69, subtotal VA (Marsh 
IIIb) in 23/69, and total VA (Marsh IIIc) in 17/69 patients. The overall sensitivity for 
EMA was 60% (42/69), but in a subgroup of CD patients with Marsh IIIc, EMA 
sensitivity was 100% (17/17). In patients with Marsh IIIa and Marsh IIIb, 9/29 (31%) 
and 16/23 (70%), respectively, were EMA positive. Total IgA   was measured in all 
patients. Three of 69 coeliacs with Marsh IIIb and Marsh IIIc had IgA deficiency and 
were excluded from the study. None of the CD patients with Marsh IIIa was IgA 
deficient. All immunocompetent patients with total VA  (17/17) were EMA positive 
(sensitivity, 100%) (Fig. 6, Table 1). Three of 16 first-degree relatives (Marsh I, II) had 
positive AGA (21%). None of those relatives had positive EMA (specificity, 100%). 
AGA was positive in 9/29 (31%) patients with Marsh IIIa, 16/23 (70%) with Marsh 
IIIb, and in 14/17 (82%) with Marsh IIIc. AGA was detected in the sera of 39 of 69 
(56%) patients. A combination of EMA and AGA tests showed a sensitivity of 76% 
(53/69) for all histopathological subgroups. The difference in EMA-positive results 
between the Marsh IIIa and Marsh IIIc groups was significant (p 5 0.013). The 
differences between Marsh IIIa and Marsh IIIb, compared with Marsh IIIc for AGA, 
were significant as well (p, 0.01). 
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DISCUSSION 
 
The problem of negative serology in untreated celiac disease patients is underestimated, 
and data about the subgroup with minor tissue damage are lacking in the literature. In 
the majority of studies, the sensitivity of EMA is evaluated in patients with severe VA 
and an intestinal biopsy has been suggested only in those cases showing at least one 
abnormality on serology (11, 13, 27–29). Most likely a subgroup of nonsymptomatic 
coeliac patients negative for AGA or EMA will be under diagnosed, especially those 
with partial VA (Marsh IIIa). We feel that the true prevalence of CD is higher than has 
been quoted in most previous reports. Interestingly, partial VA and negative serology 
coexist, with a co-occurrence of approximately 70% in our study. Therefore, the 
predictive value of serology in celiac patients with Marsh IIIa appears to be 
disappointing. Our results confirm the earlier suggestion in the paediatric literature in 
which patients with detectable EMA at the time of biopsy exhibited more advanced VA 
(14). Data related to the value of EMA in untreated celiac patients with partial VA 
(Marsh IIIa) are lacking in the literature. An editorial in the Lancet considered the 
results of serology for CD often disappointing in clinical practice (30). 
Our histopathological sub classification (Figs. 3–5) of Marsh III (Marsh IIIa [partial 
VA]), Marsh IIIb [subtotal VA], and Marsh IIIc [total VA] shows the correlation 
between the severity of mucosal damage and the appearance of antibodies. Partial VA 
seems to be a quite frequent histopathological presentation in our celiac population 
(29/69; 42%). The question is how many CD patients will be missed in screening 
programs that rely too much on serology. Of 69 untreated CD patients and 16 first-
degree relatives, AGA was detected in 39/69 and 3/16, respectively. The sensitivity of 
57% as our cut-off limit for AGA was relatively low. There is a further consideration 
needing attention. At present there is no discussion in the literature about EMA negative 
celiac patients. It is important to avoid a self-fulfilling prophecy, taking biopsies only 
from EMA-positive individuals. Small bowel biopsy should be the first diagnostic 
procedure when there is a clinical suspicion of celiac disease, in spite of positive or 
negative results of serology, because not only false negative but also false positive 
results have been reported (31). For small intestinal biopsy to be replaced by the 
serological testing method as the diagnostic test of choice for CD, a sensitivity and 
specificity approaching 100% would be required. This standard is as yet unachievable. 
Valentin et al. have investigated the relationship between EMA and persistence of 
jejunal lesions after institution of a gluten-free diet in 24 EMA-positive patients. In their 
study, jejunal lesions persisted in 17 of 24 treated celiac patients who had become EMA 
negative (19). This would suggest that the disappearance of circulating antibodies on a 
gluten-free diet does not reflect the histopathological recovery, in spite of the clinical 
remission. 
Serology is strongly correlated with the severity of mucosal change such as total VA. 
However, not all gluten-sensitized individuals develop total VA (Marsh IIIc) at 
presentation. The negative predictive value of EMA is not 100% and CD patients with 
partial VA (Marsh IIIc) lacking antibodies will not be correctly diagnosed without small 
bowel biopsy. Clearly, EMA is not exclusively positive in every gluten-sensitized 
individual. Whether the EMA test is positive or not depends entirely on a severe lesion 
and possibly on the length of intestine involved. This point needs to be remembered in 
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population studies, especially when a flat, severe lesion is taken as the sole 
manifestation of CD. There is a need for more sensitive markers to optimize the 
screening efficiency and to detect those patients with milder histopathological 
abnormalities compatible with CD. Interpretation of negative serology needs great 
awareness. In future studies, the value of cells expressing the g/d T-lymphocyte 
receptor, HLA Class 2 subtyping (32), and tissue tranglutaminase (tTG) (33, 34) should 
be interpreted with regard to the histopathological features of CD. 
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Figure 1. Marsh I. A normal mucosal architecture in which villous epithelium is 
infiltrated by lymphocytes is observed (25×; inset, 100×). 
 
Figure 2. Marsh II. Near-normal villi. A hyperplastic lesion comprising enlarged crypts 
and infiltrated by lymphocytes is seen (50×).
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Figure 3. Marsh IIIa. This micrograph shows a specimen of small intestinal mucosa 
obtained from a negative antiendomysium celiac disease patient, revealing partial 
villous atrophy with shortened blunt villi infiltrated by lymphocytes and hyperplastic 
enlarged crypts (25×). 
 
Figure 4. Marsh IIIb. Subtotal villous atrophy, clearly atrophic villi but as such still 
recognizable and elongated hyperplastic crypts in which immature epithelial cells are 
being generated at a more increased rate, accompanied by an influx of inflammatory 
cells, are seen (25×). 
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Figure 5. Marsh IIIc. Total villous atrophy, nearly total absence of villi, and severe 
atrophic, hyperplastic, and infiltrative lesion are noted (25×). 
 
 
Figure 6. See Table 1 (below) for figure legend. 
 
 Table 1. EMA Sensitivity W ith Regard to the Histopathological Features of CD (see fig 6 
above) 
 EMA Sensitivity (% )
 
Marsh I–II 0 
Marsh IIIa (partial villous atrophy) 31 
Marsh IIIb (subtotal vilous atrophy) 70 
Marsh IIIc (total villous atrophy) 100 
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OBJECTIVES: In patients with signs and symptoms of malabsorption, suggestive of 
gluten-sensitive enteropathy, small intestinal biopsies sometimes only reveal infiltration 
of lymphocytes into the mucosal epithelium. This infiltrative lesion (Marsh I) is not a 
definite proof for gluten-sensitive enteropathy. However, in the present study, we aimed 
to show that a subgroup of these patients could ultimately be identified as being gluten 
sensitive. 
METHODS: A total of 38 patients with a Marsh I lesion were subjected to a gluten 
challenge comprising 30 g of gluten added daily to a normal gluten-containing diet for 8 
wk. 
Before and after the challenge, small intestinal biopsies were taken, and symptoms and 
signs of malabsorption were scored. 
RESULTS: In 12 patients we demonstrated a significant change in mucosal 
histopathology, i.e., subtotal villous atrophy (Marsh IIIB, n 5 1), partial villous atrophy 
(Marsh 3A, n 5 6) or infiltrative-crypthyperplastic lesions (Marsh II, n 5). In the other 
26 patients, the small intestinal mucosa remained unchanged. After initiation of a 
glutenfree diet, follow-up small intestinal biopsies in 12 patients who initially had 
progressive mucosal pathology after gluten challenge showed normalization of mucosal 
pathology in seven cases, regression to a Marsh I lesion in four and to a Marsh II lesion 
in one. Symptom relief was seen in all 12 patients. Ten of 26 patients without 
histological response to the gluten challenge were motivated to adhere to a glutenfree 
diet. Follow-up biopsies revealed unchanged Marsh I lesions in eight patients and 
normalization (Marsh 0) in two patients. Three patients had follow-up biopsies while on 
a normal diet. All had unchanged Marsh I lesions. 
CONCLUSIONS: In the present study we demonstrated that a gluten challenge might 
be useful in identifying patients as being sensitive to gluten if initial small intestinal 
biopsies reveal only minor abnormalities.  
 
INTRODUCTION 
 
Coeliac disease is a permanent state of intolerance to gluten, i.e., alcohol-soluble 
proteins of wheat, rye, and barley (1, 2). The immunological response to gluten in 
sensitive individuals causes histological abnormalities of the small intestine consisting 
of influx of lymphocytes into the epithelium, hyperplasia of crypts, and, ultimately, 
villous atrophy. This results in a diversity of symptoms including chronic diarrhea,
malabsorption, anemia, abdominal distension, weight loss, and growth disturbances. 
Treatment consists of strict adherence to a gluten-free diet, on which histology and 
symptoms should normalize. The histological abnormalities of the small intestinal 
mucosa in reaction to gluten are thought to develop in subsequent phases within a 
glutensensitive spectrum. This spectrum has been described by Marsh (3) and comprises 
three consecutive states of mucosal pathology. Marsh I is the first phase, in which the 
epithelial cells of the villi are infiltrated by lymphocytes (arbitrarily we state .30 
lymphocytes per 100 enterocytes) (4, 5). In Marsh II, the intraepithelial lymphocytosis 
is accompanied by hyperplasia of crypts, i.e., enlargement and budding of crypts in 
which there is an increased mitotic rate.  
Marsh III is characterized by influx of inflammatory cells, hyperplasia of crypts and 
villous atrophy. We recognize three distinct stadia of villous atrophy. In Marsh IIIA, 
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i.e., partial villous atrophy, the villi are blunt and shortened (arbitrarily we classify the 
situation as partial villous 
atrophy if the villous/crypt 
ratio is, 1:1). In Marsh IIIB 
(subtotal villous atrophy), villi 
are clearly atrophic, but 
separate villi are still 
recognizable; in Marsh IIIC 
(total villous atrophy), villi are 
rudimentary or absent, with 
the mucosa resembling 
colonic mucosa (4, 5) (Fig. 1). 
Marsh also described a class 
IV lesion in which there is 
total villous atrophy, but no 
significant inflammation 
(atrophic-hypoplastic lesion). 
Per definition, the diagnosis 
coeliac disease can only be made by demonstration of Marsh III lesions in small 
intestinal biopsies (2). A clinical problem arises when patients present with symptoms 
suggestive of gluten sensitivity but small intestinal biopsies reveal only minor 
abnormalities, particularly intraepithelial lymphocytosis with or without crypt-
hyperplasia. These abnormalities could reflect early or incomplete manifestations of 
coeliac disease, but without villous atrophy, the diagnosis can not be made, according to 
the current ESPGAN criteria (2). If other causes of malabsorption are ruled out, the 
strong suspicion of gluten sensitivity remains to be confirmed. Serological tests as 
determination of antigliadin- and antiendomysium antibodies have their limitations and 
are not likely to be found in subjects with Marsh I-II lesions (5–12). HLA-DQ typing 
can support the suspicion of gluten sensitivity, but also a typical HLA-DQ2 or DQ8 
phenotype is not specific enough to establish the diagnosis coeliac disease. Besides 
initiation of an appropriate treatment for their presenting symptoms, identification of 
gluten-sensitive individuals is necessary, because it cannot be ruled out that these 
patients, if gluten sensitive, are at risk for secondary complications of untreated coeliac 
disease such as osteopenia and lympho reticular malignancy (13–19). In approaching 
this clinical problem, in keeping with Weinstein et al., who challenged dermatitis 
herpetiformis patients with gluten in 1971 (20, 21), we proposed to challenge these 
patients with high doses of gluten to aggravate the mucosal pathology leading to gluten 
sensitivity. This could potentially identify patients as being gluten sensitive and could 
justify treatment with a gluten-free diet. In 1991 we challenged a patient in whom a 
strong suspicion of gluten sensitivity could not be confirmed by small intestinal 
histology. Only severe intraepithelial lymphocytosis was present. After 2 months of 
adding 30 g of gluten to his normal gluten-containing diet, small intestinal biopsies 
showed intraepithelial lymphocytosis, crypt hyperplasia, and subtotal villous atrophy, 
i.e., Marsh IIIB. The patient then adhered to a gluten-free diet, after which his 
symptoms (aphtous stomatitis, fatigue, weight loss) and small intestinal mucosa 
normalized. This formed the basis of the present open, non–placebo controlled study, in 
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which we aimed to evaluate a gluten challenge as a diagnostic test for gluten sensitivity 
in a group of patients who presented with signs and symptoms suggestive of coeliac 
disease but in whom small intestinal biopsies only revealed minor mucosal 
abnormalities, i.e., intraepithelial lymphocytosis. 
Histopathological aspects of coeliac disease 
 
 
 
50 
 
 
 
 
Chapter III 
 
51 
MATERIALS AND METHODS 
 
Between 1991 and 1998, 38 patients participated in the study (29 women, nine men; 
mean age 40 yr, range 16–74 yr). All were referred to the outpatient clinic for signs and 
symptoms compatible with malabsorption due to gluten sensitivity (Table 1). Because 
of the suspicion of coeliac disease as underlying pathology, small intestinal biopsies 
were taken, but these revealed only minor abnormalities, i.e., intraepithelial 
lymphocytosis of the mucosa. Other possible underlying diseases, such as inflammatory 
bowel disease, bacterial overgrowth, giardiasis, hypogammaglobulinemia, eosinophilic 
enteritis and lymphoma could not be demonstrated. Patients were liable to enter the 
study if they gave their informed consent and had an infiltrative small intestinal mucosal 
lesion (Marsh I), combined with one or more disturbed malabsorption parameters, the 
presence of antigliadin or antiendomysium antibodies, or a positive family history of 
CD. All patients added 30 g of gluten (Cerestar) daily, to their normal gluten-containing 
diet for 2 months. The average normal intake of gluten in Dutch society is reported to be 
approximately 14 g/day (22). Before and after the gluten challenge period, small 
intestinal biopsies were taken from the jejunal mucosa by an endoscopically introduced 
Crosby capsule (23) and the patients were interviewed with respect to complaints and 
possible side effects of the high doses of gluten. Furthermore, small intestinal function 
tests were performed by a lactulose/ mannitol sugar absorption test and IgA antibodies 
to gliadin and endomysium were measured in a limited subgroup of patients, as these 
tests were not available to us in the first years of the study. Small intestinal biopsies 
were interpreted independently by two of the authors (J.W.M. and P.J.W.) according to 
the gluten-sensitivity spectrum described above (Marsh 0–IIIC). As an endpoint of the 
study we stated that, to be diagnosed as being gluten sensitive, patients should at least 
have progression of mucosal pathology, i.e., intraepithelial lymphocytosis, 
crypthyperplasia, and partial villous atrophy (Marsh IIIA). These patients were 
subsequently treated with a gluten-free diet, and follow-up biopsies were taken after 6 –
12 months. 
The sugar absorption test was performed using a solution of lactulose, mannitol, and 
sucrose, supplemented with demineralised water to 100 ml (24, 25). The upper limit of a 
normal lactulose/mannitol ratio in our laboratory is 0.089, i.e., 2 SD above the mean 
value. Serum IgA antigliadin antibodies (AGA) were determined by ELISA 
(Biochemistry Laboratory, Rijnstate Hospital, Arnhem, The Netherlands); IgA 
antiendomysium antibodies (AEA) by an indirect immuno-fluorescence test 
(EuroIMMUN). HLA-DQ typing was performed to determine whether coeliac-specific 
patterns were present in the patients who responded to the gluten challenge. As virtually 
all coeliacs in Northern European countries carry either the serological HLA-DQ2 
(90%) or HLA-DQ8 (10%) markers, we performed a polymerase chain reaction (PCR)–
based molecular typing method in our patients to evaluate if the DQA1*0501 and 
DQB*02 alleles or the DQA1*0301 and DQB1*0302 alleles encoding these proteins, 
respectively, were present in this group of patients (26). Genomic DNA was extracted 
from EDTA anti-coagulated peripheral blood according to a standard proteinase K 
digestion and phenol/chloroform extraction technique. Generic primers were used for 
the amplification of the second exons of the HLA-DQA1 and HLA-DQB1* genes on a 
thermal cycler Perkin-Elmer 9600 (Perkin-Elmer, Norwalk, CT). HLA-DQA1* and 
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HLA-DQB1* typing was performed with a combined single-stranded conformation 
polymorphism (SSCP) /heteroduplex method by a semi automated electrophoresis and 
gel staining method on the Phastsystem (Amersham-Pharmacia-Biotech, Sweden). The 
study was approved for by the local ethics committee. 
 
 
RESULTS  
 
All 38 patients completed the challenge period without severe adverse reactions or 
complications (29 women and nine men; mean age 40 yr, range 16–74 yr). A total of 17 
patients, including all in the group with progression of mucosal pathology, experienced 
more or less aggravating symptoms during the period of high gluten intake (i.e., fatigue, 
abdominal discomfort, abdominal distension, and aphtous stomatitis). Twelve of 38 
patients (32%) who were challenged with high doses of gluten showed a significant 
progression of small intestinal mucosal pathology (nine women and three men, mean 
age 41 yr), as shown in Table 2. 
 
 
 
 
In one patient, small intestinal biopsy revealed histopathological deterioration to 
subtotal villous atrophy (Marsh IIIB); six patients developed partial villous atrophy 
(Marsh IIIA); and five patients progressed to infiltrative crypthyperplastic lesions 
(Marsh II). After 6–12 months of adherence to a gluten-free diet, these 12 patients had 
follow-up biopsies taken. Five of seven patients with villous atrophy after challenge had 
normalization of the mucosa; in one patient, histopathology returned to a Marsh I lesion 
and in another patient to a Marsh II lesion. Of the five patients with mucosal 
progression to Marsh II, follow-up biopsies revealed mucosal normalization to Marsh 0 
in two; in the other three, histology improved to Marsh I. All 12 patients experienced a 
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significant improvement of symptoms while on a gluten-free diet, including weight gain 
and improvement of fatigue, abdominal discomfort, and diarrhoea. HLA-DQ typing was 
performed in 11 of the 12 patients who responded to the gluten challenge with 
progression of mucosal pathology. Five carried the coeliac-associated serological DQ2 
markers, of whom one had Marsh IIIB lesions, one Marsh IIIA lesions, and three Marsh 
II lesions. Two patients carried DQ8 markers, which are also associated with coeliac 
disease. In one of these patient’s mucosal pathology progressed to Marsh IIIA, in the 
other to Marsh II. In the other 26 patients (68%) small intestinal biopsies during the 
gluten challenge revealed unchanged Marsh I lesions (n 5 20) or normalization of the 
mucosa, Marsh 0 (n 5 6) (20 women and six men, mean age 40 yr). Ten of these patients 
were motivated to adhere to a gluten-free diet. Follow-up biopsies in this group after 6–
12 months showed unchanged Marsh I lesions in eight patients and normalization to 
Marsh 0 in two patients. Symptoms of fatigue and abdominal complaints improved in 
three of these patients. The other patients experienced no influence of the gluten-free 
diet. Three patients had follow-up biopsies taken without adhering to a gluten-free diet. 
In all three the lymphocytic infiltration of the mucosa was unchanged. 
AGA was measured in 37 patients. In the sera of eight patients AGA was elevated, of 
whom four responded to the challenge with aggravation of mucosal pathology. AEA 
were determined in 23 patients. In sera of four patients AEA were present, of whom two 
had mucosal deterioration and one had unchanged histology. AEA in both of these 
patients disappeared during follow-up while on a gluten-free diet. A sugar absorption 
test (SAT) was performed in 33 patients. In 16 patients, SAT was elevated above 
normal values, of which eight had progression of mucosal lesions. During follow-up, 
while on a gluten-free diet, SAT normalized in four patients, and improved but 
remained elevated in two. The remaining two patients were not tested. Serum antibodies 
and SAT did not correlate with the histological outcome. 
 
DISCUSSION 
 
In the present study we demonstrated that, of 38 patients suspected of having coeliac 
disease but with only Marsh I histological abnormalities of the small intestine, 12 
patients (32%) developed more severe histological lesions when 30 g of gluten was 
added to their usual diet. Seven patients (58%) developed at least partial villous atrophy 
(Marsh IIIA), and five (42%) showed less severe but significant progression to 
infiltrative-crypthyperplastic (Marsh II) small intestinal lesions. Furthermore, all 12 
patients experienced a clear improvement in symptoms after starting a gluten-free diet, 
including improvement of abdominal complaints, fatigue, stool consistency, and weight 
gain. This was accompanied in most patients by concomitant near-normalization of 
small intestinal mucosal pathology in follow-up biopsies. HLA-DQ typing was 
performed in 11 of the 12 patients who showed deterioration of mucosal pathology. 
Coeliac-associated DQ2 or DQ8 markers were present in seven of these patients, which 
provide supporting evidence of their gluten sensitivity. The lack of coeliac-associated 
HLA-DQ markers in the other four patients is in contradiction of the classical diagnosis 
coeliac disease, but does not exclude it (27). However, the histological and clinical 
response of these patients to gluten challenge and gluten withdrawal was clearly noted 
and, therefore, strongly suggests that they are indeed sensitive to gluten. Serum 
Histopathological aspects of coeliac disease 
 
 
 
54 
 
antigliadin and antiendomysium antibodies did not show any correlation with 
histological findings, although these factors were not studied in all patients. This could 
be explained by the findings of Rostami et al. (5), who demonstrated low sensitivity of 
antibodies in partial and subtotal villous atrophy in coeliac disease. Sugar absorption 
testing was also not of additional value for interpreting the challenge tests. The 
interpretation of Marsh 0 and Marsh I lesions remains speculative. The degree of 
lymphocytic infiltration may fluctuate in time and location, and may also vary around 
the arbitrary cut-off point of 30 lymphocytes per 100 enterocytes. Moreover, the 
lymphocytic infiltration is recognized in both naive patients without a diet and in 
patients who are in clinical remission when on a gluten-free diet. The 26 patients who 
did not respond to gluten challenge with progression of mucosal pathology can be seen 
as control group in the study. Although the number is relatively small, 13 patients 
consented to follow-up biopsies, of which 10 were motivated to follow a gluten-free 
diet. Eleven of 13 follow-up biopsies in this group were unchanged and only three 
patients on a gluten-free diet reported symptom relief, including improvement of fatigue 
and abdominal complaints. These findings support the thesis that our patients who 
showed progressive mucosal abnormalities during gluten challenge are indeed sensitive 
to gluten, and that the challenge is useful to identify patients appropriate for therapy. 
It could well be that we are looking at an intermediate or borderline presentation of 
gluten sensitivity. Successful treatment of the presenting symptoms and improvement or 
normalization of mucosal pathology may justify the treatment of these patients with a 
gluten-free diet. Whether they would have had an increased risk for developing the 
secondary complications seen in untreated coeliacs if they have not been recognized as 
gluten sensitive remains speculative. The interpretation of the results of five patients 
with histological progression to Marsh II is challenging. Strictly speaking, they cannot 
be classified as coeliacs. However, their symptoms at presentation, the progression of 
symptoms and histological abnormalities during gluten challenge, and the clear 
improvement of symptoms when on a gluten free diet support the assumption that these 
individuals are sensitive to gluten and may justify treatment with a gluten free diet. For 
the patients themselves, this is indisputable, inasmuch as their quality of life has 
improved. It may be that the variety of mucosal pathology in gluten sensitivity at 
presentation depends on immunogenetic factors as HLADQ1 T-cells, g/d T-cells and 
cytokine (28 –34). Further studies in patients with Marsh II, IIIA-B, and C are therefore 
mandatory. We conclude that a gluten challenge may be of diagnostic help if patients 
are suspected of being gluten sensitive but small intestinal biopsies reveal only mild 
mucosal abnormalities. 
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 Abstract: 
 
Background: For diagnosis and follow-up of coeliac disease, paediatric societies advise 
that intestinal mucosal specimens should be obtained using suction capsule from the 
jejunum. This procedure is strenuous for patients, time-consuming, expensive and 
requires radiographic guidance. Mucosal biopsies from the distal duodenum can be 
obtained more easily under endoscopic vision using forceps. The aim of the present 
study was to compare biopsies taken from the duodenal mucosa by forceps and from the 
jejunal mucosa using suction capsule with respect to histological outcome.  
Methods: For this study, 171 paired biopsies were taken from 109 patients (1-75 years) 
from the distal duodenal mucosa using jumbo forceps and from the jejunal mucosa 
using Crosby suction capsule. Histological interpretation was performed according to a 
modified Marsh classification, including partial-, subtotal and total villous atrophy as 
Marsh IIIA, B, and C.  
Results: Fourteen suction capsule biopsies were of insufficient quality to be interpreted 
(8%). All duodenal forceps biopsies produced adequate material for histological 
scoring. No differences in histological scoring were seen in 145 of 157 compared 
biopsies (92%). Of 12 biopsies in which a discrepancy was present, 4 showed more 
severe lesions in the duodenum and 8 more severe lesions in the jejunum. The 
differences were of clinical significance, i.e., including the presence and absence of 
villous atrophy in 9 of 157 paired biopsies (6%).  
Conclusion: In the present study, we demonstrated that mucosal specimens taken from 
the distal duodenal and jejunal mucosa are strongly correlated. Clinically significant 
discrepancies were present in only 6% of paired biopsies. Therefore we suggest that, in 
diagnosis and follow-up of coeliac disease, mucosal specimens may be taken from the 
duodenum using forceps to obtain adequate material for histological interpretation.  
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Introduction  
 
Coeliac disease is a chronic state of gluten-sensitive enteropathy, in which there are 
characteristic, but not specific, small intestinal mucosal abnormalities that impair 
absorption of nutrients. Per definition, mucosal histopathology normalizes after 
withdrawal of wheat gliadins and the equivalent barley and rye from the diet [9, 19]. 
Although the presence of antibodies to gliadin, endomysium and tissue transglutaminase 
as well as human leukocyte antigen (HLA)-DQ typing can support the diagnosis, the 
small intestinal biopsy (SIB) remains the hallmark of the diagnosis of coeliac disease. 
Small intestinal mucosal pathology may be interpreted according to the modified Marsh 
criteria [8, 17, 18]. This spectrum consists of a progressive sequence of mucosal 
abnormalities of the small intestine, comprising infiltration of the epithelium with 
lymphocytes, hyperplasia of crypts, progressive loss of surface epithelial cells and, 
ultimately, villous atrophy. Coeliac disease, i.e., gluten-sensitive enteropathy, affects 
the entire gastrointestinal tract but has its main manifestation in the proximal small 
bowel. Therefore, Sibs are traditionally taken from the jejunal mucosa as representative 
locus for diagnosing coeliac disease. In fact, the European Society of Paediatric 
Gastroenterology and Nutrition (ESPGAN) criteria for coeliac disease require jejunal 
biopsies be taken by capsule [9, 19]. Mucosal specimens can be obtained using 
radiographic guided suction capsules (Crosby, Quinton), which may or may not be 
introduced by endoscope [5, 11, 12, 15]. Unfortunately, this technique is strenuous for 
patients, requires radiographic support, is time consuming and is expensive. 
Alternatively, biopsies may be obtained using jumbo forceps with a flexible endoscope 
introduced into the distal duodenum. Actually, since the mid-1990s the majority of 
gastroenterologists prefer the duodenal-forceps biopsies. The crucial point concerning 
the validity of such biopsies lies in the representative quality of the distal duodenal 
mucosa with respect to small intestinal pathology. Not only is there more natural 
irregularity of the proximal duodenal mucosa, but, specifically, the influence of 
nutrients mixed with gastric acid from the stomach and digestive fluids released into the 
duodenum in reaction to a meal may induce a chronic mild inflammatory response [13]. 
This may alter the appearance of mucosal inflammation and villous architectural 
changes and therefore disqualify duodenal biopsies for diagnostic use, especially when 
minor architectural changes and intraepithelial lymphocytosis must be considered. 
Furthermore, capsule-suction biopsy specimens have been reported to be inadequate for 
interpretation due to artefacts. Previous reports on the reliability of histological 
interpretation and success of obtaining adequate specimens of the capsule suction 
biopsies from the jejunum and the forceps biopsies from the duodenum are 
contradictory [1, 2, 3, 4, 6, 7, 10, 14, 16]. To investigate the validity of distal duodenal 
biopsies in diagnosis and follow-up of gluten-sensitive enteropathy, we performed the 
present study in which we took biopsies from both distal duodenum mucosa using 
endoscopic guided forceps and jejunal mucosa using endoscopically introduced, 
radiographic guided Crosby capsule. The objective was to compare the histological 
classification from the two biopsy sites in the same patient and, in extension, to evaluate 
the clinical consequences of possible discrepancies.   
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Materials and methods 
 
Between 1988 and 2000, 171 combined Sibs were taken at the endoscopy unit of our 
hospital for either diagnostic purposes or follow-up of coeliac disease from both the 
duodenal and jejunal mucosa in 109 patients [34 men, 75 women; mean age 41 years (1-
5 years)]. The patients were chosen sequentially, without selection. After informed 
consent, the patients were sedated with midazolam (0.05-.20 mg/kg i.v.) and monitored 
by means of pulse-oxymetric and blood pressure control. A flexible endoscope  
(Olympus GIF 140, -IT100 or Fujinon 300 double lumen) was then introduced twice for 
obtaining mucosal specimens from the jejunum using Crosby capsule and four mucosal 
specimens from the distal duodenum (pars ascendens/flexura lienalis) using jumbo-
forceps (MTW), respectively. The tissue samples were orientated and fixed in a 
formaldehyde solution. After processing in the pathology laboratory, the histological 
slices were interpreted by two of the authors (JWRM and PJW) according to the Marsh 
criteria. Marsh 0 comprises normal mucosal architecture without signs of inflammation. 
In a Marsh-I, lymphocytic enteritis, the small intestinal epithelium is infiltrated with 
lymphocytes; arbitrarily, the number that we consider as pathological is more than 30 
lymphocytes per 100 enterocytes. Marsh-II, lymphocytic enteritis with crypthyperplasia 
is characterized by intraepithelial lymphocytosis and is accompanied by elongation and 
branching of crypts in which there is a (much) higher proliferation rate. In advanced 
mucosal pathology, Marsh-III, villous atrophy is present in the infiltrative- crypt 
hyperplastic mucosa. We introduced a modification of the original Marsh classification 
in interpreting advanced mucosal lesions and recognize three distinct stages of villous 
atrophy [17, 18]. In Marsh-IIIA lesions, partial villous atrophy, villi are shortened and 
blunt. Arbitrarily, we classify as Marsh IIIA if the villous: crypt ratio is below 1:1. Villi 
are clearly atrophic, but still recognizable in Marsh-IIIB lesions: subtotal villous 
atrophy. Finally, in Marsh III-C, total villous atrophy, the villi are absent or 
rudimentary, the mucosa resembling colonic mucosa (Fig. 1). For a representative 
interpretation of specimens, we considered an intact mucosa comprising at least five 
villi, or a length of at least 1000 m to be obligatory. Discrepancies in the classification 
of mucosal abnormalities were considered to be of clinical significance, if they included 
the absence (Marsh 0, I, II) or presence of villous atrophy (Marsh IIIABC), as this 
criterion is mandatory for establishing the diagnosis of coeliac disease as well as 
histological remission. In other words, discrepancies crossing the line between Marsh II 
and Marsh IIIA are clinically significant,  as (1) the presence of villous atrophy in 
diagnostic biopsies is mandatory for the diagnosis of coeliac disease justifying the 
installment of a gluten-free diet, (2) the absence of villous atrophy is mandatory for 
diagnosing histological remission in follow-up biopsies in patients on a gluten-free diet, 
and (3) persisting villous atrophy suggests the diagnosis of (diet) refractory coeliac 
disease. Differences between duodenal and jejunal mucosal pathology remaining on 
either side of the line between Marsh II and Marsh IIIA do not differentiate in the 
diagnostic decision of whether coeliac disease or coeliac disease in histological 
remission is present.  
Results: The quality of 14 (8%) of the 171 jejunal biopsies obtained using Crosby 
capsule was insufficient for interpretation. All duodenal biopsies were eligible for 
interpretation. Therefore, 157 paired duodenal/jejunal mucosal specimens were 
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available for comparison (Table 1). Of these specimens, 51 paired biopsies were taken 
at diagnosis of gluten-sensitive enteropathy, 106 paired biopsies were taken as follow-
up samples during a gluten free diet. In 145 of 157 paired biopsies (92%) the 
histological scores were identical. In 12 paired biopsies (8%) a discrepancy was seen in 
the classification of mucosal pathology. Of 51 biopsies taken at the time of diagnosis of 
coeliac disease, 4 showed a discrepancy, including 2 paired biopsies with more severe 
lesions in the proximal specimens (both Marsh IIIA in the duodenum and Marsh II in 
the jejunum) and 2 paired biopsies with more severe lesions in the distal specimens 
(respectively, duodenum Marsh I versus jejunum Marsh IIIB and duodenum Marsh I 
versus jejunum Marsh IIIA). In 8 of 106 paired biopsies taken during follow-up. We 
recognized a discrepancy in mucosal pathology. Two paired biopsies showed more 
severe lesions in the proximal specimens (respectively, duodenum Marsh II versus 
jejunum Marsh I and duodenum Marsh IIIA versus jejunum Marsh II). Six paired 
biopsies showed more severe lesions in the distal specimens (respectively, duodenum 
Marsh I versus jejunum Marsh II, three paired biopsies with duodenum Marsh II versus 
jejunum Marsh IIIA, duodenum Marsh II versus jejunum Marsh IIIB and duodenum 
Marsh IIIA versus jejunum Marsh IIIB). In 3 of these 12, the differences included 
Marsh I versus Marsh II, or Marsh IIIA versus Marsh IIIB, thereby not influencing 
clinical outcome. Therefore, a clinically significant discrepancy was seen in 9 of 157 
paired biopsies (6%), 4 of 51 at diagnosis and 5 of 106 during follow- up. Three paired 
biopsies showed more severe lesions in the duodenal mucosa, and six paired biopsies 
showed more severe lesions in the jejunal mucosa. Differences including normal 
mucosa versus inflamed mucosa with or without villous atrophy were not seen.  
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Discussion 
 
In the present study we have demonstrated a strong correlation of mucosal pathology in 
gluten-sensitive enteropathy between specimens taken from the distal duodenal mucosa 
and the jejunal mucosa. In 145 of 157 paired biopsies (92%), the classification of 
mucosal pathology was identical and in 3 paired biopsies the differences were only 
gradual and did not influence clinical outcome (148/157: 94%). Only in nine paired 
biopsies (6%) did we see a clinically significant discrepancy between the duodenal and 
jejunal mucosal pathology. The severity of mucosal lesions was more aggravated in the 
duodenal mucosa in three paired biopsies (two at diagnosis and one during follow-up) 
and more aggravated in the jejunal mucosa in six paired biopsies (two at diagnosis and 
four during follow-up). This contradicts the assumption that duodenal mucosa is 
chronically irritated by gastric acid and digestive juices from the pancreas and liver 
thereby exaggerating the interpretation of mucosal inflammation [13]. If only the 
duodenal specimens would have been taken, this would have led to a missed diagnosis 
of villous atrophy in only 6 of 157 biopsies (4%) and a possible over-classification of 
mucosal pathology in 3 of 157 biopsies (2%). Furthermore, in 14 of 171 (8%) paired 
biopsies; the quality of the Crosby capsule suction specimens was insufficient for 
interpretation, whereas all duodenal forceps biopsies produced adequate material for 
interpretation. The arbitrary interpretation of mucosal inflammation, with a cut-off point 
of 30 intra-epithelial lymphocytes per 100 enterocytes and/or a villous: crypt ratio of 1:1 
for the classification of partial villous atrophy is surely in part responsible for the 
discrepancies in interpreting mucosal pathology. Furthermore, mucosal abnormalities 
may be patchy and fluctuate around the arbitrary cut-off point. In conclusion, we 
demonstrated that when comparing specimens taken from the distal duodenal and 
jejunal mucosa for diagnosis or follow-up of coeliac disease, a clinically significant 
discrepancy is seen in a minority of 6% of paired biopsies. We assume a clinically 
significant discrepancy is present when the differences in mucosal pathology include 
crossing the line between Marsh II and Marsh IIIA because the presence or absence of 
villous atrophy determines whether or not the diagnosis of coeliac disease or coeliac 
disease in histological remission can be made. Furthermore, when taking specimens 
only from the distal duodenum, clinically important villous atrophy is missed in only 
4% of biopsies. All paired biopsies with discrepancies included mucosal pathology, i.e., 
at least intraepithelial lymphocytosis. Therefore, we suggest that obtaining mucosal 
specimens from the distal duodenal mucosa in the diagnosis and follow-up of coeliac 
disease can replace the procedure of taking Sibs from the jejunal mucosa. If the 
suspicion of coeliac disease is strong, but biopsies show only Marsh-I or Marsh-II 
lesions, then jejunal biopsies should be taken, considering the small risk of duodenal 
biopsies being false-negative for villous atrophy.  
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A b s t r a c t 
 
To assess histologic recovery in response to gluten withdrawal in coeliac disease, 158 
patients seen in our hospital during a 15-year period underwent follow-up small 
intestine biopsies (Sibs) within 2 years after starting a gluten-free diet; further Sibs were 
done if villous atrophy was present. A modified Marsh classification was used (IIIA, 
partial villous atrophy; IIIB, subtotal villous atrophy; IIIC, total villous atrophy). Of 
patients with Marsh IIIA, IIIB, or IIIC lesions, histologic remission was seen in 65.0% 
within 2 years, 85.3% within 5 years, and 89.9% in long-term follow-up. Eleven 
patients (7.0%) with persisting (partial) villous atrophy had symptoms and signs of 
malabsorption and were considered to have refractory coeliac disease; 5 of them 
developed an enteropathy associated T-cell lymphoma. Children recovered up to 95% 
within 2 years and 100% in the long-term. Histologic recovery in coeliac disease after 
starting a gluten-free diet takes time and is incomplete or absent in a substantial 
subgroup of patients (10.1% villous atrophy after 5 years). Systematic follow-up of 
patients with coeliac disease and the malabsorption syndrome and secondary 
complications is needed. 
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Introduction: 
 
Coeliac disease is a permanent state of intolerance to gluten, i.e., alcohol-insoluble 
proteins of wheat, rye, and barley.1,2 The immunologic response to gluten in 
glutensensitive people causes histologic abnormalities of the small intestinal mucosa, 
comprising influx of lymphocytes into the epithelium, crypthyperplasia, and, ultimately, 
villous atrophy.3-5 This results in a diversity of symptoms and signs 
of malabsorption, including chronic diarrhea, abdominal distention, fatigue, weight loss, 
growth  disturbances, and iron, folic acid, and other vitamin deficiencies. Treatment 
consists of starting a gluten-free diet, after which histologic findings and symptoms 
should normalize. Histologic recovery of small intestinal mucosa is assumed to occur 
within 6 to 12 months after starting a gluten free diet, simultaneously with clinical 
remission. Surprisingly, follow-up data on small intestinal recovery in coeliac disease 
are scarce and contradictory. Shmerling and Franckx 6 reported complete normalization 
of the small intestinal mucosa in all of 91 children with coeliac disease who were on a 
gluten-free diet. Congdon et al 7 found persisting villous atrophy in 2 of 10 children 
with coeliac disease. Grefte et al 8 reported slow and incomplete histologic and 
functional recovery in 22 adults with coeliac disease after 24 to 48 months of a gluten-
free diet. Furthermore, Selby et al 9 demonstrated that persistent mucosal abnormalities 
seen in their series of patients with coeliac disease were not due to the ingestion of trace 
amounts of gluten. This rejects the suggestion that persisting mucosal abnormalities in 
coeliac disease usually are due to a poor compliance with a gluten-free diet. Based on 
follow-up sugar absorption tests in patients with coeliac disease while on a gluten-free 
diet, Uil et al 10 suggested a discongruency, i.e., faster mucosal recovery in children than 
in adults. In clinical practice, we also have the impression that recovery in childhood 
and adult coeliac disease is not equally time-related. For that matter, histologic recovery 
has not been defined specifically in the literature, and there is no discussion about 
persisting crypthyperplasia and lymphocytic infiltration. When villi reappear and 
normalize, do the hyperplasia of crypts and the intraepithelial infiltration of 
lymphocytes also disappear? And if they do not, is this without consequences, or are the 
patients still at risk for malabsorption and long-term complications such as osteopenia 
and malignancy? The aim of the present study was to assess the histological recovery 
profiles of patients with coeliac disease, mainly adults, who were seen in our hospital 
during a 15-year period. 
 
Materials and Methods 
 
We studied 158 patients with coeliac disease (114 female, 44 male; mean age, 44 years, 
range, 0-74 years) who were seen in our hospital between January 1985 and December 
2000. All initially had signs and symptoms of malabsorption. Small intestine biopsies 
(Sibs) revealed coeliac-related pathology, i.e., intraepithelial infiltration with 
lymphocytes, crypthyperplasia, and partial, subtotal, or total villous atrophy. Other 
possible underlying diseases, such as inflammatory bowel disease, bacterial overgrowth, 
Crohn’s disease, giardiasis, amyloidosis, intestinal lymphangiectasia, Whipple disease, 
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hypogammaglobulinemia, eosinophilic enteritis, and lymphoma were excluded. All 
received dietary counseling from their gastroenterologist and a dietitian. After informed 
consent, follow-up Sibs were done within 1 to 2 years after starting a gluten-free diet. 
Further Sibs were done if the first revealed villous atrophy or if symptoms of relapse 
occurred. We categorized follow-up Sibs in time intervals: 1 to 2 years, 2 to 5 years, and 
more than 5 years (long-term follow-up). The Sibs were done by using an endoscopic-
guided Crosby capsule,11 with or without large forceps biopsies of the distal 
duodenum. Small intestinal histologic features were interpreted according to the Marsh 
classification 3-5 by two of us (P.J.W. and J.W.R.M.), who were not informed about the 
clinical status of the patients. This scoring system comprises a spectrum of consecutive 
mucosal abnormalities that can be seen in glutensensitive enteropathy   
Marsh 0 is described as normal mucosal architecture, without significant intraepithelial 
lymphocytic infiltration. 
Marsh I (lymphocytic enteritis) is normal mucosal architecture with a marked 
infiltration of villous epithelium by lymphocytes; arbitrarily we defined marked as more 
than 30 lymphocytes per 100 enterocytes.  
Marsh II (lymphocytic enteritis with crypthyperplasia) consists of intraepithelial 
lymphocytosis and elongation and branching of crypts in which there is an increased 
proliferation of epithelial cells.  
Marsh III comprises intraepithelial lymphocytosis, crypthyperplasia, and villous 
atrophy. We recognize 3 distinct stages of villous atrophy. 5 In Marsh IIIA, partial 
villous atrophy, the villi are blunt and shortened. Arbitrarily, we classified samples as 
partial villous atrophy if the villus-crypt ratio was less than 1:1. In Marsh IIIB, subtotal 
villous atrophy, villi are clearly atrophic, but still recognizable, and in Marsh IIIC, total 
villous atrophy, villi are rudimentary or absent, and the mucosa resemble colonic 
mucosa. 
Remission of mucosal pathologic features, with normalization of villi, i.e., regression to 
Marsh 0 to II, was stated as the end point of follow-up. Although one can doubt Marsh 
II lesions as being a state of remission or normalization of mucosal pathologic features, 
we did not perform further follow-up Sibs in these patients for ethical reasons, as their 
symptoms had improved and malabsorption parameters normalized. 
Apart from the 158 patients with villous atrophy (Marsh III), we studied 22 patients 
with symptoms and signs of malabsorption in whom lymphocytic enteritis with 
crypthyperplasia (Marsh II) was seen at diagnosis. These patients also adhered to a 
gluten-free diet, and follow-up clinical and histologic parameters were monitored. 
 
Results 
 
Histologic recovery profiles are given in (Figure 1). Histologic remission was seen in 
65.0% of the patients within 2 years, in 85.3% within 5 years, and in 89.9% after 5 
years of follow-up. Of 59 patients with coeliac disease with a Marsh IIIC lesion 
revealed by the initial SIB and who started a gluten-free diet, 30 (51%) of them 
recovered within 2 years, 48 (81%) within 5 years, and 51 (86%) in long-term follow-
up. Of 59 patients with a Marsh IIIB lesion revealed by the initial SIB, 34 (58%) 
recovered within 2 years, 46 (78%) within 5 years, and 52 (88%) in long-term follow-
up. Of 40 patients with a Marsh IIIA lesion revealed by the initial SIB, 35 (88%) 
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recovered within 2 years, 39 (98%) within 5 years, and 39 (98%) in long-term follow-
up. The end-stage histologic score of patients in remission in the total study group, i.e., 
142 of 158 patients, was as follows: Marsh 0, 41.3%; Marsh I, 23.8%; and Marsh II, 
25.9%. Of the 59 patients starting a gluten-free diet with an initial Marsh IIIC lesion, 25 
(42%) experienced improvement to Marsh 0, 15 (26%) to Marsh I, and 11 (19%) to 
Marsh II. Of the 59 patients with an initial Marsh IIIB lesion, 19 (32%) improved to 
Marsh 0, 15 (26%) to Marsh I, and 18 (31%) to Marsh II. Finally, of the 40 patients 
with a Marsh IIIA lesion starting gluten withdrawal, 18 (46%) improved to Marsh 0, 8 
(20%) to Marsh I, and 13 (32%) to Marsh II (Figure 2).  
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Eleven of 16 patients in whom persisting villous atrophy was found during long-term 
follow-up experienced symptoms of active coeliac sprue and had signs of 
malabsorption, i.e., abdominal distress, diarrhea, weight  loss, steatorrhea, iron and folic 
acid deficiencies, and/or abnormal sugar absorption test results. Hence, they were 
considered to have refractory coeliac disease (7% of all patients). One of the patients 
with refractory disease (a 57-year-old woman who had coeliac disease for 10 years) 
died of malabsorption and secondary infectious complications. Disseminated 
enteropathy-associated T-cell lymphoma developed in 5 other patients with refractory 
disease. The lymphoma did not respond to chemotherapy, and all died within months 
after the diagnosis. Enteropathy-associated T-cell lymphoma was not seen in any of the 
patients with non refractory disease. Apart from the 158 patients in the study group, 22 
patients (13 women, 9 men; mean age, 42 years; range, 19- 76 years) with signs and 
symptoms of gluten-sensitive enteropathy with lymphocytic enteritis with 
crypthyperplasia (Marsh II lesion) revealed by the SIB started a gluten free diet. In 18 
patients (82%), mucosal histologic findings improved to Marsh 0 within 2 years; 4 
(18%) improved to Marsh I within 2 years. Symptoms and malabsorption parameters 
improved in all 22 patients after a gluten-free diet was started. In a subgroup of 25 
children (17 girls, 8 boys; mean age, 3 years; range, 1-16), which is included in the total 
group of 158 patients, 24 (96%) showed histologic recovery within 2 years, and 100% 
recovered in long-term follow-up. Five with a Marsh IIIA lesion, 5 with a Marsh IIIB 
lesion, and 14 with a Marsh IIIC lesion started a gluten-free diet. In 1 child, histologic 
recovery was found only after 3 years of adherence to a gluten-free diet. The recovery 
was faster in children than in adults (P < .01, chi-square test) and tended to be more 
complete in children (P < .20, chi-square test).  
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Discussion 
 
Histological recovery profiles of 158 patients with coeliac disease in our hospital 
revealed that only 65.0% of the patients reached histologic remission within 2 years. 
Moreover, within 5 years, 85.3% were in remission, and in long-term follow-up, 89.9% 
showed normalization of villous architecture. Recovery numbers in cases with subtotal 
or total villous atrophy (Marsh IIIB and IIIC) revealed by the initial SIB were lower 
than those in subjects with partial villous atrophy (Marsh IIIA) revealed by the initial 
SIB (Marsh IIIB, 88%, and IIIC, 86%, respectively, vs. IIIA, 98%, respectively). After 
5 years of follow-up, 10.1% of patients with coeliac disease still had at least partial 
villous atrophy, of whom most (7.0%) are considered to have clinically refractory 
coeliac disease. The incidence of enteropathy-associated T-cell lymphoma was high in 
this group (5 patients). Furthermore, the recovery in children seemed to progress faster 
and more completely than in adults, but the group of children diagnosed with coeliac 
disease in our cohort was small. Until the early 1990s, endoscopy in children was 
performed only in academic hospitals, so the majority of childhood cases of coeliac 
disease in our region have been diagnosed elsewhere. We considered regression of 
mucosal abnormalities, with normalization of villi to Marsh 0, I, or II, as histologic 
emission and, thus, the end point of the follow-up study. The working group on coeliac 
disease of the European Society for Pediatric Gastroenterology and Nutrition does not 
specifically define histological remission.1,2 However, one can question the inclusion of 
Marsh II in the remission group, because little is known about the implications of 
lymphocytic enteritis with crypt hyperplasia. When we disqualify this group as being in 
remission, the overall outcome would be even lower. Interestingly, in clinical practice 
we have recognized a subgroup of patients who seem to be sensitive to gluten, 
according to symptoms and signs of gluten-dependent malabsorption, but in whom the 
SIB revealed only a Marsh II lesion, which does not strictly meet the criteria for the 
diagnosis of coeliac disease. However, the condition of these patients responds to a 
gluten-free diet, according to symptomatology, malabsorption, and histology 
parameters. Follow-up SIB of 22 patients with Marsh II lesions who started a gluten-
free diet revealed normalization of mucosal pathologic features to Marsh 0 or I lesions 
in 100% within 2 years. Retrospectively, 18 of 22 patients with Marsh II disease carry 
coeliac-related HLA-DQ 2 (15 patients) or HLA-DQ8 (3 patients) markers,12 which 
supports the assumption that they are indeed gluten-sensitive. When histological 
improvement from partial to total villous atrophy to Marsh II lesions is found in patients 
with coeliac disease, however, the patients  symptoms and malabsorption parameters 
concomitantly improve. Whether these patients with histological improvement to a 
Marsh II lesion are different from patients with a naive Marsh II lesion and whether 
they are at risk for developing secondary complications such as osteopenia or 
malignancy13-19 requires further study. Again, the European Society for Paediatric 
Gastroenterology and Nutrition has not provided a ruling on this point. We suggest that 
working groups on adult coeliac disease (during the American Digestive Disease 
Week/United European Gastroenterology Week) accurately define exactly what  
constitutes the diagnosis of coeliac disease (i.e.,  When is a coeliac a coeliac? 20,21).  
In a long-term follow-up study of 158 patients with coeliac disease in our hospital, the 
histologic recovery in gluten-sensitive sprue after starting a gluten-free diet takes time 
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(more than 2 years in 35.4% of patients) and is incomplete or absent (10.1% villous 
atrophy in long-term follow-up) in a substantial subgroup of patients. Considering the 
morbidity of the malabsorption condition and the risk for secondary complications such 
as osteopenia and malignant neoplasm, these results imply the need for a systematic 
follow-up of patients with coeliac disease, including small intestine biopsies.  
 
 
Chapter V 
 
 
77 
References 
 
1. McNeish AS, Harms HK, Rey J, Shmerling DH, Visakorpi JK, Walker-Smith JA. 
The diagnosis of coeliac disease: a commentary on the current practice of the European 
Society for Paediatric Gastroenterology and Nutrition (ESPGAN).  
Arch Dis Child. 1979 Oct;54(10):783-6. 
2. Walker-Smith JA, Guandalini S, Schmitz J, et al. Revised criteria for diagnosis of 
coeliac disease: report of the working group of the European Society of Paediatric 
Gastroenterology and Nutrition. Arch Dis Child. 1990 Aug; 65(8):909-11. 
3. Marsh MN. The immunopathology of the small intestinal reaction in gluten 
sensitivity. Immunol Invest. 1989 Jan-May; 18(1-4):509-31. 
4. Marsh MN. Gluten, major histocompatibility complex and the small intestine: a 
molecular and immunobiologic approach to the spectrum of gluten sensitivity (“coeliac 
sprue”). Gastroenterology. 1992 Jan; 102(1):330-54. 
5. Wahab PJ, Crusius JB, Meijer JW, Mulder CJ. Gluten challenge in borderline gluten 
sensitive enteropathy.  Am J Gastroenterol. 2001 May; 96(5):1464-9. 
6. Shmerling DH, Franckx J. Childhood coeliac disease: a long-term analysis of relapses 
in 91 patients. J Pediatr Gastroenterol Nutr. 1986 Jul-Aug;5(4):565-9. 
 7. Congdon P, Mason MK, Smith S, Crollick A, Steel A, Littlewood J. 
 Small bowel mucosa in asymptomatic children with coeliac disease: mucosal changes 
with gluten free diets. Am J Dis Child. 1981 Feb; 135(2):118-21.  
8. Grefte JM, Bouman JG, Grond J, Jansen W, Kleibeuker JH. 
 Slow and incomplete histological and functional recovery in adult gluten sensitive 
enteropathy. J Clin Pathol. 1988 Aug; 41(8):886-91. 
9. Selby WS, Painter D, Collins A, Faulkner-Hogg KB, Loblay RH. Persistent mucosal 
abnormalities in coeliac disease are not related to the ingestion of trace amounts of 
gluten. Scand J Gastroenterol. 1999 Sep; 34(9):909-14. 
10. Uil JJ, van Elburg RM, van Overbeek FM, Meyer JW, Mulder CJ, Heymans HS. 
 Follow-up of treated coeliac patients: sugar absorption test and intestinal biopsies 
compared. Eur J Gastroenterol Hepatol. 1996 Mar;8(3):219-23. 
 11. Mulder CJJ, Simoons PP, van Nierop AJ, et al. Jejunal biopsy with an endoscopic 
guided capsule. Eur J Gastroenterol Hepatol. 1992; 4:868-869. 
12. Crusius JBA, Mulder CJJ, Wahab PJ, et al. HLA-DQ typing of gluten sensitive 
patients with a Marsh II lesion [abstract].Gastroenterology. 1999; 116(suppl):A942.
13. Harris OD, Cooke WT, Thompson H, et al. Malignancy in adult coeliac disease and 
idiopathic steatorrhoea. Am J Med. 1967; 42:899-912.  
14. Brandt L, Hagander B, Norden A, et al. Lymphoma of the small intestine in adult 
coeliac disease. Acta Med Scand 1978; 204:467-470. 
15. Holmes GKT, Prior P, Lane MR, et al. Malignancy in coeliac disease: effect of a 
gluten free diet. Gut. 1989; 30:333-338. 
16. Marsh MN. Bone disease and gluten sensitivity: time to act, to treat, and to prevent 
[editorial]. Am J Gastroenterol. 1994; 89:2105-2107. 
17. McFarlane XA, Bhalla AK, Reeves DE, et al. Osteoporosis in treated adult coeliac 
disease Gut. 1995;36:710-714. 
18. Corazza GR, Di Sario A, Cecchetti L, et al. Bone mass and metabolism in patients 
with coeliac disease. Gastroenterology.1995;109:122-128. 
Histopathological aspects of coeliac disease 
 
 
 
 
 
 
78 
 
19. Collin P, Reunala T, Pukkala E, et al. Coeliac disease: associated disorders and 
survival. Gut. 1994; 35:1215-1218. 
20. Mulder C, Rostami K, Marsh MN. When is a coeliac a coeliac? 
[Letter] Gut. 1998; 42:594. 
21. When is a coeliac a coeliac? Report of a working group of the United European 
Gastroenterology week in Amsterdam, 2001.  Eur J Gastroenterol Hepatol. 
2001;13:1123-1128.
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter VI 
 
 
Interobserver variation in the histopathological diagnosis of coeliac disease 
 
Meijer, JW, Wahab PJ, Mulder CJJ and van Krieken JH 
 
From the departments of histopathology and Gastroenterology of Rijnstate 
Hospital, Arnhem 1,2, Department of Gastroenterology of VU Medical Centre, 
Amsterdam 3  and department of Pathology Nijmegen Medical Centre Nijmegen 4 
 
Submitted 
  
 
 
 
 
 
 
 
 
 
Chapter VI 
 
 
81 
Abstract 
 
Coeliac disease (CD) is a chronic condition caused by an inflammatory reaction to 
gluten, which is treated by a lifelong gluten-free diet. The underlining lesion caused by 
this disease is an intraepithelial lymphocytosis with or without hyperplastic/destructive 
lesions in the small bowel (SB). The small bowel biopsy is still the gold standard for 
this disease. It is of the utmost importance that a reliable histopathological diagnosis is 
given of the small bowel biopsy. In this article 494 SB biopsies taken from supposed 
coeliacs throughout the Netherlands, were reviewed from 1985 until 2003.  Eleven 
percent of the biopsies were discordant when compared with the panel diagnosis of two 
experienced investigators, JM and JvK. In comparison to this panel diagnosis, the 
diagnosis of coeliac disease was rejected in more than 6% of these biopsies and hence 
shown to be false positive due to an overestimation of atrophy in the absence of a 
significant intra-epithelial lymphocytosis or lack of realisation that not all intraepithelial 
lymphocytosis is coeliac disease related. 
In 5 % of the cases, the panel diagnosis was positive for coeliac disease, whereas the 
original diagnosis was negative, and these false negative interpretations were mainly 
due to an underestimation of intraepithelial lymphocytosis with or without an 
underestimation of atrophy. 
From this, it can be concluded that the interpretation of intraepithelial lymphocytosis as 
the hallmark lesion in coeliac disease and the realization that not all intra-epithelial 
lymphocytosis is CD- related is important.  The diagnosis should be supported with 
adequate clinical and serological information before a patient is put on a lifelong gluten-
free diet. 
Keywords: Coeliac disease, morphology, interobserver variation 
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Introduction 
 
Coeliac disease is a T-cell driven disease seen in genetically susceptible individuals 
following an enteric encounter with gluten proteins in wheat, rye and barley and is often 
accompanied by malabsorption of nutrients. This disease is a T-cell driven immunologic 
reaction in which small peptides are deaminated by tissue transglutaminase and 
presented via certain HLA molecules on antigen presenting cells to CD4 and CD8 
cytotoxic cells. On immunohistological examination, the intraepithelial lymphocytes in 
CD show a surface CD3+, CD8+, CD103+ phenotype and evoke a vacuolar destructive 
response in the surface epithelial cells. Mucosal damage, which is most marked in the 
proximal small intestine, is characterized by a spectrum of morphological alterations 
that range from minimal to complete villous atrophy, an increased infiltrate of 
lymphocytes, increased numbers of intraepithelial lymphocytes and crypthyperplasia.  
The result is a multiorgan disease with a variable clinical manifestation. Other mucosal 
sites such as the colon, stomach, oesophagus and upper digestive mucosa can also be 
affected.  
A small bowel biopsy is considered the gold standard in the diagnosis of coeliac 
disease1,2.  In earlier literature the diagnosis of coeliac disease was accepted only when a 
total atrophic lesion was recognized in the biopsy3,4. In the last decade, earlier 
histological stages of the disease have been reported in which infiltration of only T-
lymphocytes in the epithelium and less severe architectural abnormalities are 
present5,6,7,8. One should realize that a differential diagnosis of these earlier stages is 
much broader than that of the atrophic stages of coeliac disease. The currently used 
basis of classifying lymphocytic enteritis, with or without crypthyperplasia and (partial) 
villous atrophy, was given by Marsh et al, who described in detail classifiable 
morphological abnormalities which are presented in the discussion. A relation between 
the severity of histological abnormalities and the serological parameters of the disease is 
also described; in the early stages of the disease, classical serological parameters could 
even be negative 9,10. Especially in these early stages the histological diagnosis is 
equivocal since other diseases, such as Helicobacter pylori gastritis, peptic duodenitis, 
Crohn’s disease, Giardia, viral illnesses, etc., could give rise to abnormalities that could 
easily be misinterpreted as early coeliac disease18,19,21. The role of the pathologist is 
critical in the diagnosis of coeliac disease because there are pitfalls in assessing biopsy 
specimens. 
It is vital to get an adequate number of biopsies from the distal duodenum or jejunum to 
ensure an optimal sectioning of the biopsy specimen as all of these can result in false 
positive and negative diagnoses 11. There are difficulties if there are no architectural 
abnormalities and changes are limited to an increase of intraepithelial lymphocytes. 
There is a debate in the literature about abnormal counts with arbitrary values of 
between 30-40 lymphocytes per 100 enterocytes being used where normal counts are 1 
to 25 lymphocytes per 100 epithelial cells5,6,7,8.  
The objective of this paper is to investigate the accuracy of the histopathological 
diagnosis of coeliac disease and to give an overview for reasons of possible 
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histopathological mistakes in diagnosing coeliac disease.  One has to consider that in a 
disease such as coeliac disease, in which a continuum of histopathological abnormalities 
exists; one always will encounter discrepancies between histopathological evaluations. 
Many studies have been performed in different areas of cyto- and histopathology, which 
have never shown a perfect correlation even between highly experienced observers12. 
 
Material and methods 
 
In the period between 2000 and 2003 a series of SB biopsies were reinvestigated for 
reasons of second opinion and nationwide studies of different aspects of coeliac disease 
for which second opinions of the biopsies to confirm or exclude coeliac disease were 
necessary27,28,29,30.  These biopsies were taken between 1985 and 2002 from patients 
from throughout the Netherlands. From all of these cases at least 2 H&E slides were 
available and, when necessary, a tissue block was requested. The original 
histopathological reports were also available for this comparative study. 
Two of the authors (JWM, JHK) independently revised the biopsy cohort of the above-
mentioned period. In cases where discrepancies existed between the two observers in a 
multihead-microscope discussion, agreement on abnormalities was reached in all cases 
(expert opinion). 
The reviewers scored the biopsies according to the modified Marsh classification in 
which Marsh 0 is light microscopically a normal biopsy.  A Marsh I showed only 
intraepithelial lymphocytosis of more than 30 IEL per 100 epithelial cells without 
architectural abnormalities. In Marsh II a significant rise of IEL and crypthyperplasia 
was present but without shortening of the villi. Marsh IIIA is characterized by a villus to 
crypt ratio of less than 1:1 in addition to a significant rise of IEL. Marsh IIIC is 
characterized by a total absence of crypts. A Marsh IIIB lesion is in an intermediate 
position between Marsh IIIA and IIIC9, 13 with subtotal atrophy of the villi. 
In the original histopathological reports, there frequently were no clear general 
statements regarding the modified Marsh classification9, so that a reconstruction of the 
Marsh classification was made based on the statements concerning atrophy and 
inflammation in the original reports. A difference between the original and the review 
diagnosis with more than one class difference was considered disconcordant. Because 
the clinical importance of the threshold between Marsh II and IIIA (Marsh IIIA is 
considered definite proof of coeliac disease), an exception was made in these cases. 
 
Results 
 
In the above-mentioned period a total of 494 SB biopsy samples of different patients 
were revised (see table I).  The male/ female ratio was 1: 2. One hundred and fifty SB 
biopsies were from patients diagnosed 20 years or younger.  Age ranged from 4 to 78 
years.  
From the total of 494 SB biopsies, 463 were concordant (89%) and 58 were discordant 
(11 %) when compared to the expert diagnosis. In the discordant group (58 patients), 31 
(6.28%) were over-classified and 22 (4.45%) under-classified.  
Over-classification was mainly caused by overestimating a real or pseudo-atrophy in the 
absence of significantly elevated IEL’s (13/31). Ten out of 31 cases of over-
Histopathological aspects of coeliac disease 
 
 
 
 
 
 
 
84 
 
classification were caused by badly orientated and/or small biopsies, and the remaining 
cases of over-classification were the result of peptic inflammation due to Helicobacter 
pylori gastritis (in cases where gastric biopsies were also available) or ectopic gastric 
mucosa (picture I) in the small bowel (5/31) and non-recognized Giardia parasites as a 
cause of inflammation and atrophy (3/31, picture II). Peptic-like lesions in the small 
bowel showed minor atrophic lesions with a moderate increase in intraepithelial 
lymphocytes but with much more polymorphic granulocytes within an edematous 
lamina propria stroma with or without erosions. Crohn’s disease was not histologically 
recognized in our series. 
Under-classification was mainly caused by under appreciating the significance of the 
presence of intraepithelial lymphocytes (13/22) in architecturally normal biopsies and of 
underscoring intraepithelial lymphocytosis in combination with partial villous atrophy 
(9/22). In 5 biopsies an underestimate was made in the grade of structural abnormality: 
the original histological diagnosis was Marsh I/II and the second-opinion diagnosis was 
Marsh III, implying villous atrophy. A difference between Marsh I and II was 
considered as concordant as was the case with one class difference between the class III 
lesions. 
 
Discussion 
 
The histological abnormalities in coeliac disease have been described in detail by  
Marsh14,15,16.  He described a spectrum of histological changes ranging from “normal” 
in which only elevation of enzymatic tissue markers could be detected to flat lesions 
characterized by intraepithelial lymphocytosis and hyperplastic/atrophic lesions.  Type I 
infiltrative lesion is characterized by intraepithelial lymphocytosis without architectural 
changes. Type II infiltrative/hyperplastic lesion shows intraepithelial lymphocytosis 
with crypt hyperplasia with more or less normal villi (the epithelial damage is 
compensated by regeneration). Because regeneration cannot cope with the destruction 
rate, the villi eventually disappear and a type III destructive lesion results. In most cases 
this is the end situation, but in a few cases an atrophic lesion without much more 
inflammation can be recognized (type IV). 
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Fig I: Original Marsh classification (from Marsh, MN, ed. M (2000) Coeliac Disease: 
Methods and Protocols. Humana Press Inc) 17 
 
Our group modified classification9,13. We subdivided type III lesions into partial villus 
atrophy (IIIA), subtotal (IIIB) and total villus atrophy (IIIC). By definition Marsh IIIA 
lesion shows intraepithelial lymphocytosis with a villus crypt height ratio of equal to or 
less than 1:1. In Marsh IIIC no villi are recognized, and Marsh IIIB is an intermediate 
between the two. The rationale for this classification is threefold. First, it fits the former 
classification that is well recognized among histopathologists. Furthermore, it marks the 
important transition from Marsh II to Marsh III lesions, which parallels the clinical 
interpretation of the pathological reports: Marsh IIIA lesions are conclusive for coeliac 
disease, whereas Marsh II lesions have not been until now. Third, these histological 
abnormalities correlate with serological findings9,10,13 
The primary and basic histopathological abnormality is intraepithelial lymphocytosis. 
The measurement of intraepithelial lymphocytes (IEL) seems straightforward, but in 
clinical practice one should realize that unless strict criteria are met, there is a risk of 
over-interpretation of intraepithelial lymphocytosis. In other illnesses, such as 
Helicobacter-associated gastritis18, Giardia19,20, Crohn’s disease21, and autoimmune 
disease, intraepithelial lymphocytosis can be recognized, albeit it is less severe. In the 
diagnostic evaluation of supposed coeliac disease, it is strongly advisable to take 
biopsies from the stomach as well to exclude Helicobacter-associated gastritis, which 
could give rise to peptic duodenitis and intraepithelial lymphocytosis18. In Crohn’s 
disease, a biopsy of the stomach (in which a so-called focally-enhanced gastritis with or 
without granulomas could be present) is more informative and gives more histological 
clues about the diagnosis of Crohn’s disease than do the non-specific abnormalities in 
the proximal bowel and it can place intraepithelial lymphocytosis in the small bowel 
into perspective. (own experience,24,25)  
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Because histology with interpretation of small bowel biopsies and classification of 
abnormalities using strict criteria plays such an important role in the treatment of 
coeliac disease, it seemed useful to investigate the reliability of these histopathological 
diagnoses in a review study.  
In this 4-year study in which we reviewed 494 samples, a wrong diagnosis as compared 
to the expert diagnosis was made in more than 11% of the biopsies. In 6.2 % the 
diagnosis was false positive and in 5 % false negative (table III). The most important 
reasons for false positives are (pseudo)atrophic lesions resulting from badly orientated 
or small biopsies in the absence of IEL’s26.  
This stresses the importance of the presence of the intraepithelial lymphocytosis as the 
primary lesion and the presence of multiple biopsies of sufficient size in which at least 3 
intact villi can be evaluated.  
In healthy persons the number of intraepithelial lymphocytosis is reported to be 1.8-
26/100 epithelial cells (measured in full epithelial length), with an upper limit of 25 
lymphocytes per 100 epithelial cells 7. One has to realize that, when counting the IEL’s 
by using CD3-staining, one “overestimates” the number of IEL’s as compared to an 
H&E-stained slide. Veress et al 8 looked for the expression of CD3 and found a mean of 
10.8 intraepithelial cells per 100 epithelial cells in an H&E stain and 13.2 when a CD3 
stain is used. It seems clear that a CD3 stain gives better results in reproducibility, but it 
is also more time-consuming. A practical approach suggested by Biagi 22 is the 
estimation of the intraepithelial lymphocytes. This could be done be determining the 
ratio epithelial/lymphocytes which should be 1:5 (20 lymphocytes per 100 epithelial 
cells). For values above this number one should perform a CD3 stain in which the upper 
limit should be 25 lymphocytes. Values between 25 and 29 should be reported as 
borderline and values of 30 and more constitute a pathological diagnosis for 
intraepithelial lymphocytosis. Biagi et al22 suggested measuring intraepithelial 
lymphocytes in the villous tip in which IEL scores were 4.6 (SD, 1.5; range, 1.4–7.8) in 
non-coeliac controls and 9.2 (SD, 4.7; range, 5.8–21.8) in patients with CD.  
The significance of recognizing intraepithelial lymphocytosis in a small bowel biopsy 
without an atrophic lesion in an otherwise “healthy” patient is far from clear. In their 
study, Kakar et all5, found that 10% of patients  with an isolated intraepithelial 
lymphocytosis will develop coeliac disease. In a series of studies by Mahadeva et al6, 42 
% of cases with isolated intraepithelial lymphocytosis develop CD or are considered to 
have latent coeliac disease. After describing gluten challenge in Marsh I cases, we 
described a progression to a Marsh III lesion in 12 of 38 cases. After treatment with a 
gluten-free diet, all 12 patients showed relief from their symptoms23 with normalization 
of mucosal architecture.  
Intraepithelial lymphocytosis could give rise to a false positive diagnosis. A rise in 
IEL’s with or without structural abnormalities can caused by Helicobacter-associated 
gastritis, Giardia and other enteric infections, which could be an important reason for 
mistakes.  
Peptic lesions are recognized by the presence of erosions, polymorphic granulocytes, 
but usually cause a non-significant increase in intraepithelial lymphocytosis. In the 
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literature Crohn’s and autoimmune enteropathy are mentioned as other pitfalls for an 
incorrect diagnosis. In our series we did not have a single case of Crohn’s disease. 
Helicobacter gastritis, and probably also Crohn’s disease, might be better recognized in 
gastric biopsies, and we strongly advise combining a duodenal with gastric biopsies in 
evaluating small bowel pathology. In Crohn’s disease diagnostic abnormalities (focally 
enhanced gastritis: focal collections of lymphocytes and histiocytes) seem more 
prominent in the stomach than in the duodenum of patients who are clinically suspected 
of having Crohn’s involvement of the proximal bowel24, 25. 
One should keep in mind that coeliac disease can also co-occur with Giardia, Crohn’s 
diseases and autoimmune abnormalities. 
 
 Conclusion 
 
Biopsies of the small bowel remain the gold standard for diagnosing coeliac disease. 
The recognition of epithelial lymphocytosis as the primary lesion followed by variable 
atrophic lesions is the key to evaluating the spectrum of gluten-sensitive enteropathy. 
Recognizing earlier phases of the disease challenges the interpreting capacities of the 
histopathologists and differential diagnostic problems will increase in these situations. 
Lesions such as gastritis, Crohn’s disease, infections etc. give rise to intraepithelial of 
lymphocytosis.  Clear communication between histopathologists is mandatory in order 
to prevent over-diagnosing cases of intraepithelial lymphocytosis and pseudo-atrophy 
(without significant rise of IEL). When in doubt, an experienced gastrointestinal 
pathologist should be consulted.  
A “normal” biopsy in which mild lesions are present within the spectrum of 
glutensensitive enteropathy (Marsh I an II) should not exclude the diagnosis of coeliac 
disease and could give lead to a further evaluation of the patient, including the 
possibility of gluten challenge. 
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Table 1     
Number of 
biopsies 
Male Female Age < 20 Age > 
20 
494 165 329 170 324 
Table 2   
Total 494 
Concordant 436 
Discordant 58 
%  Discordant 11,74 
False positive 31 
% FP 6,28 
False negative 22 
% FN 4,45 
Underestimated 
Atrophy 
5 
%Underestimate 
Atrophy 1,01 
Table 3  
False positive  
(pseudo)atrophy, no 
IEL,s 
23 
Peptic inflammation 5 
Giardia 3 
Crohn’s disease and 
others 
0 
False negative  
Missed IEL 13 
Missed IEL and atrophy 9 
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Figure I: Gastric metaplasia 
 
 
 
 
 
 
 
 
 
 
 
 
H&E, x100: Overview: Atrophic duodenal mucosa    
 
 
 
 
 
 
 
 
 
 
 
H&E, x200: increased number of intraepithelial    lymphocytes and underlying gastric 
glands 
 
Figure II: Giardia 
 
 
 
 
 
 
 
 
 
 
 
H&E; x200; Duodenitis with increased number of intraepithelial lymphocytes, Giardia 
lamblia parasites (arrow)
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Abstract 
 
Refractory coeliac disease (RCD) can be subdivided into subtypes I and II. Type II 
contains phenotypically abnormal cells. In this study, we have evaluated the subtypes of 
lymphocytes in 27 RCD patients by using immunohistochemistry (IHC), flowcytometry 
(FCM) and T-cell receptor rearrangement (TCR). The data are compared to normal 
controls, uncomplicated CD and CD-related T-cell lymphoma. The data were also 
related to the patients’ final situation. 
Results:  In 27 cases of refractory coeliac disease the IHC and FCM data compared well 
in 25 cases. In only 2 cases a discrepancy was seen between FCM and IHC. The 
prognosis for the group of patients with phenotypically abnormal lymphocytes detected 
by ICM and FCM (n=14) was far worse than in the group without these cells. Eight of 
these 14 patients died. Four died of an enteropathy-associated T-cell lymphoma 
(EATL), and one of them also had ulcerative jejunitis. Three died of ulcerative jejunitis, 
two of whom died of a concomitant sepsis. One patient died of sepsis only. In the group 
of patients tested for clonal versus non-clonal TCR rearrangements in their biopsies 
(N=33), 7 patients of the patients with clonal rearrangement (N=20) died. Two patients 
died of EATL, one of ulcerative jejunitis, two of sepsis and jejunitis and two of sepsis. 
In the group of patients with the polyclonal rearrangements (n=9) two died of EATL, 
one of whom also had an ulcerative jejunitis. In both patients phenotypically abnormal 
T-cells were found by using IHC and FCM. 
Conclusion: Both IHC and FCM are capable of detecting relevant phenotypically 
abnormal T-cells in the biopsies of RCD patients. IHC is an easy technique that can be 
performed in most routine pathology departments. 
The T-cell receptor rearrangement could be an addition to both techniques but, since it 
is also seen in normal persons and in classical CD clonal rearrangement, it therefore 
seems less specific. 
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Introduction 
 
Coeliac disease is a wasting (small) bowel disease in childhood and adulthood and is 
characterized by small bowel mucosal inflammation and mucosal injury. The disease is 
seen in genetically predisposed individuals following an enteric encounter with gluten 
proteins in wheat, rye and barley1. 
Histologically this disease is characterized by an increase of inflammatory cells in the 
lamina propria, particularly plasma cells and lymphocytes. The most striking lesion is 
an intraepithelial influx of lymphocytes. This is followed by the destruction of epithelial 
cells and a reparative hyperplastic reaction in the crypts. Because the reparative 
response cannot cope with the rate of destruction there is a progressive loss of villi. The 
immunological reaction is an HLA-DQ restricted lymphocytic reaction towards 
deaminated peptides from gluten. Antigen presenting cells present these to CD4- 
positive T-cells. The stimulation and attraction of intraepithelial CD8 positive effector 
T-cells, which are also positive for CD103, CD3, CD5 and CD7, is much less well 
understood.  Interleukin 15 is believed to play an important role2. These cells have a 
predominant /ß T-cell receptor and, to a lesser extent, a / T-cell receptor. 
Most symptomatic patients with coeliac disease respond well to the instigation of a 
gluten-free diet (GFD). Less than 5% of these patients fail to responds to a GFD or 
show a relapse of symptoms and morphological abnormalities after initial response to 
GFD.  This serious condition is called refractory coeliac disease (RCD,) that is further 
subdivided into refractory coeliac disease type I and II 3. 
In RCD type I there is a variable histological picture with phenotypically normal 
intraepithelial cells. Thorough diet evaluation is necessary because unrecognized dietary 
mistakes may be present.  RCD type I patients responds in general to treatment with 
immunosuppression by Prednisone/Azathioprine16 
In RCD type II refractory coeliac disease phenotypically abnormal T-cells are detected 
either by immunohistochemistry (IHC) or flowcytometry (FCM)5, 14.  
RCD type II is a serious clinical condition with a high rate of complications including 
ulcerative jejunitis and an aggressive type of malignant lymphoma (EATL). In the 
treatment of patients with RCD type II one has to consider potentially heavy treatment 
protocols such as chemotherapy and bone marrow transplantation. 
In patients without a clear-cut malignant tumor it could be very hard to decide between 
these potentially life-threatening treatment options.  Reliable techniques are needed to 
make a reliable diagnosis. 
The purpose of this study is to investigate the usefulness of the different techniques 
(IHC, FCM, and TCR) to detect abnormal lymphocytes in the mucosa in relation to the 
patient’s final situation in a patient group with RCD. As our control, we have used 
patients with non-complicated CD, patients with upper abdominal complaints but with 
no signs or symptoms of CD and a small group of patients with coeliac disease-related 
lymphoma. 
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Material & Methods 
 
Patients and Controls 
 
Thirty-three adult patients (20 women, 13 men) with a mean age of 59 years (30-82 
years) with RCD were studied between 1998 and 2002. There was no history of coeliac 
disease (CD) in childhood, but patients either had a short history of CD or were directly 
diagnosed as having RCD 1998 and 2002. Most of them failed to improve (clinically 
and histologically) on a gluten-free diet; all of them were negative for anti-gliadine- and 
anti-endomysium-antibodies, except one patient who was antigliadine-negative and anti 
endomysium positive. Clinical progress varied: some patients did quite well without 
additional therapy, some needed immunosuppression or chemotherapeutics 
(Azathioprine/Cladribine) and some deteriorated very fast, including a few who 
developed obvious enteropathy associated T-cell lymphoma (EATL). 
As controls the following patient groups were chosen: 
Fourteen adult patients with CD, with a mean age of 49 years (19-71 years), improved 
(clinically and histologically) on a GFD. 
Fifteen adults with a mean age of 42 years olds (20-66 years) examined mostly for 
upper abdominal complaints or diarrhea without histological or other abnormalities in 
the small bowel. 
Three patients with Enteropathy Associated T-cell Lymphoma (2 men, 62 and 59 years 
and a woman, 50 years) 
 
Methods 
 
Assessment of TCRB and TCRG gene rearrangement by Polymerase Chain Reaction 
(PCR) amplification  
DNA was extracted from 10-20 µm frozen sections of small intestinal biopsy specimens 
by using proteinase K treatment (20 mg/ml) and ethanol precipitation of the genomic 
DNA. The quality of the genomic DNA was assessed by PCR-amplification of a 
housekeeping gene (FSH-receptor) by using the forward primer p125 (5’- 
CTACCCTGCACAAAGACAGTG–3’) and the reverse primer p129 (5’-
CAAGGAGGGACATGACATACAGC –3’). The expected FSH-R product of 830 base 
pairs (bp) was amplified in all genomic DNA’s examined. 
TCRB and TCRG gene rearrangements were assessed using the primers and PCR 
protocols developed in the Biomed-2 concerted action BMH4-CT98-3936 18. Different 
multiplex PCR systems were performed to amplify VJ-and DJ-rearranged TCRB genes 
(2+1 multiplex PCRs) and VJ-rearranged TCRG genes (2 multiplex PCRs). Multiplex 
PCRs were performed in 50µl reactions, using 100 ηg of genomic DNA, 10 ρmol each 
of forward and reverse primer, and 0.2 mM dNTPs, buffer ll, with the concentration of 
MgCl2 and AmpliTaq Gold DNA polymerase being target-dependent. For DJ-
rearranged TCRB and VJ-rearranged TCRG genes 1, 5 mM MgCl2 and 1 µ AmpliTaq 
Gold DNA polymerase was used, whereas 3,0 mM MgCl2 and 2 µ AmpliTaq Gold 
DNA polymerase was used for VJ-rearranged TCRB genes. 
PCRs were performed on an automated thermocycler (PTC-200, Peltier Thermal 
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Cycler). DNA was denatured at 94°C for 10 minutes, followed by 35 cycles of 
denaturation at 92°C for 30 seconds, primer annealing at 60°C for 40 seconds, and 
extension at 72°C for 1 minute. A final elongation step was performed for 10 minutes at 
72°. For each TCR target a monoclonal control (DNA from a cell line or from a clonal 
sample), a polyclonal control (DNA from mononuclear cells) and a negative control (no 
template DNA) were used as controls in the multiplex PCRs. After the presence of a 
PCR-product on agarose-gel had been confirmed, clonality assessment was monitored 
by heteroduplex analysis. 
For heteroduplex analysis, 3.5µl of the PCR-product was diluted 1:1 with loading 
buffer, denatured at 94°C for 5 minutes and subsequently renatured for 1 hr at 4°C to 
allow formation of homo- and heteroduplexes. Separation of the duplexes was 
performed on polyacrylamide gels, by using the Amersham Pharmacia GeneGel Excel 
Kit on a Pharmacia Biotech Electrophoresis Unit. Duplexes were visualized, after 
fixation of the gel in ethanol (29 %) by silver staining, using the Amersham Pharmacia 
silver staining kit.  
 
 
Histology and Immunohistochemistry 
 
2-4 Endoscopic duodenal biopsies of RCD patients and controls (in the period 1998 to 
2002) were fixed in 10% formalin and embedded in paraffin. The same amount of 
samples were frozen at -80°C in ethanol 100% in a histocompound medium (Histocon, 
Polysciences, Inc.) and stored at -80°C. H&E sections were made. Control H&E 
sections of the frozen tissue were made before and after taking material for DNA-
extraction in order to get a sample control. Separate biopsies were taken for 
flowcytometric evaluation.  Intra-epithelial lymphocytosis, crypthyperplasia and villous 
atrophy were defined on the basis of Marsh classification in which Marsh I showed only 
intraepithelial lymphocytosis of more than 30 IEL per 100 epithelial cells without 
architectural abnormalities. In Marsh II there was a significant rise of IEL and 
crypthyperplasia but no shortening of the villi. Marsh IIIA is characterized by a villus to 
crypt ratio of less than 1:1 in addition to a significant rise of IEL. Marsh IIIC is 
characterized by a total absence of crypts. Marsh IIIB lies between Marsh IIIA and 
Marsh IIIC3,4 
A three-stage indirect immunoperoxidase technique was used to label paraffin sections 
with a panel of monoclonal antibodies (CD3/PS1, CD8/4B11, CD30/BerH2, monosan 
extra line Sanbio), respectively. CD3/CD8 ratio was measured in an intact part of the 
mucosa. The total number of epithelial cells and as the total number of intraepithelial 
CD3 + and CD8 + lymphocytes were counted in 3 mm- surface lengths of villi. The 
numbers of CD3 and CD8 positive cells were divided.  A CD3/CD8 ratio greater than 2 
was considered abnormal5 
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Isolation of IEL and cell-staining for immunophenotyping 
 
For immunophenotypical evaluation 3-4 biopsies were taken and preserved in RPMI 
medium. IEL and enterocytes were isolated by homogenising tissue samples and 
passing fragments through a 100µm-nylon sew (Becton Dickinson, Cell strainer) in 
RPMI medium supplemented with 1% FCS. The released cells were subsequently 
washed and labelled by 3-color staining for 30 minutes at room temperature with 
fluorescin, rhodamin or PerCP-labeled monoclonal antibodies to CD3, CD4, CD8, CD2, 
CD7, CD95, CD103, CD19, CD16/56, γδTCR and cytoplasmicCD3. The FACS method 
used in this study was in accordance with the manufacturer’s guidelines. 
Cell surface immunophenotyping of IEL was performed by 3-colour FACS analysis. 
CD45 CD14 and CD33 were used to select IEL’s from all epithelial cells. Intraepithelial 
localisation of lymphocytes was confirmed by surface expression of CD103, a member 
of the integrin family (αEβ7). IEL’s were analysed based on their expression of cell 
markers: cytoplasmic CD3, surface CD2, CD3, CD4, CD7, CD8, CD16/56, CD19, 
CD94, CD95, CD103 and TCRγδ on CD45+ gated IEL’s. 
An abnormal T-cell population is defined as lacking surface expression of CD3 in the 
presence of cytoplasmic CD3 and sometimes lacking CD8 in the presence of CD2, CD7 
and CD103. 
 
Results 
 
In this study the data of morphology, IHC, FCM and the molecular profiles of TCRB 
and TCRG gene rearrangements were assessed in 34 cases of refractory coeliac disease, 
14 cases of classical coeliac disease, 3 cases of Enteropathy Associated T-cell 
Lymphoma and 15 subjects with endoscopy for upper abdominal complaints but whose 
morphology showed no histological abnormalities in the proximal small bowel biopsy. 
 
Histological and Phenotypic findings 
 
Of the CD patients 5 were histologically classified as MII, 4 as MIIIA, 3 as MIIIB and 2 
as MIIIC. No aberrant T-cell population was seen. Of the RCD patients, 3 were 
histologically classified as MI, 7 as MII, 12 as MIIIA, 6 as MIIIB and 3 as MIIIC (table 
I).  In 27 of the 31 patients in whom a TCR was performed, a CD4/CD8 ratio was 
determined and an FCM was determined in 28. 
The CD3/CD8 ratio of 27 patients, determined with IHC and FCM data, could be 
compared (table II). All were positive for CD3, and a both techniques showed a 
significant loss of CD8 in 14. In the series in which no abnormal cells in FCM could be 
detected, IHC data showed 2 cases in which the CD3/CD8 ratio was abnormal. 
In the group of patients with an abnormal phenotype (n=14), 7 were found to have focal 
CD30-positive intraepithelial lymphocytes. This CD30 staining highlighted focal 
slightly abnormal T-cells. In three of these patients an EATL developed.  
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Molecular findings 
 
In the small intestinal biopsy of the group of classical coeliac disease patients, 12 of the 
14 samples showed a polyclonal pattern of TCR rearrangements, indicating the presence 
of a polyclonal T-cell population, as expected.  Two of the patients, however, showed a 
weak clonal TCR or TCR rearrangement in a polyclonal background (weak clone), 
indicating the presence of T-cell clones in these tissues.  
As expected, we observed TCR rearrangements in the TCR gene and, in some cases, in 
the TCR gene in all (3) of the EATL patients.   
In the group without aberrations we found a large number of patients with clonal 
rearrangements in the TCR and/or TCR genes: 4 of 15 showed obvious TCR 
monoclonality (and 2 a weak clone), of whom 3 also showed TCR monoclonality. One 
showed a TCR clone and weak monoclonality for TCR. The other 8 did not show 
TCR gene rearrangement.  
Thirty-three patients were analyzed in the group of RCD. Of these patients, 20 showed 
obvious TCR gene rearrangement for TCR, TCR or both. (Another 2 ‘developed’ 
TCR gene rearrangement within one to two years). Seven of the monoclonal group of 
RCD patients have died, 2 of whom of a (EAT) lymphoma, 2 of sepsis, 2 of sepsis and 
ulcerative jejunitis and 1 of ulcerative jejunitis. 
The other 13 are doing well clinically; although 7 have received therapy (5 with 
Cladribine, 2 with 6-Thioguanine), and 6 are not doing well. 
Two of the 9 polyclonal RCD patients have died, one of an EATL, and the other of 
panniculitis-like extra intestinal T-cell lymphoma. The other 7 go clinically well, 
however 6 with therapy (Azathioprine + Prednisone) and one without. 
There were 4 RCD-patients who showed only ‘weak’ monoclonality; 1 of them died of 
sepsis (immune compromised), and 3 were doing well clinically with therapy 
(Azathioprine + Prednisone). 
 
Discussion 
 
Most symptomatic patients with coeliac disease respond well to the instigation of a 
gluten-free diet (GFD). Especially in adults, this recovery could take several months or 
longer 6,8.  More than 5 % of patients do not respond at all to a GFD or show a relapse 
of symptoms and morphological abnormalities after an initial response to GFD 9.  This 
is in part due to reasons outside the small bowel, i.e. lymphocytic colitis, pancreatic 
insufficiency, infections etc.  In the patient group with remaining histological 
abnormalities (more than 12 months after instigation of a GFD or with earlier serious 
complaints and where no other cause of the clinical detoriation could be found), this 
potentially serious condition is called refractory coeliac disease, which is, further 
subdivided into refractory coeliac disease type I and II.  
In type I there is a variable histological picture with phenotypically normal 
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intraepithelial cells.  
In type II refractory coeliac disease phenotypically abnormal T-cells are detected by 
IHC and FCM. A variable loss of CD3, CD7 and CD8 surface markers by IHC and 
FCM may be found. In FCM a transition from membranous towards cytoplasmic CD3-
positive T-cells (more immature phenotype) and a shift from T-cells with an /ß T-cell 
receptor to a / T cell receptor can be present. Molecular biological techniques can be 
used to detect a monoclonal rearrangement of the T-cell receptor.  
In RCD I the risk of lymphoma is very low. We had none and all patients survived so 
far, but the risk   and increased mortality are reported in literature. 8,17 
RCD II is considered by more than a few authors to be a so-called cryptic lymphoma 
13,16,17,
. The definition of a malignant tumour is uncontrolled growth leading to some 
kind of a mass effect. This could be solid or circulating/disseminated, as is the case in 
leukaemia. In RCD II circulating abnormal T-cells are present 16. Also in other organs, 
abnormal cells could be detected, most frequently described in the stomach as 
lymphocytic gastritis and in the colon as lymphocytic colitis16.  
The present study shows that the detection of abnormal T cells by means of a loss of 
marker CD8 found by IHC, a loss of surface markers CD8 and a transition to a more 
immature T-cell type with transition from membranous CD3 to cytoplasmic CD3 by 
means of FCM give good comparable data.  
In 14 patients an abnormal phenotype, defined as a significant loss of CD8 positivity in 
intraepithelial lymphocytes in immunohistochemistry (IHC), a loss of CD8 positivity 
and a switch from normal surface CD3 to cytoplasmic CD3 in flowcytometry (FCM) 
were equally detected by both IHC and FCM. In 13 patients with normal FCM results 2 
patients showed loss of CD8 in IHC. Both patients did well on a strict gluten-free diet. 
Of fourteen patients with an abnormal phenotype, 4 developed an EATL, 3 an ulcerative 
jejunitis (2 of whom with sepsis) and 1 developed only sepsis. 
None of the thirteen patients with normal lymphocytic phenotype developed an EATL 
or a UJ.  
In the control group, formed by patients with non-specific abdominal complaints, 2 of 
the 14 patients showed clonal TCR or TCR.  In a routine histological exam, a very 
low number of lymphocytes were present, a possible reason being pseudo-clonality in 
which one or a few cell(s) are amplified.  
In the classical non-complicated coeliac disease group, 4 of 17 patients had clonal 
rearrangements in their biopsies. Two of the four abnormal clones were weak clones. In 
the follow-up, no adverse events took place; one patient with clonal rearrangement did 
not use a GFD at the time of the biopsy.  
In the group of patients with RCD, 20 of the 33 patients showed obvious TCR gene 
rearrangement. Another 2 developed a clonal pattern within 2 years. In this clonal group 
7 patients died: 2 of lymphoma (EATL), 3 of ulcerative jejunitis (2 of whom with 
sepsis) and 1 of isolated sepsis. Of the 13 patients who had phenotypically abnormal 
cells on FCM/IHC, 11 had a clonal pattern. One of the polyclonal patterns with 
phenotypically abnormal cells developed an extra-intestinal T-cell lymphoma. In 
conclusion we can say that the measurement of CD3/CD8 ratio in small bowel biopsies 
of RCD patients is useful because it can divide the patients into two groups with 
different prognoses.  
Especially the IHC measurement of the CD3/CD8 ratio can be performed in most 
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routine pathology departments and is easy to implement; an adjunct CD30 stain in these 
patient groups easily highlights few larger atypical cells. It is tempting to say that these 
are the cases which are not far away from developing a T-cell lymphoma, although 
roughly half of the cases with CD30 positive cells have not yet developed a T- cell 
lymphoma..With regard to the usefulness of sophisticated techniques such as TCR 
rearrangement, more studies are needed. Since classical cases of CD can be positive, 
care should be taken not to overinterpret the results. A place could be reserved for 
selected cases in which all the support is needed to make a difficult decision about 
aggressive type of therapy in these seriously ill patients. 
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Table I: Marsh classification in classical coeliac disease and refractory coeliac disease 
 
 MI MII MIIa MIIIb MIIc 
CD  5 4 3 2 
RCD 3 7 12 6 3 
 
 
Table II: Phenotype in coeliac disease measured with FCM and IHC  
 
 FCM Normal Aberrant 
CD3/CD8    
Normal  11 0 
Aberrant  3 14 
 
Table III: Deaths in patients with phenotypically aberrant cells (no deaths in 
phenotypically normal group) 
 
 
 EATL Sepsis 
IHC aberrant 6 2 
FCM aberrant 5 2 
TCR polyclonal 2  
TCR small clone*  1 
TCR clonal 2 2 
*:  Small clone in a polyclonal background 
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Abstract  
 
Intestinal lymphomas encompass those lymphomas with a dominant or only localization 
in the intestinal tract. Coeliac disease is highly associated with enteropathy associated 
T-cell lymphomas (EATL). Coeliac disease-related lymphomas can appear at nodal or 
extranodal sites. EATL is often multifocal with ulcerative lesions, which explains the 
high perforation rate at presentation or during chemotherapy. 
Staging includes ear-nose-throat examination, CT-scan of chest and abdomen. PET-
scanning may be valuable. Accurate diagnosis based on endoscopic biopsies is 
preferable, if necessary full thickness laparoscopic small-bowel biopsies are mandatory. 
Refractory coeliac disease (RCD) with aberrant T-cells is extremely at risk to develop 
EATL. No satisfactory treatment for EATL exists, the only possibility seems to prevent 
EATL-development in RCD, autologous bone marrow transplantation might be a 
possibility. EATL can present in 20% as extra-small bowel T-cell lymphomas; such as 
subcutaneous panniculitis-like lymphoma, hepatosplenic / lymphoma, nodal and as 
sinus, gastric or colon lymphomas. The majority presents as large cell lymphoma CD3+, 
CD8-, CD30+, however they also present as small cell lymphoma CD3+, CD8+, CD30-. 
Sometimes we recognize / lymphomas in CD. Workup of EATL must include 
immunohistology, T-cell flow cytometry, T-cell rearrangement and adequate imaging 
with CT and PET-scanning. 
 
Keywords 
Coeliac Disease; T-cell lymphoma; Aberrant T-cells; Refractory Coeliac Disease; 
Ulcerative Jejunitis; / lymphoma; subcutaneous panniculitis-like T-cell lymphoma; 
extraintestinal lymphomas. 
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Introduction  
 
Primary gastro-intestinal lymphomas encompass those lymphomas with a dominant or 
only localization in the gastrointestinal tract and further fulfilling criteria as stated by 
Isaacson (1). Coeliac disease (CD) can be complicated by enteropathy-associated T-cell 
lymphoma. Recently we showed that CD is highly associated with enteropathy 
associated T-cell lymphoma also on a population-based level (2). An overview of the 
epidemiology, pathogenesis, clinical aspects, diagnosis and treatment of intestinal 
lymphomas and its relation to risk factors such as Helicobacter pylori and especially 
gluten is the purpose of this overview. 
Depending to the used definition, up to 40% of non-Hodgkin lymphomas arise in 
extranodal sites, especially in the gastrointestinal tract. In the Western world 
localization in the stomach is more frequent (± 55%) compared to localization in other 
intestinal sites, as small bowel (± 30%), large bowel (± 10%) and ileocaecal region (± 
5%) (3). Worldwide, large geographic differences exist in the relative distribution of 
intestinal lymphomas. It is not possible on clinical and endoscopic features to 
distinguish between primary gastro-intestinal lymphomas and nodal lymphomas with 
secondary gastrointestinal localization.  
Many different lymphoma classifications have been used in the past. A major 
shortcoming was that typical differences between nodal and extranodal lymphomas 
were not adjusted for (1). It has been emphasized in the recently formalized WHO 
classification to view the different lymphomas as “disease entities” with a characteristic 
morphological spectrum, immunological marker pattern and discriminative 
chromosomal aberrations (4).  
Monoclonality can be demonstrated in most intestinal lymphomas, both on paraffin-
embedded and fresh specimens, most conveniently by immunohistochemistry (IHC) in 
B-cell proliferations. If diagnostic difficulties arise, a polymerase chain reaction (PCR) 
or immunoglobulin gene T-cell receptor rearrangement can be performed. The vast 
majority of intestinal lymphomas are B-cell lymphomas (2,3).  
A major step forward has been the introduction of the MALT-concept by Isaacson and 
Wright in 1983 (5). Lymphomas originating in the Mucosa-Associated Lymphoid 
Tissue (MALT) were recognized as a separate entity that was characterized histological 
by a diffuse monotonous infiltrate of neoplastic centrocyte-like B-cells surrounding 
non-neoplastic follicles, with invasion and destruction of glandular tissue, forming 
characteristic lympho-epithelial lesions that are most easily recognized in gastric 
Helicobacter pylori related MALT-lymphomas (6). Intestinal T-cell lymphomas can be 
divided in: 1. Enteropathy (coeliac disease)-associated T-cell non-Hodgkin lymphoma 
(EATL), 2. Other T-cell non-Hodgkin lymphomas not associated with CD. However, 
we have to realize that CD-related lymphomas can appear at nodal or extranodal sites 
(7). 
 
Chapter VIII 
109  
Diagnostic criteria and molecular background 
 
The demonstration of monoclonality with an IHC / PCR on gastroscopic biopsies may 
support the diagnosis MALT-lymphoma. In 70-80% of these cases, monoclonality can 
be demonstrated (8,9). Biopsies may be histological lymphoma negative, but still show 
the presence of PCR-monoclonality in patients with concurrent lymphoma at other sites 
in the stomach or a previous gastric lymphoma. This can be explained by the presence 
of a low number of not yet microscopically detectable numbers of clonal cells in parts 
of the stomach or it may be a sign of minimal residual disease. In the large majority of 
cases it is possible to establish the diagnosis and subtype of gastric lymphomas on 
biopsy specimens (10).  
In large B-cell lymphoma of the stomach with or without MALT features the pattern of 
chromosomal aberrations is different compared to (low-grade) MALT lymphoma, 
suggesting different pathogenetic mechanisms (11). 
 
Small bowel malignancies 
 
In descending order of frequency the four malignant tumours of the small intestine most 
commonly encountered are primary adenocarcinoma, carcinoid, lymphoma and 
leiomyosarcoma (12). Most leiomyosarcomas are nowadays classified as 
gastrointestinal stromal cell tumours (GIST). 
High-grade lymphomas can be seen in association with coeliac disease (13). The 
following criteria should be met before defining a lymphoproliferative malignancy as a 
primary intestinal lymphoma: I: Absence of palpable lymphadenopathy; II: Normal total 
and differential leukocyte counts; III: Absence of mediastinal lymphadenopathy on 
chest radiography; and IV: Grossly demonstrable disease confined to the affected 
segment(s) of the gastrointestinal tract. 
Primary small bowel lymphomas in patients from Western countries were thought to 
present as localized tumours in contrast to diffuse small bowel lymphomas that are seen 
in the Middle East in patients with IPSID-related lymphomas (14). The Ann Arbor 
system has been used to stage small bowel lymphomas (15). Apart from the T-cell 
lymphomas that arise in the small bowel of coeliacs, the great majority of these are of 
B-cell origin (2). 
 
Clinical presentation of small bowel lymphoma 
 
The patient with small bowel lymphoma often presents with abdominal pain, signs of 
obstruction or even (spontaneous) perforation or haemorrhage. A palpable tumour may 
be found. Diarrhoea and weight loss due to malabsorption are important symptoms in 
IPSID and refractory coeliac disease (14,16). A history of CD in this context should 
alert the physical to look for a possible small bowel lymphoma or adenocarcinoma. 
Only in a minority of patients with localization in the proximal small bowel the 
diagnosis can be established on endoscopic biopsies. In most cases laparotomy is 
necessary to establish the diagnosis as well as part of the treatment (17). 
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Enteropathy associated T-cell lymphoma 
 
In the small bowel special precursor clones can be recognized with phenotyping and the 
presence of TCR-γ gene rearrangements (16). The immunophenotype of these cells 
differs from other nodal and extranodal lymphomas and is consistent with a derivation 
of intraepithelial T-lymphocytes (4). Macroscopically, Enteropathy Associated T-cell 
Lymphoma (EATL) is often multifocal with ulcerative lesions, which explains the high 
perforation rate at presentation or during chemotherapy (18). In 50% of the cases, the 
patient presents with an EATL, while the underlying CD was still silent. As the 
prognosis of overt EATL is extremely poor, the early detection of precursor clones with 
an abnormal T-cell population is of paramount importance.   
 
Burkitt-lymphoma 
 
The most frequent localization of Burkitt-lymphoma is the ileocaecal region. It often 
presents in children and young adults. Aggressive chemotherapy is indicated, also after 
surgical resection. 
 
Immunoproliferative Small Intestinal Disease (IPSID) 
 
If the disease, a variant of MALT lymphoma is recognized at an early stage, 
abnormalities restricted to mucosa and submucosa, antibiotic treatment alone may be 
sufficient to obtain a remission (14). In the past surgical exploration to determine the 
possible multifocal localization of the disease and high-grade transformation was 
strongly advocated. However, nowadays laparoscopy can probably replace a staging 
laparotomy. In later stages of the disease, chemotherapy including anthracyclins is 
indicated (19). 
 
Staging 
 
After establishing the diagnosis and histological grading/subtyping of intestinal 
lymphoma, the determination of the extension of the disease or stage is of paramount 
importance, both prognostically and for the choice of treatment. Staging procedures 
include physical examination, including an ear-nose-throat examination, full blood 
count and biochemistry, imaging of chest and abdomen by CT-scan, and bone marrow 
biopsy. PET-scanning (positron emission tomography) may be valuable, especially in 
large-cell lymphomas (20).  
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Treatment – General principles 
 
Intestinal lymphomas are nowadays considered as "disease entities" with a characteristic 
morphological spectrum, clinical presentation and course (4). As different diseases 
should be treated accordingly, a basic requirement to choose a therapeutic regimen is an 
accurate histological diagnosis, including subtyping, grading and staging. Obviously, an 
accurate diagnosis based on endoscopic biopsies is preferable, if necessary full-
thickness laparoscopic small-bowel biopsies should be taken. The group of primary 
intestinal lymphomas encompasses more different subtypes compared to primary gastric 
lymphomas (21).  
 
Coeliac disease and lymphomas 
 
CD is an inflammatory condition of the small intestine in which dietary gluten causes 
damage to the mucosa in genetically susceptible individuals. CD is a common disorder 
affecting 1:100 to 1:200 of the general Caucasian population (22). In the past it was 
unclear whether small bowel lymphoma was able to mimic CD or longstanding CD 
gave rise to intestinal lymphoma (23). Moreover, CD, ulcerative jejunitis and EATL 
have similar frequencies of HLA-haplotypes (24). A number of reports provide 
evidence that lymphomas arise in chronic CD, and malignant degeneration may be 
prevented by a strict gluten free diet (25). CD is associated with many complications, 
including osteoporosis, infertility, unfavourable outcomes of pregnancy, autoimmune 
diseases and malignancies. The most common malignancy associated with CD is a high-
grade, T-cell non-Hodgkin lymphoma of the small intestine, known as Enteropathy-
Associated T-cell Lymphoma (EATL). The relative risk for developing malignant 
tumours in coeliacs has been estimated as 2-3-fold: for cancers of the mouth, pharynx 
and esophagus as 2-3-fold, for EATL 30-40-fold and for small intestinal 
adenocarcinoma 80-fold. Patients with untreated CD are also at high risk of developing 
T-cell-lymphomas of any primary site (7). 
Most studies on the relationship between CD and lymphomas are centre-based and 
concern only clinically diagnosed (recognized) CD (25). Since the introduction of 
antibody tests for the purpose of mass-screening it became clear that CD is a far more 
common disorder that is undiagnosed in the majority of cases. Therefore, reassessment 
of the association of CD and lymphoma is necessary. In a case-series of patients with 
small-bowel lymphoma and adenocarcinoma a high frequency of CD was found (12). In 
a case-control study in lymphoma patients, the association between CD and EATL was 
confirmed (26). In a cohort study on cancer incidence in clinically diagnosed coeliacs 
the association with both lymphoma and intestinal adenocarcinoma was also confirmed 
(27). In the latter studies the relative risks were found to be much lower than thought 
before. However, data on CD in clinicallly diagnosed small bowel lymphoma patients 
are rare. In a recent study CD was highly associated with enteropathy-associated T-cell 
lymphoma. The odds ratio involved were extremely high, but since EATL is a very rare 
disease the resulting actual risk is low (2). 
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Refractory Coeliac Disease 
 
In a small subgroup of coeliacs, the clinical and histological abnormalities of CD persist 
or recur after initial improvement, despites strict adherence to a GFD (28). This non-
responsiveness leaves a poorly understood syndrome, known as refractory coeliac 
disease (RCD). Acknowledged pitfalls are a deliberate or unrecognized non-compliance 
with GFD, slow recovery of small intestinal mucosa, misinterpretation of the biopsies 
and failure to recognize other small-bowel diseases (29,30). Additional features 
supporting coeliac diasease should be sought, such as HLA-DQ typing, presence of 
autoantibodies in the past and reappearence of autoantibodies. Additional biopsies 
should be taken for immunohistology and T-cell flow cytometry to look for aberrant T-
cells and study T-cell receptor re-arrangement. With the availability of monoclonal 
antibodies against specific surface epitopes on T-cells, immunohistochemical staining 
for T-cell antigens has become an integral tool in the diagnosis of lymphomas and 
lymphoma related diseases. Aberrant T-cells are recognized by abnormal 
immunophenotyping. T-cell receptor ((TCR) gene arrangement have permitted the 
investigation of the clonality and differentiation of T-cells in tissues and peripheral 
blood. Refractory coeliacs can be divided into those without aberrant T-cells (type 1) 
and those with aberrant T-cells (type 2). A European working group considers coeliacs 
with ulcerative jejunitis to be RCD2, since their histology is not (yet) compatible with 
small bowel lymphoma (29). For treatment trials to be designed, DQ-typing and 
immunohistology are essential to compare results. RCD2-patients are extremely at risk 
to develop an EATL, and the majority of these patients dies within years due to an 
EATL (31,32). 
 
Ulcerative jejunitis (UJ) 
 
UJ is a rare condition first described in 1949 (33). Synonyms for this condition include 
idiopathic mucosal enteropathy, idiopathic chronic ulcerative enteritis, non-responsive 
coeliac disease, unclassified sprue and malignant histiocytosis. It develops in patients 
with coeliac disease and is characterized by villous atrophy, the presence of numerous 
granulocytes and small bowel ulcerations that fail to improve upon a gluten free diet. 
The etiology of UJ has only recently been elucidated (31). 
UJ occasionally occurs without a prior history of intestinal disease, and it differs from 
CD in its more extensive distribution and its failure to respond to gluten free diet. On 
the other hand, both UJ and CD can present with splenic atrophy (etiology unknown), 
and most cases of UJ are preceded by a variable period of suspected or proven CD. It 
seems therefore likely that UJ invariably develops as a complication of CD. 
UJ usually presents as a chronic illness with symptoms of diarrhoea, steatorrhoea, 
weight loss, and mid-epigastric pain. Bleeding, perforation, and stricture commonly 
complicate the clinical course but are rarely the presenting signs. The patients are 
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typically older than those with simple CD, and no paediatric cases have been reported 
(34). Most patients have a long history of malabsorption; over 80% admitted to have 
more than 1.5 years of severe symptoms (23), and patients with previously diagnosed 
CD were symptomatic for a mean of 13 years (35). 
There are no specific clinical findings. The majority of patients present with low-grade 
fever and signs of malnutrition. Physical findings may include finger clubbing, muscle 
wasting, oedema, and ascites (protein calorie malnutrition and protein loosing 
enteropathy), dermatitis (vitamin and iron deficiency), and hypocalcaemia. A subgroup 
develops complications of their ulcerations within a short period after their presentation 
including small bowel obstruction, meleana, and perforations, another subgroup 
develops an EATL. 
UJ occurs mainly in the proximal jejunum but usually extends into the ileum. 
Occasional cases of colonic and gastric involvement have also been reported. Mucosal 
ulceration is a frequent finding at surgery, although it is rarely seen in per oral biopsies. 
Formation of a distinct tumour mass is uncommon, but diffuse infiltration of lymphoid 
organs such as lymph nodes, spleen, liver, and bone marrow can be present already at 
the time of diagnosis. Some of these patients have splenic atrophy (36). 
The histological features include villous atrophy, crypt hyperplasia, intraepithelial 
lymphocytic infiltration, irregularity of surface enterocytes, and a dense infiltrate in the 
lamina propria consisting almost solely of plasma cells with a relatively high but 
variable number of eosinophils and neutrophils. In classical cases overt lymphoma 
localisation is not present. The infiltrate may obscure dispersed malignant cells, and the 
diagnosis of an early EATL may be missed (29). Phagocytosis of erythrocytes, platelets, 
and cell debris is a common feature, and invasion of the epithelial layer may cause 
ulceration. Other histological findings may include a subepithelial layer of collagen and 
prominent fibrosis of the ulcer base. 
 
Enteropathy-Associated T-Cell Lymphoma 
 
Lymphomas of the small intestine, especially of the jejunum are commonly of T-cell 
origin. T-cell lymphomas often occur in patients with a history of CD or dermatitis 
herpetiformis and are therefore called Enteropathy-Associated T-Cell Lymphoma 
(EATL). Occasionally, patients without a recognized history of CD are diagnosed with 
a T-cell lymphoma involving the small intestine, and CD is only recognized after the 
diagnosis of lymphoma has been made. Patients with EATL present usually in their fifth 
or six decade with worsening symptoms of diarrhoea and malabsorption. Imaging 
techniques don’t recognize in a subgroup abnormalities at this stage. Ultimately many 
present with an acute abdominal event such as perforation or obstruction. EATL often 
involves the abdominal lymph nodes but rarely spreads beyond the abdominal cavity. 
No satisfactory treatment for EATL exists. Curative surgery is often precluded by the 
extent of the small bowel involvement.  
In most cases these lymphomas behave aggressively and the prognosis is usually grim. 
The multifocal occurrence with ulceration explains the substantial perforation rate, both 
spontaneously and with chemotherapy. In overt EATL anthracyclin containing 
chemotherapy is indicated. Treatment options in the “premalignant/early malignant 
phase” of refractory coeliac disease in the window just before developing an EATL are 
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an area of much debate (16,32). No satisfactory chemotherapeutical treatment for EATL 
exists.   
 
Histopathology of T-cell small bowel lymphomas 
 
The T-cell lymphomas of the small bowel are roughly divided into one type with 
enteropathy and one without. The type with enteropathy is also observed following 
dermatitis herpetiformis (CD of the skin). Although the intraepithelial lymphocytes in 
uncomplicated CD has a TCR /, CD3+, CD4-, CD8+, CD30+ phenotype, the phenotype 
of EATL is CD3+, CD7+, CD4-, CD8-, CD30+. The immunophenotype is not absolutely 
specific, however CD3 may be lacking, CD8 can be positive and CD30 could be negative. 
This corresponds to the cytology of an EATL with small-cell pleomorphic (mostly CD8+ 
and CD30-) and large-cell pictures (mostly CD8- and CD30+). Imprint azurophil granules 
(TIA-1+) are present, as seen in about 25% of normal intraepithelial T-lymphocytes. The 
tumours are not derived for TCR / cells, as initially speculated, but from TCR /ß 
cells. There is almost no information on T-cell lymphomas of the small intestine 
without enteropathy. Nodal peripheral T-cell lymphomas in relation with enteropathy 
have been recognized (7). Data about the histology of these lymphomas are limited, 
especially if TCR / positive lymphomas do occur (extra)nodal in relation with 
enteropathy due to CD. 
 
Coeliac disease and extra intestinal T-cell lymphomas  
 
Subcutaneous panniculitis-like T-cell lymphoma 
 
This variant of peripheral T-cell lymphoma describes a distinctive clinical syndrome. 
This lymphoma is not EBV-related. Biopsy specimens demonstrate a panniculitis 
pattern of disease in which an atypical lymphoid cellular infiltrate between adipocytes 
of the subcutis in a manner reminiscent of that seen in panniculitis. The neoplastic cells 
have a mature T-cell phenotype and may express either CD4 or CD8 subset antigens. 
The diagnosis of CD must be considered (37). Rare cases of / T-cell lymphoma may 
present with a similar clinical and morphologic picture. 
 
Hepatosplenic / T-cell lymphoma 
 
This is a mature / T-cell lymphoma with infiltration of spleen, liver and bone marrow. 
The function of / T-cells remains poorly understood, but there is good evidence that 
/ß and / T-cells represent distinct cell lineages. Although the antigenic specificity of 
/ T-cells is yet unknown, it appears that these cells may have evolved to recognize a 
limited number of high-frequency antigens encountered at epithelial surfaces and 
provide a first line of defence against antigens at these sites prior to the recruitment of a 
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more specific immune response. The so-called hepatosplenic / T-cell lymphoma 
seems the prototype of / T–cell lymphomas. Recently / T-cell lymphomas 
presenting in the GI-tract have been described (38). 
 
 
Nodal 
 
T-cell lymphomas with the histopathology of an EATL with nodal presentation can be 
seen, however we have the impression that the relationship without a history of CD 
makes it difficult to consider and to recognize an underlying CD (21). 
 
 
Intestinal – “Non-Small bowel” – EATL’s 
 
CD can result in changes in parts of the GI-tract other than the small intestine. It has 
been associated with lymphocytic infiltration of the gastric and colon mucosa (39,40). 
Additionally, gluten challenge to the rectal mucosa via gluten enemas in patients with 
untreated CD produces immunologic changes in the rectal mucosa including an increase 
in CD3+ and CD25+ lymphocytes (41). Presentation of EATL’s in stomach and colon 
might be expected due to the presentation of these precursor cells to malignancy in 
small bowel, but also stomach and colon (42). 
 
Metastatic EATL’s 
 
Lymphomatous involvement of extraintestinal-sites in patients with complicated 
enteropathies has been reported. This diagnostic possibility should be borne in mind in 
doctors treating coeliacs (37,43-44). 
 
Tertiary referral center for Coeliac Disease 
 
In Arnhem we serve as a large reference centre for CD with special interest in the 
treatment of refractory coeliac disease. In a period of ten years we had twenty-six 
lymphomas in conjunction with coeliac disease. The mean age of the patients was 63 
years, 16 were male and 8 female. Of these lymphomas 3 were extra intestinal; one case 
originated in the frontal sinus, the other case in the skin and the last case in the adrenal 
and cervical lymph nodes. In the case of the sinus tumour there was interestingly a high 
number of intraepithelial cytoplasmic CD3+ lymphocytes in the sinus epithelium. The 
skin case presented as a panniculitis like process with necrosis and a large number of 
histiocytes and inflammatory cells. Two other cases were located in the stomach and 
one in the colon. The twenty others (80%) originated in the small intestine. The 
morphology of the lymphomas was as follows: twenty-one had classical large cell 
cytology with a CD3+, CD8-, CD30+ phenotype, three had a small cell cytology with a 
CD3+, CD8+ and a CD30- phenotype, two cases had a phenotype of a / phenotype and 
one presented as a liver lymphoma with clinical symptoms of a malabsorption and a 
Marsh I lesion of intraepithelial lymphocytosis. One other case presented as a / 
lymphoma of the small bowel. All had histological proven intraepithelial lymphocytosis 
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and a variable degree of atrophy. Four coeliacs had Marsh I, four Marsh II and the 
remainder had Marsh III lesions at presentation of their T-cell lymphoma. The treatment 
outcome in our group is extremely poor with 2 survivors for more than 1 year, both with 
a large cell T-lymphoma. Both had initial surgical treatment with adjuvant 
chemotherapy. Both with a large cell T-lymphoma type. The other patients had a very 
short survival after discovery of the malignant lymphoma as expected from this type of 
disease. 
 
Conclusion 
 
The MALT lymphomas represent a distinct subset of non-Hodgkin’s lymphomas, and 
gave us an unique opportunity to understand the pathophysiology and the relationship 
between infection with Helicobacter pylori and the lymphoma (5,6). Such disease is 
associated with a long period that appears to arise from an inappropriate or excessive 
stimulation of the mucosal immune system. Early changes appear to be benign, but with 
time, if Helicobacter pylori left untreated, malignant lymphoma emerges. 
Other examples of this slow transition from benign to malignant disease include 
Hashimoto’s thyroiditis and thyroid lymphoma, coeliac disease and EATL, the pre-
lymphomatous phase of IPSID and IPSID lymphoma. The reversibility of IPSID by 
antibiotics and later gastric MALT lymphomas constituted the first milestone of 
chemoprevention of cancer in man. In coeliac disease we recognize refractory coeliac 
disease and ulcerative jejunitis as the last stop between benign and malignant disease 
(16,29). It seems essential to develop a chemotherapy directed to prevent lymphoma in 
this window between benign and malignancy. Treatment options so far with 
immunomodulation with Azathioprine and Prednisone are disappointing (32). However 
the work-up for RCD is insufficient in the majority of cases. Immunohistology, T-cell 
flow cytometry (TCR) have permitted adequate staging (31). Treatment options with 
cladribine do improve clinical parameters, but the percentage of aberrant T-cells 
remains the same (45). In follow-up of EATL survivors after chemotherapy we have the 
impression that their T-cell precursor clones remain the same. An autologous bone 
marrow transplantation might be an alternative targeting the premalignant T-cell clones 
in RCD. 
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ABSTRACT: 
 
Patients with coeliac disease (CD), particularly those who are undiagnosed or do not 
adhere to a strict gluten free diet (GFD), are prone to develop complications. Malignant 
complications are the most serious and should be suspected when expected responses to 
GFD are not achieved or sustained. Lymphomas, mostly T-cell type, and other 
malignant tumours, particularly carcinoma of the small bowel, less frequently of 
stomach and oesophagus, are associated with CD. Loss of response to a gluten free diet 
(refractory coeliac disease) and ulcerative jejunitis are two recently described 
complications of CD that may progress to an Enteropathy-Associated T-cell Lymphoma 
(EATL). Coeliac disease-related lymphoma most often appears at extra-nodal sites, 
essentially the small bowel, although one have to realize that T-cell lymphomas arising 
in sites outside the small bowel could be related to coeliac disease. Workup of an EATL 
must include immunohistology and if necessary T-cell flow cytometry and T-cell 
rearrangement. Adequate imaging with CT and PET-scanning is mandatory.  
 
 
Patients with coeliac disease (CD), particularly those who are undiagnosed or do not 
adhere to a strict gluten free diet (GFD), are prone to develop many complications or 
related lesions, including osteoporosis, infertility, auto-immune diseases and 
malignancies. 
An increased overall cancer mortality has been reported in adult patients with CD and 
their relatives, which supports the clinical importance of this disorder.1–4 
Prevention is better than cure and it is important that patients are diagnosed before 
complications occur, because a GFD may prevent or reduce the risks. Malignancies are 
the most serious complications and should be suspected when expected responses to 
GFD are not achieved or sustained. Lymphomas, mostly T-cell type, and other 
malignant tumours, particularly carcinoma of the small bowel and oesophagus, are 
associated with CD.5 Loss of response to a gluten free diet in refractory coeliac disease 
and ulcerative jejunitis are two recently described complications of CD that may 
progress to Enteropathy-Associated T-cell Lymphoma (EATL). 
Numerous retrospective1,3 and prospective studies looked for differences in prognosis 
for patients with CD and observed different increased risks for malignancy or 
mortality.6,7 The pioneering study by Holmes et al indicated in CD patients an overall 2-
fold relative risk of cancer, with the risk increased 10-fold for certain gastro-intestinal 
carcinomas and 43-fold for lymphomas. Recent surveys, including a retrospective 
Swedish study, provided lower figures, with an overall risk of cancer only moderately 
increased (1.3-fold)2 and 3–6-fold increased risk of lymphoma.2,3,8,9 However, the risk 
remained 10-fold increased for small intestinal carcinoma.2 In a recent European study, 
although prevalence of CD was increased only 2.6-fold in patients with lymphoma, the 
odds ratio reached 11.8 for small bowel lymphoma and 28 for an EATL.10 
A very recent Swedish study including a prospectively defined population based cohort 
of 11 650 patients hospitalized with CD has demonstrated that the association between 
CD and lymphoma is not confined to EATL but includes other types of T-cell 
lymphoma and, more importantly, B-cell lymphoma. EATL cases comprised in this 
study only one third of lymphoma cases and half of all T-cell lymphomas.11 The 
Histopathological aspects of coeliac disease 
 
 
 
 
 
 
 
124 
 
mortality excess is mainly accounted for by deaths occurring within a short time after 
diagnosis. A recent population based cohort study was aimed to quantify the risks of 
malignancy and mortality in people with CD compared with the general population in 
UK. Out of 4732 patients with CD, they observed a modest increase in overall risks of 
malignancy and mortality. Most of this excess risk occurred in the year of follow-up 
after diagnosis. The increased risk was only for lymphoproliferative disease (hazard 
ratio 4.80). There was a hazard ratio of 1.85 for gastrointestinal cancer. Interestingly, 
people with CD had a noticeably reduced risk of breast cancer. However, there were no 
details on both lymphoproliferative disease and gastrointestinal cancer.6,12–14 A strict 
gluten-free diet (GFD) may be protective, the risk for malignancy returning to that of 
the general population after 5 years1 or more.2 Furthermore, in the Swedish study, 
patients with CD diagnosed in childhood and adolescence and who presumably were 
adhering to the GFD had no increased cancer risk during follow-up. These results 
suggest a possible link between chronic intestinal inflammation and malignant 
transformation more than a constitutive inherited defect. Coeliac disease is in a limited 
number of cases complicated by lymphoproliferative disease. The lymphoma is located 
in most instances in the small intestine but localization in other parts of digestive tract 
or in remote places such as skin or other places may occur.11,15 Also there is an 
indication that this disease gives rise to a somewhat higher incidence of epithelial 
carcinomas. The epithelial malignancies are preferentially located within the small 
intestine. Esophageal and pharyngeal malignancies are also found with a small but 
significantly raised incidence.  
 
EPITHELIAL TUMORS 
 
An association with squamous carcinoma of the aero digestive tract, including the upper 
esophagus and the pharynx, is well established. There is some doubt about an 
association with carcinoma of small bowel, which could be fortuitous rather than a 
direct consequence. The Dutch group of patients with possible association between 
coeliac disease and carcinoma consisted of ten patients of whom eight patients had 
adenocarcinoma of the digestive tract. Three of them where located in the small 
intestine. 
 
 
Carcinoma of jejunum 
 
The development of carcinoma may bring a patient with CD to diagnosis16 or provoke 
symptoms in a patient previously well controlled on a gluten free diet.17 Anemia is the 
most common presenting feature and is associated with either overt or occult 
gastrointestinal blood loss. Weight loss, abdominal pain and intestinal obstruction are 
other prominent complains.  Small intestinal adenocarcinomas are rare tumours. The 
small bowel is the site of only 1% of all gastrointestinal carcinomas. Small intestinal 
adenocarcinoma is well recognized in association with long-standing gluten 
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enteropathy, particularly in patients in whom the mucosa remains flat even after 
appropriate dietary treatment12,16. It has been documented a 40–80-fold increase of 
incidence in coeliacs. Different explanations have been put forward to this increased 
risk of developing carcinomas. The mucosal damage in CD may make the small 
intestine more permeable to environmental carcinogens. Known predisposing factors for 
the development of small intestinal adenocarcinoma include Crohn’s disease, 
adenomatous polyps and Peutz-Jeghers syndrome. These adenocarcinomas have 
macroscopic and microscopic features similar to adenocarcinoma arising in the colon. 
Survival is dependent on the presence or absence of nodal involvement at presentation. 
As some patients are potentially curable by resection, limiting postoperative morbidity 
and recognizing potential complications become very important. So, it is important to 
rule out CD prior to surgery in patients with small intestinal malignancies. 
 
Carcinoma of the aerodigestive tract, including the oesophagus 
 
 It usually presents with dysphagia, anemia or bleeding and can be diagnosed by biopsy 
at endoscopy. There is neither precise histopathological description nor specificity for 
this carcinoma. 
 
INTESTINAL LYMPHOMA AND RELATED LESIONS 
 
CD is now proved to be associated with an increased risk for non Hodgkin lymphoma, 
especially of T-cell type and primarily localized in the gut and called Enteropathy- 
Associated T-cell Lymphoma (EATL). However, the association does not represent 
such a risk to justify mass screening for CD.3 In the workup of the diagnosis of T-cell 
lymphoma of the digestive tract the diagnosis of villous atrophy is frequently found. 
The lymphoma is a major complication in CD. Its diagnosis is often missed. Lymphoma 
can be both of the B- and T-cell lineage in patients with CD, the increase in incidence is 
most striking for EATL, a rare type of very aggressive T-cell lymphoma, almost 
exclusively observed in patients with CD3,4,11,18–20. The presenting symptoms of 
lymphoma are weight loss, which affects 80% of patients, associated with lethargy, 
abdominal pain and/or diarrhea. These symptoms are often mistaken for dietary 
indiscretions5,18. The prognosis is usually very poor and is further aggravated due to 
malnutrition. 
 
Pathological features 
 
Primary intestinal T cell lymphoma have been extensively described and distinguished 
in Isaacson’s lymphoma classification.21 They are now recognized in WHO 
classification under the name of enteropathy-type T-cell lymphoma (ETL).22 In this 
chapter, we use the name Enteropathy-Associated T-cell lymphoma (EATL). They are 
rare, accounting for less than 5% of primary gastro-intestinal lymphomas, contrary to 
primary gastrointestinal lymphoma that account for 4–12% of all non Hodgkin 
lymphomas and are usually of B-cell origin. Primary T-cell gastrointestinal lymphomas 
are rare and the only defined clinico-pathologic entity is an EATL. Most of them are 
located in the small intestine5,23,24. Initially thought to be of histiocytic cell origin and 
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consequently named malignant histiocytosis of the intestine, it is now known that the 
malignant cells are derived from T cells and more specifically from intra-epithelial 
lymphocytes. Immunological and molecular studies have now confirmed the T-cell 
origin of primary digestive lymphoma associated with CD25. 
Macroscopically, EATL is often multifocal with ulcerative lesions, which explains the 
high perforation rate at presentation or during chemotherapy. Enteropathy-associated T-
cell lymphomas usually have a high grade of malignancy. They are pleomorphic with a 
mixture of large cells, some showing features of phagocytosis, and eosinophilic 
leucocytes. 
At pathological examination, the specific finding is the tumoriform infiltration of the 
wall of the intestine with a diffuse T-cell tumour. A large and a small cell type exist. 
More than 80% of the tumours is of large ‘anaplastic’ cell type. The small cell type T-
cell lymphoma are CD3+, more CD8+ and often CD30 negative. These lymphomas are 
CD56 positive. 
In the case of uncomplicated coeliac disease the intra-epithelial antigen responsive cells 
(intra-epithelial lymphocytes) are of CD3 surface+, CD8+, CD5+, CD7+, CD103+ 
subtype. In a subset of patients who become unresponsive to gluten withdrawal the 
intraepithelial cells show a shift towards a T-cell with aberrant phenotypic expression. 
The cells could lose CD826, CD5 expression and shows a shift towards a more immature 
phenotype with expression of cytoplasmic CD3. It is tempting to consider such cell 
phenotype as a precursor lesion for the development for lymphoma. 
 
 
Immunophenotype 
 
Tumour cells have a peculiar immunological phenotype (CD3 ±, CD7+, CD5-, CD4-, 
CD8-). They overall express the antigen E7 recognized by CD103 antibody (HML1 
antibody), an integrin which binds to E-cadherin expressed by surface epithelial cells 
and which characterizes the intra-epithelial lymphocytes (IEL) population27,28. 
The tumor cells contain cytotoxic granules recognized by the cytotoxic phenotype, as 
revealed by granzyme B and T-cell restricted intra-cellular antigen TIA-1 which are 
components of the cytotoxic granules.29 These phenotypic studies suggested that T-cell 
lymphomas associated with CD originate from intra-epithelial T lymphocytes. In a 
minority of cases, the neoplastic cells express natural killer phenotype, such as 
CD5630,31. 
Other phenotypes such as CD4C and CD8C have also been described32. 
In almost all cases, a varying proportion of the tumour cells express CD30. In the subset 
comprised of small to medium-sized cells the tumour cells usually are CD8+, often 
CD30 negative and express CD56. 
 
Non involved mucosa 
 
This primary lymphoma is now termed ‘enteropathy-associated T-cell lymphoma’ or 
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‘EATL’ because of its association with villous atrophy and hyperplasia of mucosal 
crypts in non-tumoral zones. The epithelium of atrophic but non-tumoral zones may, 
nevertheless, contain a few scattered larger tumour cells which could be highlighted 
with CD30 staining. The mucosa not involved by the tumor appears to show changes in 
the subsets of intraepithelial lymphocytes present which mimic the markers expressed 
by the tumour cells. 
The intra-epithelial lymphocytes in the adjacent enteropathic mucosa may show an 
abnormal immunophenotype usually CD3 cytoplasmic+, CD5-, CD8-, CD4- identical to 
that of the lymphoma15. There is strong evidence that EATL is a consequence of coeliac 
disease. 
 
 
Cytogenetic alterations 
 
Genetic alterations in EATL are largely unknown. A recent study of 38 cases of EATL 
analyzed by comparative genomic hybridization (CGH) revealed chromosomal 
imbalances in 80% of cases analyzed, with recurrent gains of genetic material involving 
chromosomes 9q, 7q, 5q and 1q. Recurrent losses of genetic material occurred on 
chromosomes 8p and 13q, and 9p.21,33. Chronic inflammation may have a role in the 
induction of chromosome abnormalities and emergence of malignancies, which 
preferentially affect the small intestine, the main site of inflammation34,9. 
 
 Intestinal T-cell lymphoma with eosinophilia.  
 
Shepherd has described a T-cell lymphoma of the small intestine associated with an 
intense eosinophilic reaction. The tumours are often multiple, sometimes necrotic or 
ulcerated, and may be revealed by an intestinal perforation. The infiltrate consists of 
scattered large cells, sometimes multinucleated, and similar to Reed-Sternberg cells, 
intermingled with numerous eosinophils. The eosinophilic reaction may be induced by 
the release by tumoral T-cells of eosinophilic chemotactic factor (ECF), or interleukins 
such as IL5 (eosinophilic differentiation factor)35. 
 
Other types of T-cell lymphoma 
 
Other rare and isolated cases of primary digestive T-cell lymphoma have been 
described: immunoblastic CD8+ lymphoma with azurophilic granules in the cytoplasm 
of tumour cells or low grade T-cell lymphoma.36 In a proportion of patients, there is a 
prodromal period of refractory CD that is sometimes accompanied by intestinal 
ulcerations (ulcerative jejunitis). 
 
Ulcerative jejunitis 
 
Isolated ulcerative jejunitis often has relatively non-specific histological features. It may 
occur in several specific situations. So-called ulcerative jejunitis should be considered 
to be a neoplastic complication of CD: there is immunopathological and molecular 
evidence that most, if not all, of such cases represent early T-cell lymphomas 
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complicating CD although a tumoriform infiltration is not often found. 
The clinical picture is fairly well defined. Most patients are in their 6th or 7th decade 
and present with a chronic history of abdominal pain and distension, fever, weight loss, 
diarrhoea and often steatorrhoea. The diagnosis should be considered only after 
exclusion of other well-known causes of small intestinal ulceration such as Crohn’s 
disease, ischemic enteritis, polyarteritis, irradiation enteritis, lymphoma and drugs. In 
addition, rare infective processes should be ruled out. Jejunal biopsy, when performed, 
is mostly unhelpful or shows features consistent with CD. The majority of the patients 
undergo exploratory laparotomy for a full thickness small bowel biopsy to make a 
diagnosis. The European Working Group for CD in Amsterdam 2001 considered 
patients with ulcerative jejunitis to be type II refractory coeliacs since their histology is 
not yet compatible with small bowel lymphoma. Future research must give an answer if 
we have to treat ulcerative jejunitis like Refractory Coeliac Disease type II or like an 
EATL.37 
 
 Pathology 
 
At operation, the small intestine may show one or more abnormal areas; the wall is 
thickened and edematous and there may be strictures with proximal dilatations. 
Inspection of the mucosa reveals multiple ulcers in general in the jejunum but also 
common in the ileum and sometimes in the colon. The ulcer bed is made up by 
granulation tissue; it is a non-specific inflammatory infiltrate composed by lymphoid 
cells, histiocytes and acute inflammatory cells. Eosinophils may be prominent. The 
mucosa adjacent to the ulcer almost invariably shows villous atrophy and crypt 
hyperplasia similar to the lesions in CD. The mucosa in more distal areas may be 
normal. 
The relationship of ulcerative jejunitis to CD remains controversial. If some patients, 
clearly coeliacs, improve on a gluten free diet, others do not respond to gluten 
withdrawal or become resistant to a gluten-free diet and show monoclonality on 
molecular biology. The prognosis of these patients is poor. 
A new interesting and controversial aspect of ulcerative jejunitis is its relationship to 
lymphoma. Some cases have been described of clinical and pathological features of 
ulcerative jejuno-ileitis in whom the presence of T-cell lymphoma of the intestine was 
demonstrated by careful histological, immunophenotypical and molecular examination 
of the intestinal infiltrates. The authors consider these cases of ulcerative jejunitis as 
occult form of intestinal T-cell lymphoma. Other cases of patients with ulcerative 
jejunitis progress to develop EATL and, interestingly, multiple inflammatory mucosal 
ulcers frequently accompany EATL itself. 
The diagnosis is always difficult and repeated and multiple biopsies are required to 
confirm the diagnosis. Ashton-Key et al showed TCRg monoclonality in the non-
specific ‘inflammatory’ ulcers and intervening enteropathic mucosa in ulcerative 
jejunitis in the absence of overt lymphoma. In cases of ulcerative jejunitis, where 
lymphoma subsequently developed, the same clone could be detected in the malignant 
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cells by PCR and sequence analysis.38–41 
The presence of a similar increase in CD3c+, CD4-, CD8- IEL in the ‘uninvolved’ 
enteropathic mucosa in ulcerative jejunitis and EATL, which in both conditions 
harbours a monoclonal T-cell population, strongly suggests that the clonal population 
resides in the IEL compartment.38 Ulcerative jejunitis is now considered as a 
premalignant or malignant condition. 
 
 
Refractory coeliac disease (RCD) 
 
Refractory coeliac disease is characterized by severe malabsorption and total or severe 
duodenal villous atrophy, without evidence of lymphoma, which fails to improve after 6 
months on a gluten free diet. 
Differential diagnosis between refractory coeliac disease and CD can be difficult. 
The most common cause of apparently refractory coeliac disease is failure to adhere to a 
strict gluten-free diet, but deliberate or inadvertent gluten ingestion may be difficult to 
detect. Some CD patients respond to GFD only after months and may require steroid 
therapy to obtain a clinical and histological improvement. 
 
Pathology 
 
Architectural alterations of the duodenal mucosa are comparable in coeliac disease and 
refractory coeliac disease, i.e. subtotal or total villous atrophy, crypt hyperplasia, a 
moderate lymphoplasmacytic infiltrate of the lamina propria and a marked increase 
number of IEL with a normal cytological appearance. More than in the general 
population in these patients there are a high to very high number of intraepithelial 
lymphocytes and in selected cases there are abnormal large intraepithelial lymphocytes. 
 
 
Phenotype 
 
Non-responsive CD may correspond to refractory CD. In RCD type the IEL phenotypes 
are the same as in CD. RCD-II is distinct from active CD, IEL showing a mostly normal 
cytological appearance but an abnormal phenotype. These aberrant T-cells make the 
difference between RCD-I and RCD-II. Biopsy specimens show, both in CD and in 
RCD, a massive infiltration of the epithelium by IEL with a normal cytology. But in 
RCD-II, the phenotype differs: if normal IEL or IEL in CD have a classical phenotype, 
CD3+, CD8+, in RCD-II IEL have a markedly aberrant immuno-phenotype sCD3-, 
cCD3+, CD4-, CD8-, TCR- and -. This phenotype contrasts with the major sCD3+, 
CD8+, TCR+ and minor CD4-, CD8-, TCR+ populations of T-cells that comprised 
the increased IEL in uncomplicated CD. IEL still express the CD103 integrin, 
characteristic of IEL. They variably express the natural killer cell receptor CD94. The 
abnormal phenotype cCD3+, CD8- of the IEL population can easily be demonstrated in 
paraffin sections of mucosal biopsy specimens by sequential double staining for CD8 
and CD3 which allows an estimation of CD3+, CD4-, CD8-T-cells.26 This simplified 
immunostaining method using anti-CD3 and anti-CD8 antibodies on paraffin sections 
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can distinguish active CD from refractory coeliac disease and should prove useful in 
clinical practice. 
 
Molecular studies 
 
IEL show a clonal rearrangement of the TCR  chain. Abnormal phenotype associated 
with clonal T-cell receptor (TCR) g rearrangements indicate that RCD-II is a low-grade 
intraepithelial lymphoma.25 
As these cytologically normal IEL, but phenotypically aberrant and monoclonal, do not 
form tumour masses; they may be the first step in the genesis of lymphoma. 
 
Cytogenetic alterations 
 
Refractory coeliac disease type II (RCD) has been strongly associated with partial 
trisomy of the 1q region (involving the region 1q24–1q44). Gain of chromosome 1q, 
recently found in 16% of enteropathy-type T-cell lymphoma, may be an early event in 
lymphoma genesis related to CD and provides a key to investigate molecular 
mechanisms of lymphoid transformation in this disease.42  
 
Refractory coeliac disease (RCD-II), a diffuse gastrointestinal disease 
 
Refractory coeliac disease type II is indeed a diffuse gastrointestinal disease, as shown 
by the immunophenotypically aberrant monoclonal IEL population disseminated to the 
gastric and colonic mucosa in, respectively, 64 and 55% of patients with RCD-II. The 
intra-epithelial lymphoid infiltration can subsequently diffuse into the lamina propria 
and in some patients in the blood.43 
 
Refractory coeliac disease, the link between active CD and EATL 
 
RCD may be the initial manifestation of overt EATL. It is now considered as a 
neoplastic condition and may represent a cryptic variant of enteropathy-type T-cell 
lymphoma. IEL in patients with RCD are phenotypically heterogeneous. CD30 
expression by these cells may indicate a worse prognosis. A recent study suggested that 
CD30 expression by IEL of patients with refractory sprue indicates a poor prognosis, 
including the presence of overt EATL. Moreover CD30+ IEL may be observed a long 
way away from overt tumours and even in jejunal biopsy specimens. This suggests that 
CD30 should be included in the screening for malignant development in patients with 
RCD, so called cryptic EATL.18,44 
 
Molecular mechanisms involved in the development of refractory coeliac disease 
 
The origin of the abnormal lymphocytes infiltrating the gut epithelium and the 
mechanism driving their expansion are not well defined. A better understanding should 
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be useful to define possible therapeutic targets. 
The presence of a subset of IEL lacking surface T-cell receptors but containing clonal 
DNA rearrangement of the g chain may result from the clonal expansion of mature T-
cells losing their T-cell receptor by an unknown mechanism or of immature 
lymphocytes blocked at an early stage of maturation. 
The two malignant complications unique to CD, Enteropathy-associated intestinal T-
cell lymphoma and RCD, arise within the intra-epithelial compartment. These data point 
to a profound alteration of IEL homeostasis in CD, which could result from alterations 
of the innate immune mechanism. IL15 is a major candidate to promote alterations of 
IEL in CD. IL15 over expression in the intestine leads to massive expansion of CD8 
intestinal T-cells accompanied by a CD-like enteropathy. 
Uncontrolled expression of IL15 in RCD promotes the emergence and/or expansion of 
clonal IEL and likely contributes to the pathogenesis of epithelial lesions by activating 
their cytotoxicity or their release of interferon-. That IL15 is not secreted but exposed 
at the surface of enterocytes and acts only via cell-to-cell contact, likely explains why 
the expansion of abnormal lymphocytes in RCD-II remains intra-epithelial over several 
years. TCR independent activation of IEL and innate immunity may have a contribution 
in the pathogenesis of CD.13,45 
The expansion of the abnormal lymphocytes may be directly antigen-driven. An 
alternative hypothesis is the role of receptors interacting either with an epithelial ligand 
and/or with cytokins. Refractory sprue IEL selectively respond to IL15 and IL15 is 
produced in excess in the gut of RS patients. 
Abnormality of IL15 regulation may lead to consider the use of anti-IL15 antibodies if 
the survival and expansion of the abnormal IEL are IL15 dependent.  
 
Interaction of the IEL in the destruction of gut epithelial cells in the course of CD and 
RCD  
 
Villous atrophy in CD and in RCD may be ascribed by the destruction of intestinal 
epithelium induced by IEL through the NKG2D/MICA interaction after gliadin-induced 
expression of MICA on gut epithelium: IEL are able to kill epithelial cells through the 
perforin/granzyme pathway. The MICA/NKG2D pathway has just shown to have a key 
role in the destruction of intestinal epithelium by intra-epithelial T lymphocytes. MICA 
molecules interact with the NKG2D-activating receptor on NK and CD8 T-cells. The 
MICA molecules, non-conventional HLA class I molecules, were strongly expressed at 
epithelial cell surface in patients with RCD. MICA is induced by gliadin, an effect 
relayed by IL15.46 
 
RCD, a link with EATL 
 
The status of IEL in RCD with regard to malignancy and their link with an invasive 
EATL is not defined. 
These data, together with the fact that approximately 30–40% of the patients with RCD-
II will develop a high grade lymphoma sharing the same clonality, whether in the small 
intestine or elsewhere37, allow us to consider refractory coeliac disease type II as low 
grade (or cryptic) intra-epithelial T-cell lymphoma and a first step in the development of 
Histopathological aspects of coeliac disease 
 
 
 
 
 
 
 
132 
 
lymphoid malignancies in CD. An additional step of transformation may exist.19,20 
 
CD AND TRANSFORMATION OF INTRA-EPITHELIAL LYMPHOCYTES 
(IEL) AS A MODEL OF T-CELL LYMPHOMAGENESIS 
 
Increased IEL and intestinal villous atrophy characterize CD. Proliferation of IEL is 
thought to be initiated by chronic antigen stimulation with gluten rich food. In CD 
alteration of adaptive immunity is orchestrated by lamina propria gliadin-specific CD4+ 
T-cells and associated with alterations of innate immunity. Antigen stimulation leads to 
IL15 production in the epithelium. This over expression of IL15 plays a key role in 
TCR-independent expansion and activation of IEL, leading to polyclonal expansion of 
normal IEL. In uncomplicated CD, as yet unknown regulatory mechanisms can tone 
down IL15 expression following prolonged gluten free diet. IL15 plays a role in the 
maintenance of clonal CD3- IEL in RCD-II. It still remains to be clarified if there is any 
relationship between the aberrant clonal cells and the CD3-Tc precursor IEL and/or the 
CD3- NK IEL.47,13 
In contrast, in RCD-II, uncontrolled over expression of IL15 perpetuates IEL activation 
and epithelial lesions. Persistent IL15 production, p53 mutation and/or other events may 
lead to the emergence of a clonal expansion of transformed IEL and promotes the 
emergence of T-cell clonal proliferations. This multistep transformation parallels 
clinical stage of the disease. CD becomes resistant to the dietary food without gluten 
(RCD) and then gives rise to the pre-lymphomatous state ulcerative jejunitis and/or low-
grade intra-epithelial T-cell lymphoma and then to an EATL. However, in some cases 
overt T-cell lymphoma may occur as a presenting disease, if the oncogenic event has 
occurred at the early stage of the disease (CD). Blocking IL15 might thus prove a useful 
therapeutic approach in refractory coeliac disease, a most severe disease resistant to 
currently available treatments, which may ultimately transform into aggressive T-cell 
lymphomas. 
 
 
 
CONCLUSION 
 
Malignant complications of coeliac disease are very serious and should be suspected 
when responses to gluten free diet are not achieved. Malignant tumors include 
carcinoma of the oesophagus and jejunum and lymphoma, mostly T-cell type. The 
pathogenesis of the enteropathy-associated T-cell lymphoma is better understood as the 
two related complications, ulcerative jejunitis and refractory coeliac disease. They 
include cytogenetic abnormalities of intra-epithelial T lymphocytes and environmental 
factors such as over expression of IL15 by epithelial cells. On the basis of molecular 
analysis and the immunophenotypic findings, the monoclonal intra-epithelial 
lymphocytes in patients with complications of CD are neoplastic, also they are not 
cytologically abnormal and they do not form tumor masses. The accumulation of 
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phenotypically aberrant, monoclonal IEL appears to be the first step in the genesis of an 
EATL. Additional cytogenetics studies must determine if trisomy 1q observed in RCD 
is a specific phenotypic and/or prognosis marker in malignant T-cell complications of 
CD. 
With the recognition that patients with non responsive CD and/or ulcerative jejunitis are 
in fact suffering from a neoplastic T-cell disorder, often involving most of the 
gastrointestinal tract, gastroenterologists will turn to hematologists for help in treating 
these complicated patients. 
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Coeliac disease is a wasting (small) bowel disease in childhood and adulthood and is 
characterized by small bowel mucosal inflammation and injury. The disease is seen in 
genetically susceptible individuals following enteric encounter with gluten proteins in 
wheat, rye and barley. This is often accompanied by nutrient malabsorption. Mucosal 
damage, which is most marked in the proximal small intestine, is characterized by a 
spectrum of histopathological abnormalities that includes increased numbers of 
intraepithelial lymphocytes with or without crypthyperplasia, an increased infiltrate of 
lymphocytes and plasma cells in the lamina propria and villous atrophy ranging from no 
atrophy at all to complete villous atrophy. Other mucosal sites such as the colon, 
stomach, esophagus and upper digestive mucosa might be affected as well. This results 
in a multisystem disease with a varying clinical picture. Intestinal symptoms include 
diarrhea, abdominal cramping, pain and distension. This can lead to failure to thrive, 
vitamin and mineral deficiencies, osteoporosis and many other extra intestinal 
symptoms.  Most patients respond to a gluten- free diet. 
 
The small bowel biopsy is still the gold standard in the diagnosis of coeliac disease1, 2. 
In earlier literature, the diagnosis of coeliac disease was considered only when villous 
atrophy was present in the biopsy 3.  In the last two decades, however, earlier 
histological stages of the disease are also recognized in which only infiltration of T-
lymphocytes in the epithelium are present 4,5,6,7,8.  This is especially true for a subset of 
patients with dermatitis herpetiformis and in first-degree relatives of coeliac disease 
patients 9,10,11.  There is a relation between the histological abnormalities and serological 
parameters of the disease; in the early stages of the disease serological parameters can 
be absent 10. In the early stages of coeliac disease with only intraepithelial 
lymphocytosis, the histological diagnosis is equivocal. Other diseases such as 
Helicobacter pylori gastritis12, peptic duodenitis, Crohn’s disease13, Giardia14, etc. can 
give rise to abnormalities that can easily be misinterpreted as early coeliac disease. The 
abnormalities resulting in villous atrophy are listed in table I.  It is important that the 
pathologist is aware of the pitfalls in the assessment of biopsy specimens. These include 
suboptimal sectioning of the biopsy specimen since this can result in a false positive or 
negative diagnosis15; also difficulties arise when no architectural abnormalities are 
present and changes are limited to an increase of intraepithelial lymphocytes. 
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Normal histology of small bowel mucosa 
 
Small bowel mucosa normally has long tender villi with a villus to crypt ratio of 3-5 to 
1. A small bowel biopsy is considered normal when more than 4 villi on a row have a 
normal appearance 16,17. In a normal small bowel biopsy low numbers of intraepithelial 
lymphocytes are present. There is often debate about the accepted normal count, and 
arbitrary upper values between 30-40 lymphocytes per 100 enterocytes are being used. 
Most of them are membranous CD3, CD5, CD7, CD8 and CD103-positive and 
expresses an / or a / T-cell receptor. 
In the proximal duodenum the villi are more irregular and can be shorter due to peptic 
influences from the stomach. There is also more irregularity and a physiological 
increase of intraepithelial lymphocytes in areas with lymphoid follicles. In these areas 
one should be very careful about making definite statements concerning atrophy and 
intraepithelial lymphocytosis. 
Table I: list of abnormalities with atrophic small bowel mucosa: 
• Tropical sprue 
• HIV enteropathy 
• Combined immunodeficiency states  
• Radiation damage  
• Recent chemotherapy  
• Graft versus host disease  
• Chronic ischemia  
• Giardiasis  
• Crohn's disease  
• Eosinophilic gastroenteritis  
• Zollinger-Ellison syndrome 
• Autoimmune enteropathy  
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Location of biopsies for diagnosing gluten-sensitive enteropathy 
 
The proximal duodenum is not a good place to perform a biopsy (see above).  In the 
past it was considered necessary to take a biopsy of the jejunum in order to make a 
reliable diagnosis of GSE 2,3. More recently biopsies from the distal duodenum have 
been shown to have same diagnostic power 16,18.  
It is supposed that histological abnormalities in gluten-sensitive enteropathy have a non-
uniform distribution in the small bowel 19. The use of push endoscopic techniques, 
especially the double balloon endoscopy, can shed more light on this 20,21.   Other 
entities, such as ectopic stomach mucosa, which might be responsible for 
histopathological look-alikes, have a patchy distribution. That is why the American 
Gastroenterological Association advises taking at least 3 small bowel samples 22.   
In the diagnostic workup for suspected coeliac disease, it is strongly advisable to take 
biopsies from the stomach as well to exclude Helicobacter-associated gastritis, which 
can give rise to peptic duodenitis and intraepithelial lymphocytosis. Also in Crohn’s 
disease a biopsy of the stomach, in which a so-called focally enhanced gastritis with or 
without granulomas might be present, gives additional information and gives more 
histological clues for diagnosing Crohn’s disease than do the non- specific 
abnormalities in the distal duodenum and which might be helpful in differentiating 
intraepithelial lymphocytosis in the small bowel. (personal experience, 23,24). 
 
The histological spectrum of GSE 
 
Coeliac disease is a T-cell driven immunologic reaction in which small peptides from 
gluten are deaminated by tissue transglutaminase and presented via certain HLA 
molecules on macrophages and epithelial cells to CD4 and CD8 cytotoxic cells. The 
intraepithelial lymphocytes in GSE express CD3+(surface), CD8+, CD103+ phenotype 
and these cells are more often / than  /. 
Marsh 25,26,27 has described the histological abnormalities in coeliac disease in detail. He 
described a range of histological changes ranging from “normal”, in which only 
serological tissue abnormalities could be detected in small bowel mucosa to abnormal 
histopathological findings characterized by intraepithelial lymphocytosis and 
hyperplastic/atrophic lesions.   
In Marsh’s original description type 0 no histological abnormalities can be detected. A 
type 1 infiltrative lesion is characterized by intraepithelial lymphocytosis without 
architectural changes.  A type 2 infiltrative/ hyperplastic lesion shows intraepithelial 
lymphocytosis with crypt hyperplasia with more or less normal villi. The epithelial 
damage is compensated by regeneration, but when regeneration is eventually unable to 
cope with the destruction rate, the villus disappears and a type 3 destructive lesion 
results. In most cases this is the most severe lesion, but in very rare cases an atrophic 
lesion without much inflammation can be seen (type 4). 
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    Fig I (from Marsh, MN, ed. 28)  
 
Our group modified this classification in 1998. In general it is important to make a clear 
distinction between Marsh I and II on one hand and Marsh II lesions on the other hand 
as Marsh III lesions are considered as definite proof of coeliac disease by clinicians. 
Marsh I, lymphocytic enteritis, is characterized by normal villous architecture with 
increased numbers of intraepithelial lymphocytes (for a definition see below).  
 
Marsh II, lymphocytic enteritis with crypt hyperplasia, is characterized by normal villi 
but with hyperplastic crypts, which are elongated and branched.  
We subdivided type III lesions into partial villus atrophy (IIIA), subtotal (IIIB) and total 
villus atrophy (IIIC).  
By definition, a Marsh IIIA lesion shows intraepithelial lymphocytosis with a villus 
crypt-height ratio equal to or less than 1:1.  
In Marsh IIIC no villi are recognized, and Marsh IIIB is an intermediate between the 
two.  
The rationale for this classification is threefold. First, it fits well with the former 
classification, well recognized among histopathologists. Second, it marks the important 
transition between a Marsh II to a Marsh III lesion, which parallels with the clinical 
interpretation of the pathological reports: Marsh IIIA lesions are conclusive for coeliac 
disease, whereas Marsh II lesions have not been so until now. Third, these histological 
abnormalities correlate with serological findings29. 
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Figure 1: Marsh I  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Marsh II 
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Figure 3: Marsh IIIA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Marsh IIIB 
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Figure 5: Marsh IIIC 
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The measurement of intraepithelial lymphocytes (IEL) seems straightforward, but in 
clinical practice one should realize that if strict criteria are not applied there is a risk of 
over interpreting intraepithelial lymphocytosis. In other illnesses, such as Helicobacter-
associated gastritis12, Giardia14, 30, Crohn’s disease13 and autoimmune diseases, 
significant intraepithelial lymphocytosis might be present.  
 
In healthy persons the number of intraepithelial lymphocytosis is reported to be 1.8-
26/100 epithelial cells, with an upper limit of 25 lymphocytes per 100 epithelial cells4.  
Counting IEL’s by using CD3 shows that the numbers of IEL’s recognized by light 
microscopy are probably underestimated.  Veress et al looked for the expression of CD3 
and found a mean of 10.8 intraepithelial cells per 100 epithelial cells in an H&E stain 
and 13.2 when a CD3-stain was used5. It seems clear that CD3-staining gives better 
reproducible results, although it is more time-consuming and costly. A practical 
approach suggested by Biagi6 is the estimation of the intraepithelial lymphocytes. The 
following method is advised: one should determine the ratio epithelial 
cells/lymphocytes, which should be 1:5 (20 lymphocytes per 100 epithelial cells). 
Above this number one should perform a CD3-stain in which the upper limit should be 
25 lymphocytes. Values between 25 and 29 should be reported as borderline and values 
of 30 and more should be considered as relevant intraepithelial lymphocytosis. Biagi5 
also suggested assessing the villus tip, in which IEL scores were 4.6 (SD, 1.5; range, 
1.4–7.8) in non-coeliac controls and 9.2 (SD, 4.7; range, 5.8–21.8) in coeliacs. Since in 
CD the intraepithelial lymphocytes have a preference for the top of the villi31; non-
specific lymphocytosis seems more to occur more randomly and to be distributed at the 
base. 
The significance of isolated intraepithelial lymphocytosis in a random population is 
unclear. In the literature, from 10 % to 42 %8 of such cases develop CD or are 
considered to have latent coeliac disease. After gluten challenge in Marsh I cases, we 
found a progression to a Marsh III lesion in 28 of the 38 cases. After treatment with a 
gluten-free diet, all of these 12 patients showed relief from their symptoms32.  More 
data about Marsh I in a population referred for endoscopy and evaluated for CD are 
needed. 
 
In the histological follow-up of patients on a gluten-free diet, it has been reported that, 
especially in adult patients, the restoration of the mucosa is slow and incomplete. In our 
10-year follow-up study of Marsh III lesions in adults, histological remission was 
achieved in 65% of the patients within 2 years, in 85% within 5 years and in 91% within 
10 years; in children a restoration to normal was achieved in 95% within 2 years and in 
100% in the long run33. 
 
In a retrospective study34 in which we reviewed 494 biopsies, the diagnosis was 
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discordant as compared to the panel diagnosis in about 11 % of the biopsies. Moreover, 
we diagnosed 6.2 % of the biopsies as false positives and 5 % as false negatives as 
compared to the diagnoses by an expert panel. The most important reasons for false 
positives were (pseudo)atrophic lesions resulting from poor orientation or insufficient 
biopsies (too small) in the absence of IEL’s. This stresses the importance of 
intraepithelial lymphocytosis as the hallmark lesion and supports the idea of taking 
multiple biopsies of sufficient size in which at least 3 to 4 intact villi can be evaluated. 
In other illnesses, such as Helicobacter-associated gastritis12, Giardia14,30, Crohn’s 
disease13, or autoimmune disease, intraepithelial lymphocytosis might be present. In the 
diagnostic workup of suspected coeliac disease it is strongly advised to take additional 
biopsies from the stomach to exclude Helicobacter-associated gastritis, which could 
give rise to peptic duodenitis and intraepithelial lymphocytosis. In Crohn’s disease a 
biopsy of the stomach also seems more informative since it gives more histological 
clues of the diagnosis of Crohn’s disease than do the non-specific abnormalities in the 
distal duodenum in this disease and it can differentiate intraepithelial lymphocytosis in 
the small bowel (personal experience, 23,24). 
 
Refractory coeliac disease 
 
Refractory coeliac disease refers to a subset of patients who do not respond or respond 
not anymore to a gluten-free diet. Clinically, this can be due to other reasons; one has to 
exclude microscopic colitis or compliance pitfalls for a gluten-free diet (see table I). 
Because the definition of refractory coeliac disease is still inadequate, a multi-step 
diagnostic approach is recommended35. 
Phenotypic and molecular studies have revealed two types of refractory coeliac disease 
Type I is characterized by the classic histology of coeliac disease and a normal 
phenotype of the intraepithelial lymphocytes. Type II is characterized by the classic 
morphology of coeliac disease and phenotypic T-cell abnormalities characterized by a 
shift from membranous expression towards an intracytoplasmic expression of CD3. 
Furthermore, there is a loss of several surface markers of the T-cells, such as CD8 
(picture 6) and CD5. A monoclonal expansion of T-cells can be detected by means of T-
cell receptor rearrangement. Morphologically, these cells are indistinguishable from 
normal lymphocytes, but a simple and reliable although not totally specific test can be 
done by measuring the ratio between CD3 and CD8; a ratio of  2:1 should indicate the 
need for more advanced and expensive testing, such as PCR35,36,37,38.  Sometimes a very 
high number of intraepithelial lymphocytes (picture 7), nesting of intraepithelial 
lymphocytes and solitary atypical cells localized intraepithelial or in the mucosa, 
highlighted by CD30-positive cells (picture 8), might be present. Probably these are the 
early signs of a developing T-cell lymphoma. 
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Figure 6:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:  
 
 
 
 
 
 
CD30 x 400, a single positive CD30-
positive cell in the mucosa 
CD3 x 100, large numbers of intra -
epithelial CD-3 positive lymphocytes 
CD8 x 100, almost total absence of CD8-
positive lymphocytes; some positive CD8 
H&E, x 200, large numbers of 
intraepithelial lymphocytes with focal 
presence of atypical variants (arrow) 
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EATL lymphoma 
 
CD is associated with an increased risk of non-Hodgkin lymphoma, especially T-cell 
lymphoma primarily localized in the gut (enteropathy associated T-cell lymphoma, 
EATL). However, the actual risk of developing lymphoma is limited, and the risk does 
not justify mass screening for CD40,41.  When a T-cell lymphoma of the digestive tract is 
encountered, villous atrophy in the non-tumorous small bowel mucosa is frequently 
found. EATL is a major complication in CD, but rare B-cell lymphoma is also described 
in patients with CD40-44,46. The symptoms of lymphoma are weight loss, which affects 
80% of the patients, associated with lethargy, abdominal pain and/or diarrhea. These 
symptoms are often mistaken for dietary indiscretions45,46. The prognosis is usually very 
poor and the condition is further aggravated by malnutrition. 
 
Pathological features 
 
Primary intestinal T-cell lymphoma have been extensively described and reported in 
Isaacson’s monograph on extranodal lymphomas47. They are now listed in the WHO 
classification under the name of enteropathy-type T-cell lymphoma (ETL)48. In this 
chapter, we use the name enteropathy-associated T-cell lymphoma (EATL). They are 
rare, accounting for less than 0.5% of primary gastro-intestinal lymphomas, contrary to 
primary gastrointestinal lymphoma, which account for 4%–12% of all non-Hodgkin 
lymphomas and are usually of B-cell origin. Most of these EATL lymphomas are 
located in the small intestine45,48. Initially thought to be of histiocytic cell origin, they 
were consequently named malignant histiocytosis of the intestine49; however, it is now 
recognized that the malignant cells are derived from T-cells and, more specifically, from 
intra-epithelial lymphocytes. Immunological and molecular studies have now confirmed 
the T-cell origin of the primary digestive lymphoma associated with CD50. 
Macroscopically, EATL is often multifocal with ulcerative lesions, which explains the 
high perforation rate at presentation or during chemotherapy. Enteropathy-associated T-
cell lymphomas are usually high- grade malignancies. They are pleomorphic with a 
mixture of large cells, some showing features of phagocytosis and eosinophilic 
leucocytes. 
Pathological examination specifically shows the tumor forming infiltration in the wall 
of the intestine with a diffuse T-cell tumour. A large (figure 12) and a small cell type 
(Figure 9) have been reported. More than 80% of the tumours are of the large 
‘anaplastic’ cell type.  
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Figure 9: Small cell type EATL 
Figure 10: CD8 
Figure 11: CD30 
Figure 12: Large cell type. EATL  
Figure 13: CD8 
Figure 14: CD30 
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Immunophenotype 
 
In EATL the tumour cells have a peculiar immunological phenotype (CD3 ±, CD7+, 
CD5-, CD4-, CD8-; figure 13). They generally express the antigen E7 recognized by 
the CD103 antibody (HML1 antibody), an integrin which binds to E-cadherin expressed 
by surface epithelial cells and which characterizes the intra-epithelial lymphocytes 
(IEL) population51,52. 
The tumor cells have a cytotoxic phenotype, as revealed by granzyme B and T-cell 
restricted intra-cellular antigen TIA-1, which are components of the cytotoxic 
granules53. These phenotypic studies suggested that T-cell lymphomas associated with 
CD originate from intra-epithelial T-lymphocytes. In a minority of cases, the neoplastic 
cells express a natural killer phenotype, such as CD5654,55 
Other phenotypes, such as CD4C and CD8C, have also been described56. 
In almost all cases, a varying proportion of the tumour cells express CD30 (figure 14). 
In the subset comprised of small to medium-sized cells, the tumour cells are usually 
CD8+ (figure 10), often CD30-negative (figure 11), and express CD56. 
 
Non-involved mucosa 
 
This lymphoma is called ‘enteropathy-associated T-cell lymphoma’ or ‘EATL’ because 
of its association with villous atrophy and hyperplasia of mucosal crypts in non-tumoral 
zones. The epithelium of atrophic but non-tumoral zones may, nevertheless, contain 
scattered larger tumour cells that can be highlighted with CD30-staining. The mucosa 
not involved by the tumor appears to show changes in subsets of intraepithelial 
lymphocytes, which mimic the markers expressed by the tumour cells. 
The intra-epithelial lymphocytes in the adjacent enteropathic mucosa may show an 
abnormal immunophenotype, usually CD3 cytoplasmic+, CD8-, or CD4- identical to 
that of the lymphoma57.  
 
 
Cytogenetic alterations 
 
Genetic alterations in EATL are largely unknown. A recent study of 38 cases of EATL 
analyzed by comparative genomic hybridization (CGH) revealed chromosomal 
imbalances in 80% of cases analyzed, with recurrent gains of genetic material involving 
chromosomes 9q, 7q, 5q and 1q. Recurrent losses of genetic material occurred on 
chromosomes 8p and 13q, and 9p47, 58. Chronic inflammation may have a role in the 
induction of chromosome abnormalities and the emergence of malignancies that 
preferentially affect the small intestine, the main site of inflammation59, 60. 
 
  
Ulcerative jejunitis 
 
Isolated ulcerative jejunitis as a complication of coeliac disease often has relatively non-
specific histological features. It may occur in several specific situations. So-called 
ulcerative jejunitis might be considered to be a neoplastic complication of CD: there is 
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immunopathological and molecular evidence that most, if not all, of such cases 
represent cryptic or early T-cell lymphomas complicating CD, although a tumor-
forming infiltration is often not found. 
The clinical picture is fairly well defined. Most patients are in their 6th or 7th decade 
and have a chronic history of abdominal pain and distension, fever, weight loss, 
diarrhea and often steatorrhea. The diagnosis should be considered only after exclusion 
of other well-known causes of small intestinal ulceration, such as Crohn’s disease, 
ischemic enteritis, polyarteritis, irradiation enteritis, lymphoma and drugs. In addition, 
rare infective processes should be ruled out. Jejunal biopsy, when performed, is mostly 
unhelpful or shows features consistent with CD. The majority of the patients undergo 
exploratory laparotomy for a full thickness small bowel biopsy to make a diagnosis. The 
European Working Group for CD in Amsterdam 2001 considered patients with 
ulcerative jejunitis to be type II refractory coeliacs since their histology is not yet 
compatible with small bowel lymphoma63. Future research should hopefully help us to 
decide if we have to treat ulcerative jejunitis like Refractory Coeliac Disease type II or 
like EATL. 
 
 
 Pathology 
 
In surgery, the small intestine may show one or more abnormal areas where the wall is 
thickened and edematous and where there may be strictures with proximal dilatations. 
Inspection of the mucosa reveals multiple ulcers, in general in the jejunum, but also 
common in the ileum and sometimes in the colon and stomach as well. The ulcer bed, 
made up of granulation tissue, is infiltrated with non-specific inflammatory cells i.e. 
lymphoid cells, histiocytes and acute inflammatory cells. Eosinophils may be 
prominent. The mucosa adjacent to the ulcer almost invariably shows villous atrophy 
and crypt hyperplasia similar to the lesions in CD. The mucosa in more distal areas may 
be normal. 
 
 
The relationship of ulcerative jejunitis to CD remains controversial. If some patients, 
clearly coeliacs, improve on a gluten-free diet, others do not respond to gluten 
withdrawal or they become resistant to a gluten-free diet and show monoclonality of 
lymphocytes on molecular biology. The prognosis of these patients is poor. 
 
A new interesting and controversial aspect of ulcerative jejunitis is its relationship to 
lymphoma. Some cases have clinical and pathological features of ulcerative jejuno-
ileitis in which the presence of T-cell lymphoma of the intestine was demonstrated by 
careful histological, immunophenotypical and molecular examination of the intestinal 
infiltrates, but classification as a cryptic or occult form of intestinal T-cell lymphoma 
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seems to be more appropriate. Other cases of patients with ulcerative jejunitis progress 
to develop EATL and, interestingly, multiple inflammatory mucosal ulcers frequently 
accompany EATL itself. 
The diagnosis is always difficult, and it needs to be confirmed by repeated and multiple 
biopsies. Ashton-Key et all65 showed TCR monoclonality in the non-specific 
‘inflammatory’ ulcers and intervening enteropathic mucosa in ulcerative jejunitis in the 
absence of overt lymphoma. In cases of ulcerative jejunitis, where lymphoma 
subsequently developed, the same clone could be detected in the malignant cells by 
PCR and sequence analysis35, 64-66. 
The presence of a similar increase in CD3c+, CD4-, CD8- IEL in the ‘uninvolved’ 
enteropathic mucosa in ulcerative jejunitis and EATL, which in both conditions harbors 
a monoclonal T-cell population, strongly suggests that the clonal population resides in 
the IEL compartment67.  Ulcerative jejunitis is now considered as a premalignant or 
malignant condition. 
 
Concluding remarks 
 
The biopsy of the small bowel remains the gold standard for the diagnosis of coeliac 
disease. Biopsy of the distal duodenum is sufficient for the diagnosis. Multiple biopsies 
are advisable because of the non-uniform presence of abnormalities. The uniform 
classification according to Marsh and its modifications is a major advance in the 
diagnosis. The recognition of epithelial lymphocytosis as the primary lesion is of capital 
importance, and an isolated significant intraepithelial lesion in an appropriate gastro-
duodenal endoscopy in which biopsies of the distal duodenum or jejunum and biopsies 
from the gastric antrum and corpus are taken should be giving a carefully follow-up. In 
10%-40% of cases this appears to be coeliac sprue.  Moreover, data such as clinical 
history, serology, and HLA DQ status and gluten dependence should be taken into 
account. Because intraepithelial lymphocytosis can be present in other conditions, such 
as gastritis, Crohn’s disease, infections, etc., histopathologists should have a clear 
threshold before they diagnose and report this as an abnormality.  Most mistakes are 
made when a biopsy is not well orientated and shows pseudo-atrophy in the absence of 
a significant intraepithelial lymphocytosis. Attempts in daily practice to better orientate 
small biopsies are not rewarding. Other mistakes are made when intraepithelial 
lymphocyte numbers are over-interpreted or are caused by other, unrecognized, reasons 
than coeliac sprue. The first step in a case in which there is doubt about the correct 
diagnosis should be re-reviewed of the biopsy material by an experienced 
gastrointestinal pathologist.  
The most intriguing patients are patients with clear histological abnormalities but with 
no clinical symptoms, the so-called silent coeliacs. This might be related to short 
segment coeliac disease, which could be detected with double balloon endoscopy.  
Further studies are needed to evaluate the risk of complications in this patient group. 
The normalization of histological abnormalities in adults after instigation of a gluten-
free diet can be slow and incomplete and can take months to years.  In most adults 
mucosa is not restored completely.  In children restoration is much faster and complete.  
This could be due to more manageable dietary factors or better capacities of recovery of 
mucosa in children.  The normal architecture of a villus is complex with blood and 
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lymph vessels and a backbone of muscle fibers.  A small subset of patients with coeliac 
disease does not react to a gluten-free diet or the patient’s condition detoriates after a 
period of an initial response to a GFD. There are a number of reasons and the first step 
should always to reevaluate the patient’s history and diagnosis. In a subset of patients 
there are circulating and tissue-based phenotypically and genotypically abnormal T-
lymphocytes.  These cells can be found by different techniques, and an initial simple 
test is to evaluate loss of T-cell surface markers by means of immunohistochemistry. 
When necessary, this could be expanded by flow cytometry and T-cell receptor 
rearrangement.  This situation is best described as cryptic or occult lymphoma.  One has 
to keep in mind, however, that a real or pseudo-clonal pattern can also be found in 
benign conditions.  Prognosis in this patient category is dismal and therefore potential 
treatment options must be aggressive. A high number of patients develop an aggressive 
form of T-cell lymphoma, which mostly has the same pheno- and genotypic 
abnormalities in the lymphoma cells. In the other cases serious complications such as 
ulcerative jejunitis and sepsis can develop. The pathogenesis of ulcerative jejunitis in 
coeliac disease is poorly understood, and in almost all cases abnormal circulating and 
tissue T-cells are found. 
Coeliac disease potentially harbors the risk of patients developing T-cell lymphoma, 
which can be present in the small bowel but can also be present in other parts of the 
bowel or extra-intestinally. However, the actual risk of lymphoma in classical coeliac 
patients is not high.  
 
 
Table I:(adapted from Daum et al 35): Causes other than refractory CD for persisting 
villous atrophy   
  
 
 
 
Mostly with elevated numbers of IEL Mostly with normal numbers of IEL 
Giardia Tuberculosis 
Tropical sprue AIDS 
Post infectious diarrhoea Immunodeficiency syndrome 
Collagenous sprue Whipple 
Crohn Radiation enteritis 
Protein intolerance Immunoproliferative small intestinal 
disease 
 Eosinophilic gastroenteritis 
 Autoimmune enteropathy 
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The general introduction in chapter I is followed by an outline of the thesis, and an 
overview of the diverse aspects of CD is given in the form of a review article in which 
these topics are highlighted.  
 
Chapter II contains the study in which we first presented the modified Marsh 
classification. In this study we investigated the efficiency of serological tests in 
diagnosing coeliac disease (CD) during the period of January 1, 1994 to January 7, 
1997. Our aim was to evaluate the sensitivity of IgA anti-endomysium (EMA) and IgA 
antigliadin (AGA) with regard to the degree of histological abnormality in biopsy 
specimens of the small intestine in untreated coeliac disease patients and first-degree 
relatives. The study population consisted of 101 cases: 85 untreated coeliac patients and 
16 first-degree relatives with a mean age of 42 yr (range, 2–76 yrs). Sixteen of the 85 
were excluded from the study because they did not satisfy the study or diagnostic 
criteria of CD. EMA and AGA were compared with the degree of villous atrophy (VA) 
in 69 coeliac patients and 16 relatives according to the Marsh criteria of 1992. We 
divided the Marsh III histology into three subgroups as follows: Marsh IIIa (partial 
villus atrophy), Marsh IIIb (subtotal villus atrophy), and Marsh IIIc (total villous 
atrophy).  The specificity and positive predictive value of EMA for CD was excellent, 
because all EMA-positive patients (n = 42) were diagnosed with CD. The sensitivity of 
EMA, however, differed between CD subgroups; in patients with total villus atrophy, 
the sensitivity of EMA was 100% (17/17). However, in patients with partial villus 
atrophy (Marsh IIIa), the sensitivity of EMA was disappointing: only 9/29 (31%). Three 
of 72 coeliacs with Marsh IIIb and Marsh IIIc had an IgA deficiency and were excluded 
from the study. Elevated AGA was detected in the sera of 39 of 69 (62%) patients. A 
combination of EMA and AGA tests showed a sensitivity of 76% (53/69). None of 16 
first-degree relatives with Marsh I-II had positive EMA. In conclusion, interpretation of 
negative serology needs to be done with great care. Although EMA-sensitivity in total 
villous atrophy is excellent, in partial villous atrophy the sensitivity of EMA is 
disappointing. Our experience shows that EMA and AGA have only limited value in 
screening programs for CD.
 
In chapter III patients with signs and symptoms of malabsorption, suggestive of gluten-
sensitive enteropathy, sometimes show in small intestinal biopsies only infiltration of 
lymphocytes into the mucosal epithelium without structural abnormalities such as 
hyperplasia and destruction of villi. This infiltrative lesion (Marsh I) is not a definite 
proof for gluten-sensitive enteropathy. However, in the study in this chapter, we aimed 
to show that a subgroup of these patients could ultimately be identified as being gluten-
sensitive. A total of 38 patients with a Marsh I lesion were subjected to a gluten 
challenge comprising 30 g of gluten added daily to a normal gluten-containing diet for 8 
wk. Before and after the challenge, small intestinal biopsies were taken, and symptoms 
and signs of malabsorption were scored. In 12 patients we demonstrated a significant 
change in mucosal histopathology, i.e., subtotal villous atrophy (Marsh IIIB, n = 1), 
partial villous atrophy (Marsh 3A, n = 6) or lymphocytic enteritis with crypthyperplasia 
(Marsh II, n = 5). In the other 26 patients, the small intestinal mucosa remained 
unchanged. After initiation of a gluten-free diet, follow-up small intestinal biopsies in 
12 patients who initially had progressive mucosal pathology after gluten challenge 
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showed normalization of mucosal pathology in seven cases, regression to a Marsh I 
lesion in four, and regression to a Marsh II lesion in one. Symptom relief was seen in all 
12 patients. Ten of 26 patients without histological response to the gluten challenge 
were motivated to adhere to a gluten-free diet. Follow-up biopsies revealed unchanged 
Marsh I lesions in eight patients and normalization (Marsh 0) in two patients. Three 
patients had follow-up biopsies while on a normal diet. All had unchanged Marsh I 
lesions. In the present study we demonstrated that a gluten challenge might be useful in 
identifying patients as being sensitive to gluten if initial small intestinal biopsies reveal 
only minor abnormalities. 
 
In chapter IV the localisation of the biopsy is discussed.  For the diagnosis and follow-
up of coeliac disease, pediatric societies advise that intestinal mucosal specimens should 
be obtained using a suction capsule from the jejunum. This procedure is strenuous for 
patients, time-consuming and expensive, and it requires radiographic guidance. Mucosal 
biopsies from the distal duodenum can be obtained more easily under endoscopic vision 
using forceps. The aim of the study presented in this chapter was to compare the 
histological outcome of biopsies taken from the duodenal mucosa by forceps and from 
the jejunal mucosa using a suction capsule. . For this study, 171 paired biopsies were 
taken from 109 patients (1-75 years) from the distal duodenal mucosa using jumbo 
forceps and from the jejunal mucosa using a Crosby suction capsule. Histological 
interpretation was performed according to a modified Marsh classification, including 
partial-, subtotal and total villous atrophy as Marsh IIIA, B, and C.  Fourteen suction 
capsule biopsies were of insufficient quality to be interpreted (8%). All duodenal 
forceps biopsies produced adequate material for histological scoring. No differences in 
histological scoring were seen in 145 of the 157 compared biopsies (92%). Of 12 
biopsies in which a discrepancy was present, 4 showed more severe lesions in the 
duodenum and 8 more severe lesions in the jejunum. The differences were of clinical 
significance, i.e., including the presence and absence of villous atrophy in 9 of 157 
paired biopsies (6%). In conclusion we demonstrated that mucosal specimens taken 
from the distal duodenal and jejunal mucosa are strongly correlated. Clinically 
significant discrepancies were present in only 6% of the paired biopsies. Therefore, we 
suggest that, in the diagnosis and follow-up of coeliac disease, mucosal specimens may 
be taken from the duodenum using forceps to obtain adequate material for histological 
interpretation.  
 
In chapter V histologic recovery was assessed in response to gluten withdrawal in 
coeliac disease. One hundred and fifty-eight patients seen in our hospital during a 15-
year period underwent follow-up small intestine biopsies within 2 years after starting a 
gluten-free diet; further small intestine biopsies were done if villous atrophy was 
present. A modified Marsh classification was used (IIIA, partial villous atrophy; IIIB, 
subtotal villous atrophy; IIIC, total villous atrophy). Of patients with Marsh IIIA, IIIB, 
or IIIC lesions, histologic remission was seen in 65.0% within 2 years, 85.3% within 5 
years, and 89.9% in long-term follow-up. Eleven patients (7.0%) with persisting 
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(partial) villous atrophy had symptoms and signs of malabsorption and were considered 
to have refractory coeliac disease; 5 of them developed an enteropathy associated T-cell 
lymphoma. Up to 95% of the children recovered within 2 years and 100% in the long-
term. Histologic recovery in coeliac disease after starting a gluten-free diet takes time 
and is incomplete or absent in a substantial subgroup of patients (10.1% villous atrophy 
after 5 years). A systematic follow-up of patients with coeliac disease is needed, 
together with an examination of the malabsorption syndrome and secondary 
complications.  
 
Chapter VI presents a study in which the reliability of the gold standard of diagnosis in 
coeliac disease, the small intestine biopsy, is tested.  In a review of 494 biopsies from 
all over the Netherlands performed in a period from 1985 until 2003, 11 % of the 
biopsies were discordant as compared to the panel diagnosis. More than 6 % were false 
positive because of overestimating atrophy in the absence of a significant intraepithelial 
lymphocytosis.  We state that this is the primary lesion that should be present and that 
other disease could give rise to look-alikes, such as peptic influences, infections such as 
Helicobacter pylori and Giardia, or Crohn’s disease and autoimmune abnormalities. In 5 
% false negative interpretations were given mainly because of underestimating the 
intraepithelial lymphocytosis, sometimes combined with underestimating atrophy. 
 The interpretation as intraepithelial lymphocytosis as the hallmark lesion in coeliac 
disease and the realization that not all intraepithelial lymphocytosis is CD are important.  
In this respect it is important to biopsy from the distal duodenum as well as from the 
stomach in the primary histologic setting of patients suspected of having coeliac 
disease. Of course the diagnosis of coeliac disease should be supported by adequate 
clinical and serological information before a patient is put on lifelong intensive therapy. 
 
Chapter VII presents a discussion of the reliability and the value of 
immunohistochemistry (IH), flow cytometry (FCM) and PCR in the detection of 
phenotypically and genotypically abnormal T-cells in coeliac disease. Refractory 
coeliac disease can be subdivided into subtypes I and II. In type II phenotypically 
abnormal cells are present. The data of IH, FCM and PCR in a group of refractory 
coeliac disease are compared to normal controls, uncomplicated CD and de novo CD-
related T-cell lymphoma. Outcomes in patient groups are measured. 
Results: In 27 cases of refractory disease the data of immunohistology and FCM in 25 
cases compare well. In only 2 is there a discrepancy between FCM and IH. In the group 
of patients (n=14) with phenotypically abnormal lymphocytes the prognosis was far 
worse than in the group without such cells. Four patients died of a lymphoma, one also 
had an ulcerative jejunitis, one died of ulcerative jejunitis, and two of ulcerative jejunitis 
and sepsis and one died of sepsis. In the group of patients tested for clonal versus non-
clonal TCR rearrangements in their biopsies, two patients in the group with clonal 
rearrangement died of EATL, one of ulcerative jejunitis, two of sepsis and ulcerative 
jejunitis and two of sepsis. In the group of patients with the polyclonal rearrangements, 
two died of EATL, and one of these patients also had an ulcerative jejunitis. In both 
patients phenotypically abnormal T-cells were found with IH and FCM. 
Conclusion: Both IH and FCM are capable of detecting relevant phenotypically 
abnormal T-cells in the biopsies of RCD patients. IH is a technique that is easy to use 
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and that could be performed in most routine pathology departments. 
The T-cell receptor rearrangement could be an extra adjunct to both techniques but, 
since clonal rearrangement is also seen in normal persons and in classic CD, it is 
therefore less specific. 
 
Chapter VIII: Intestinal lymphomas encompass those lymphomas that are found 
predominantly or only in the intestinal tract. Coeliac disease is highly associated with 
enteropathy-associated T-cell lymphomas (EATL). Coeliac disease-related lymphomas 
can appear at nodal or extranodal sites. EATL is often multi-focal with ulcerative 
lesions, which explains the high perforation rate at presentation or during 
chemotherapy. 
Staging includes an ear-nose-throat examination, and a CT-scan of chest and abdomen; 
PET-scanning may be valuable. An accurate diagnosis based on endoscopic biopsies is 
preferable; if necessary full thickness laparoscopic small-bowel biopsies are mandatory. 
There is a very high risk of EATL developing in refractory coeliac disease (RCD) with 
aberrant T-cells. Because no satisfactory treatment for EATL exists, the only possibility 
seems to try to prevent EATL development in RCD. In this situation autologous bone 
marrow transplantation might be a possibility. EATL can be present in 20% as extra-
small bowel T-cell lymphomas, such as subcutaneous panniculitis-like lymphoma, 
hepatosplenic / lymphoma, nodal and as sinus, gastric or colon lymphomas. The 
majority presents as large-cell lymphoma CD3+, CD8-, CD30+; however, they also 
present as small-cell lymphoma CD3+, CD8+, CD30-. Sometimes we recognize / 
lymphomas in CD. Diagnostic evaluation of EATL must include immunohistology and 
adequate imaging with CT and PET-scanning. When necessary T-cell flow cytometry, 
T-cell rearrangement also can be of use. 
 
Chapter IX: Patients with coeliac disease (CD), particularly those who are undiagnosed 
or do not adhere to a strict gluten-free diet (GFD), are prone to develop complications 
such as osteoporosis, infertility, autoimmune disease etc. Malignant complications are 
the most serious and should be suspected when expected responses to GFD are not 
achieved or sustained. Lymphomas, mostly T-cell type, and other malignant tumours, 
particularly carcinoma of the small bowel, less frequently of stomach and oesophagus, 
are associated with CD. Loss of response to a gluten-free diet (refractory coeliac 
disease) and ulcerative jejunitis are two recently described complications of CD that 
may progress to an enteropathy-associated T-cell lymphoma (EATL). Coeliac disease-
related lymphoma most often appears at extra-nodal sites, essentially the small bowel, 
although one has to realize that T-cell lymphomas arising in sites outside the small 
bowel could be related to coeliac disease. Diagnostic evaluation of an EATL must 
include immunohistology and, if necessary, T-cell flow cytometry and T-cell 
rearrangement.  Adequate imaging with CT and PET-scanning is mandatory.  
 
In Chapter X an overview of the histological aspects of coeliac disease is given. 
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In hoofdstuk I wordt er een algemene inleiding gegeven gevolgd door een overzicht van 
de inhoud van dit proefschrift en een overzicht van de diverse aspecten van  CD in de 
vorm van een review artikel. 
 
In hoofdstuk II wordt het artikel gepresenteerd waar er voor de eerste keer melding 
wordt gemaakt van de gemodificeerde Marsh classificatie.  In deze publicatie wordt de 
efficiëntie van serologische testen beschreven bij CD gedurende de periode van 1 
januari 1994 tot  7 januari 1997. Ons doel was om de sensitiviteit te evalueren van IgA 
anti-endomysium (EMA) en IgA antigliadine (AGA) in relatie tot de histologische 
afwijkingen in biopten van de dunne darm in onbehandelde coeliakie patiënten en in 
eerste graad familieleden. De studie populatie bestond uit 101 gevallen: 85 
onbehandelde coeliakie patiënten en 16 eerste graads familieleden met een gemiddelde 
leeftijd van 42 jaar (spreiding: 2-76 jaar). Zestien van de 85  werden niet  meegenomen 
in deze studie aangezien zij niet voldeden  aan de studie of coeliakie criteria. Anti 
endomysium en anti-gliadine antilichamen (EMA en AGA) werden vergeleken met de 
graad van vlokatrofie ingedeeld volgens gemodificeerde Marsh criteria bij 69 patiënten 
en 16 familieleden. We deelde de Marsh III histologie in in 3 subgroepen te weten: 
Marsh IIIA: ( partiele vlokatrofie ), Marsh IIIB ( subtotale vlokatrofie ) en Marsh IIIc 
(totale vlokatrofie ). De specificiteit  en de positieve predictieve waarde van EMA voor 
coeliakie was voortreffelijk, want alle EMA positieve patiënten (n+42)  hadden 
coeliakie. De sensitiviteit van EMA was echter verschillend in de coeliakie subgroepen: 
bij patiënten  met totale vlokatrofie was de gevoeligheid van EMA 100% (17/17) .  
Echter in patiënten met partiele vlokatrofie ( Marsh IIIa) zakte de sensitiviteit  
aanzienlijk  en was positief in maar 9 van de 29 patiënten  (31%). Drie van de 72 
coeliakie patiënten  met Marsh IIIb en IIIc hadden IgA deficiëntie en werden van de 
studie uitgesloten. 
Verhoogde spiegels AGA werden ontdekt in de sera van 39 van de 69 patiënten die 
hiervoor zijn getest.  Een combinatie van EMA en AGA testen lieten een sensitiviteit  
zien van 76% ( 53/69). Geen van de eerste graads familieleden met een Marsh I-II laesie 
hadden positieve EMA. Concluderend  kunnen we stellen dat interpretatie van negatieve 
serologie met enige omzichtigheid moet gebeuren  bij deze patiënten categorie. Hoewel 
de sensitiviteit van EMA in de totale vlokatrofie groep uitstekend scoorde, was deze 
sensitiviteit bij partiële vlokatrofie teleurstellend. Onze ervaring laat zien dat de waarde 
van EMA en AGA bij screeningsprogramma’s van gelimiteerde waarde zullen zijn.
 
In hoofdstuk III wordt een groep patiënten beschreven met tekenen en klachten van 
malabsorptie, suggestief voor gluten sensitieve enteropathie maar bij wie in biopten uit 
de dunne darm enkel infiltratie aanwezig was van lymfocyten in de epitheellaag van de 
mucosa. Dit zonder structurele afwijkingen zoals hyperplasie of beschadiging van de 
villi. Deze infiltratieve afwijkingen (Marsh I) worden nog niet beschouwd als definitief 
bewijs voor gluten sensitieve enteropathie. In dit hoofdstuk beogen we aan te tonen dat 
een subgroep van deze patiënten uiteindelijk geïdentificeerd kan worden als hebbende 
gluten sensitiviteit enteropathie. Achtendertig patiënten met een Marsh I afwijking 
werden blootgesteld aan glutenbelasting welke bestond uit 30 gr. gluten toegevoegd aan 
het normale dagelijkse gluten bevattende dieet gedurende 8 weken. Voor en na de 
belasting werden er dunne darmbiopten genomen en werden tekenen en symptomen van 
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malabsorptie gescoord. Bij 12 patienten toonden de biopten significante veranderingen 
in de histopathologie van de mucosa, in concreto progressie naar (sub)totale villeuze 
atrofie (Marsh III B, n = 1), partiële villeuze atrofie (Marsh IIIa, n = 6) of lymfocytaire 
enteritis met crypthyperplasie (Marsh II, n = 5). In de overige 26 patiënten, bleven de 
dunne darmbiopten onveranderd. 
Na start van een glutenvrij dieet, lieten de follow-up dunne darmbiopten een 
normalisering zien bij 7 van de 12 patiënten die initieel een progressieve mucosale 
afwijking lieten zien. In vier van de 12 patiënten was er regressie naar Marsh I en in 1 
patiënt was er progressie naar Marsh II. Vermindering van klachten werd gezien bij alle 
12 patiënten. Tien van de 26 patienten zonder histologische progressieve reactie op 
glutenbelasting konden gemotiveerd worden om een glutenvrij dieet te volgen. Follow-
up biopten lieten zien onveranderde Marsh I in 8 patiënten en normalisatie tot Marsh 0 
in 2 patiënten. Drie patiënten hadden folluw-up biopten onder normaal dieet. Alle 
hadden onveranderd Marsh I laesies in de follow-up biopten. 
 
In hoofdstuk IV wordt de juiste plaats van de biopsie bediscussieerd. Voor de diagnose 
en follow-up van coeliakie adviseert het genootschap van kindergeneeskunde dat 
intestinale biopten genomen dienen te worden van het jejunum met behulp van een 
zuigcapsule. Deze procedure is belastend voor patiënten, kost veel tijd, is duur en 
behoeft radiografische begeleiding. 
Mucosabiopten van het distale duodenum kunnen veel gemakkelijker worden verkregen 
door middel van forceps onder endoscopische begeleiding. Het doel van deze studie, 
gepresenteerd in dit hoofdstuk, is om biopten te vergelijken met betrekking tot 
histologie, die zijn genomen van het distale duodenum met behulp van forceps biopteur 
en die genomen zijn van jejunum door middel van een zuigcapsule. 
In deze studie werden er 171 gepaarde biopten genomen bij 109 patiënten 
(leeftijdsrange 1 - 75 jaar) van het distale duodenum gebruik makende van een jumbo 
forceps biopteur en van het jejunum gebruik maken van een Crosby zuigcapsule. De 
histologische interpretatie werd verricht volgens de gemodificeerde Marsh classificatie 
ingedeeld in Marsh I, lymfocytaire enteritis, Marsh II, lymfocytaire enteritis met 
crypthyperplasie en Marsh III, partiële, subtotale en totale vlokatrofie als Marsh III A, B 
en C. Van de biopten verkregen door middel van zuigcapsule waren er 14 niet geschikt 
om te worden beoordeeld (8%). Alle duodenum forceps biopten leverden adequaat 
materiaal voor een histologische beoordeling. Geen verschillen in histologische score 
werd gezien in 145 van de 157 gepaarde biopten (92%). Van twaalf biopten, waar er een 
discrepantie aanwezig was lieten er vier meer ernstige afwijkingen zien in het 
duodenumbiopt en 8 meer ernstige afwijkingen in het jejunumbiopt. De verschillen 
waren klinisch significant, in concreto lieten aan of afwezigheid zien van vlokatrofie, in 
9 van de 157 gepaarde biopten (6%). Concluderend hebben we aangetoond dat mucosa 
biopten die genomen zijn van het distale duodenum en jejunum sterk correleren. 
Significante verschillen waren aanwezig in slechts 6% van gepaarde biopten uit de 
dunne darm. Dit geeft aan dat mucosa biopten genomen van het duodenum 
gebruikmakend van forceps biopten adequaat materiaal levert voor de histologische 
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interpretatie van dunne darm biopten in het kader van de diagnose en follow-up van 
coeliakie 
 
In hoofdstuk V werd histologisch herstel onderzocht in respons op glutenvrij dieet 
ingesteld bij patiënten met coeliakie. Honderdachtenvijftig patiënten, gezien in ons 
ziekenhuis gedurende een periode van 15 jaar, ondergingen follow-up dunne 
darmbiopten binnen twee jaar na de start van een glutenvrij dieet; vervolg dunne darm 
biopten werd gedaan als vlokatrofie aanwezig was. De gemodificeerde Marsh 
classificatie werd gebruikt (I: lymfocytaire enteritis, II: lymfocytaire enteritis met 
crypthyperplasie, III A: partiële vlokatrofie; III B: subtotale vlokatrofie; III C: totale 
vlokatrofie). Van de patiënten met Marsh III A, III B of III C laesies werd histologische 
remissie gezien in 65% na twee jaar, 85,3% na 5 jaar en 89,9% na nog langduriger 
follow-up. 
Elf patiënten  (7%) met persisterende (partiële) vlokatrofie hadden symptomen en 
klachten van malabsorptie en werden beschouwd als hebbende refractaire coeliakie. Vijf 
van hen ontwikkelden een  enteropathie geassocieerd T cel lymfoom.  
Kinderen herstelden in 95% binnen 2 jaar en in 100% bij langere follow-up.  
Histologisch herstel van coeliakie na starten van een glutenvrij dieet neemt vooral bij 
volwassenen tijd in beslag en is vaak incompleet of afwezig bij een subgroep van 
patiënten (10,1% vlokatrofie na 5 jaar). Systematische follow-up van patiënten met 
coeliakie en het malabsorptie syndroom en hun secundaire complicaties is nodig. 
 
In hoofdstuk VI word een studie gepresenteerd waarin de betrouwbaarheid van de 
gouden standaard bij de diagnose van coeliakie, de dunne darm biopsie, wordt getest. In 
een review van 494 biopten afkomstig van alle regio's van Nederland, verricht in een 
periode van 1985 tot 2003, waren 11% van de oorspronkelijke diagnoses van biopten 
discordant vergeleken met een panel diagnose. Meer dan 6% van de biopten lieten een 
vals positieve test uitslag zien tengevolge van overwaardering van atrofie in  
afwezigheid van significante intra-epitheliale lymfocytose. Intra-epitheliale lymfocytose 
is de primaire laesie die voor de diagnose coeliakie aanwezig behoort te zijn. Echter ook 
andere ziekten zoals peptische reactie, infecties zoals Helicobacter pylori en Giardia, 
auto-immuunziekten en Crohn kunnen intra-epitheliale lymfocytose veroorzaken. In 5% 
werd er een fout negatieve diagnose gegeven voornamelijk door onderwaardering van 
bestaande intra-epitheliale lymfocytose, soms gecombineerd met onderwaardering van 
de bestaande atrofie. De interpretatie van intra-epitheliale lymfocytose als de 
belangrijkste afwijking bij coeliakie en het besef dat niet alle biopten met intra-
epitheliale lymfocytose duiden op coeliakie is belangrijk. Dit zou aanleiding moeten 
zijn om in de initiële endoscopie bij patiënten waarbij men verdenking heeft op 
coeliakie zowel te biopteren van het distale duodenum als ook gelijktijdig van de maag.  
De diagnose coeliakie moet vanzelfsprekend wordt gesteund worden door adequate 
klinische en serologische informatie voordat de patiënt op levenslang glutenvrij dieet 
voortgezet. 
 
In hoofdstuk VII wordt de betrouwbaarheid en de waarde van immuunhistochemie, 
flowcytometrie en PCR bij het detecteren van fenotypische en genotypische abnormale 
T-cellen bij (refractaire) coeliakie bediscussieerd. Refractaire coeliakie kan worden 
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onderverdeeld in subtype I en II. In type II zijn fenotypische abnormale cellen 
aanwezig. De gegevens van immuunhistochemie, flowcytometrie en PCR in een groep 
van patiënten met refractaire coeliakie werden vergeleken met normale controle 
patiënten, ongecompliceerde coeliakie en patiënten met de novo coeliakie gerelateerde 
T-cel lymfomen. Het beloop in deze patiëntgroepen werd vervolgd. In 27 gevallen van 
refractaire ziekte zijn de data van imuunhistologie en flowcytometrie goed 
vergelijkbaar. In twee patiënten  was er discrepantie aanwezig tussen flowcytometrie en 
immuunhistochemie. In de groep van patiënten (n = 14) met fenotypische abnormale 
lymfocyten was de prognose veel slechter dan in de groep zonder zulke abnormale 
cellen. Vier patiënten stierven aan een lymfoom, een patiënt had tevens een ulceratieve 
jejunitis, een patiënt stierf aan ulceratieve jejunitis en  twee patiënten met ulceratieve 
jejunitis en sepsis stierven aan sepsis. 
 
In de groep van patiënten die getest werden op clonale versus non clonale TCR 
rearrangement van de lymfocyten in hun biopten waren er in de groep van patiënten met 
clonale  rearrangement 2 die stierven aan een EATL, een met ulceratieve jejunitis, twee 
met sepsis en ulceratieve jejunitis en twee met sepsis. In de groep van patiënten met 
polyklonale rearrangement stierven er twee aan EATL, een van deze patiënten had ook 
een ulceratieve jejunitis. In beide patiënten die fenotypisch abnormale T-cellen hadden 
zijn deze aangetoond met zowel immuunhistochemie als flowcytometrie. 
Zowel met behulp van immuunhistochemie als flowcytometrie zijn relevante 
fenotypisch abnormale T-cellen te detecteren. Immuunhistochemie is gemakkelijk in 
gebruik in de meeste routine laboratoria. Het bepalen van T-cel rearrangement kan een 
toevoeging zijn maar men dient zich te realiseren dat ook bij normale personen  alsook 
bij klassieke coeliakie T-cel rearrangement aanwezig kan zijn. 
 
In hoofdstuk VIII wordt een beschrijving gegeven van intestinale lymfomen. Het betreft 
die lymfomen die een dominante of solitaire lokalisatie in de tractus intestinalis hebben. 
Coeliakie is sterk geassocieerd met enteropathie geassocieerd T-cellymfoom (EATL). 
Coeliakie gerelateerde lymfomen kunnen optreden nodaal dan wel extranodaal. EATL 
is vaak multifocaal met ulceratieve afwijkingen, deze verklaren de hoge ratio van 
perforatie bij presentatie of gedurende chemotherapie. Stadiëring is niet compleet 
zonder onderzoek van het KNO-gebied, CT-scan van thorax en buik. Petscan kan van 
waarde zijn. Accurate diagnose gebaseerd op endoscopische biopten verdient de 
voorkeur, zonodig in de vorm van  zogenaamde volle dikte laparoscopische dunne darm 
biopten. Refractaire coeliakie (RCD) met abnormale B-cellen heeft een hoog risico op 
het ontwikkelen van EATL. Er is geen tot goed resultaat leidende behandeling voor 
EATL. Het voorkomen van EATL ontwikkeling uit RCD lijkt de enige mogelijkheid. 
Hierbij kan autologe beenmergtransplantatie van waarde zijn. EATL presenteert zich in 
20% van de gevallen als een extraintestinaal T-cellymfoom zoals een subcutaan 
panniculitis like lymfoom, hepatosplenisch gamma / delta T cel lymfoom, nodale, 
voorhoofdsholte, maag of colon lymfoom. In meerderheid presenteert het zich als een 
grootcellig lymfoom welke  een  CD3 +, CD8 -, CD 30 + fenotype laat zien; ze kunnen 
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zich ook presenteren als een kleincellig lymfoom met een CD3 +, CD 8 +; CD 30 - 
fenotype. Soms worden er ook gamma/delta positieve lymfomen ontdekt. 
In de diagnostiek van EATL moeten we T-cel Flowcytometrie, T-cel rearrangement en 
adequate beeldvormende diagnostiek met CT en PET gebruiken om tot een betrouwbare 
diagnose en vaststelling van de uitbreiding te komen. 
 
 
In hoofdstuk  IX wordt er een overzicht gegeven van de maligne complicaties van 
Coeliakie. Patiënten met coeliakie, speciaal die zijn onder gediagnostiseerd of die zich 
niet houden aan een strikt glutenvrij dieet hebben meer kans op het ontwikkelen van een 
van de vele complicaties van coeliakie gerelateerde afwijkingen zoals osteoporose, 
infertiliteit, auto-immuunziekte etc. Een toegenomen overall mortaliteit aan 
kwaadaardige ziekten is gerapporteerd bij volwassenen gediagnostiseerd met coeliakie 
en familieleden, wat duidt op het klinische belang van deze ziekte: preventie is beter 
dan genezing en het is belangrijk dat patiënten gediagnostiseerd worden voordat 
complicaties optreden omdat glutenvrij dieet risico's kan voorkomen of reduceren. 
Maligne complicaties zijn de meest ernstige en hierop moet men bedacht zijn wanneer 
verwachte respons op glutenvrij dieet niet wordt bereikt of gehandhaafd. Maligne 
lymfomen meestal van het T-celtype en andere maligne tumoren, met name carcinomen 
van de dunne darm, minder frequent van de maag en de slokdarm zijn geassocieerd met 
coeliakie. Het niet meer reageren op glutenvrij dieet (refractaire reactie) en ulceratieve 
jejunitis zijn twee recent beschreven complicaties van coeliakie die zich verder kunnen 
ontwikkeling tot enteropathie geassocieerd T-cellymfomen (EATL). Coeliakie 
gerelateerde lymfomen komen meestal voor op extranodale plaatsen, speciaal in de 
dunne darm, hoewel men zich moet realiseren dat coeliakie gerelateerde T-cel 
lymfomen ook buiten de dunne darm kunnen ontstaan. In het diagnostische traject van 
een EATL behoort immuunhistochemie en zonodig T-cel flowcytometrie en T-cel 
rearrangement. Adequate beeldvorming met CT en PET scanning is nodig 
 
 
In hoofdstuk X wordt nog eens een overview van histologische aspekten van coeliakie 
gegeven. 
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De meer dan voortreffelijke band met de vakgroep MDL van het Rijnstate ziekenhuis 
heeft mij de gelegenheid geboden om niet enkel op diagnostisch maar ook op 
onderzoeksgebied met hen samen te werken.  Jan, Nives, Bert, Richard,  Siebrand en in 
het bijzonder Peter ben ik veel dank verschuldigd  bij het verkrijgen en bediscussiëren 
van  de vele casus op MDL gebied. 
In het bijzonder was destijds Chris Mulder, als lid van de MDL artsen in Rijnstate 
ziekenhuis, nadrukkelijk aanwezig om mij de weg te wijzen in deze materie.  
Beste Chris, je bent een bijzonder mens.  Jouw directe drive om zaken te starten en ze 
ook hoe dan ook af te maken  heeft oa aanleiding gegeven tot vele artikelen en 
promoties waarbij ik vaak als patholoog betrokken was. Aangezien de doctorstitel voor 
mij geen doel op zich is kan ik toch rustig stellen dat jouw “zachte “ aandrang om een 
en ander af te ronden van doorslaggevende betekenis is geweest.  
Dat je naast je werk als MDL arts/hoogleraar ook nog tijd vindt om binnen en buiten het 
vak de minder goeddbedeelden onder ons met onderwijs en allerlei andere 
ondersteunende activiteiten te helpen is des te meer  opmerkelijk. 
 
Beste Han, je was wat meer op de achtergrond aanwezig maar was toch belangrijk voor 
het afronden van de laatste eigen artikelen in dit proefschrift. 
Als goede buur maar nog meer vanwege je visie op de ontwikkelingen in het vakgebied 
pathologie en je onderwijskundige kwaliteiten waardeer ik je hoog.  Je inzichten in de 
relatie en positionering van ons vakgebied zouden breder geïmplementeerd moeten 
worden. 
 
Patricia de discussie met de toepassing en betekenis van de moleculaire technieken was 
onontbeerlijk.  
 
Mijn bestuurlijke ambities hebben me de kans gegeven om in het stafbestuur van het 
Rijnstate ziekenhuis en ook in het bestuur  van de Nederlandse Vereninging voor 
Pathologie fijne contacten op te doen waarvoor mijn dank. 
 
Het werken in een flexibele maatschap waarin naast het streven het leveren van een 
hoge kwaliteit op een efficiënte manier ook ruimte wordt geboden voor 
nevenactiviteiten zoals bijvoorbeeld het afronden van dit proefschrift en het vervullen 
van bestuurlijke taken  is een genot.  Rob, Dries, Fred, Anne, Rob en sinds kort Emiel  
bedankt voor het feit dat jullie de ruimte scheppen  voor de extra taken die naar mijn 
mening ook ter meerdere eer en glorie strekken van de hele groep. Ook een woord van 
dank aan Susan Parren die in recordtempo het manuscript omzette in de juiste engelse 
taal. 
Ga nu maar weer beter op jullie coupes letten voordat ik er mee van door ben. 
 
Een goed laboratorium is de basis voor het plezier in mijn werk en de geeft 
mogelijkheden om een en ander te ontwikkelen  De afdelingen Cytologie, Histologie, 
Immunologie, Morfometrie en Administratie hebben  veel werk verzet voor het 
vervaardigen van de preparaten, opvragen van de casus en ook diverse correctieve 
activiteiten wanneer “het genie” de chaos weer even niet beheerste. 
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Alle inzendende laboratoria van Nederland  dank ik voor het genereus laten inzien van 
de preparaten en het geduld dat men opbracht wanneer deze weer eens iets te laat 
terugkeerde. 
 
Dit alles was niet mogelijk geweest als het thuisfront niet de ruimte gaf die nodig is om 
in de drukke werkzaamheden ook dit project af te ronden. 
 
Beste Nanneke, Maartje,  Kim en Frank jullie zijn mijn kinderen waar ik trots op ben.  
 
Lieve Marion  voor jouw steun en ruimte die je me gaf bij het ontwikkelen van mijn 
carrière  en de constante factor die je voor mij altijd bent geweest schieten woorden 
tekort.  
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De schrijver van dit proefschrift werd geboren op 09 november 1954 in het Bladel in de 
Brabantse Kempen. Na in Eersel de HBS-B afgerond te hebben werd door de bestaande 
numerus fixus begonnen met de studie geneeskunde in Leuven België. Aan de 
katholieke universiteit te Nijmegen werd deze studie voortgezet en in 1979 afgerond. 
Daarna is er 1 jaar gewerkt als agnio op de afdeling nucleaire geneeskunde van de KU 
te Nijmegen.  In 1980 werd begonnen met de opleiding tot patholoog aan de universiteit 
van Nijmegen onder leiding van Prof. Dr. G.P. Vooys. Op 1 februari 1985 is hij 
ingeschreven in het specialisten registratie commissie. 
 
Vanaf 1985 tot 1989 is hij werkzaam geweest als klinisch patholoog op het Canisius 
Wilhelmina Ziekenhuis te Nijmegen. 
 
Vanaf 1989 tot heden is hij werkzaam op de afdeling Pathologie van regio 
Ede/Arnhem/Doetinchem waaronder ressorteren de ziekenhuizen Alysis Arnhem/Velp, 
Gelderse Vallei te Ede, Slingeland ziekenhuis Doetinchem en Streekziekenhuis en 
verpleeghuis Zevenaar. 
 
Bijzondere belangstelling is er naast maag, darm en lever pathologie ook voor nier en 
haematopathologie 
 
Tezamen met de zeer actieve MDL groep van de Alysis zorggroep onder de bezielende 
leiding van Dr. Chris Mulder is hij al sinds 1990 intensief betrokken bij het onderzoek 
naar coeliakie en wordt ook landelijk met oa onderzoeksgroepen uit Amsterdam, Leiden 
en Utrecht vruchtbaar samengewerkt. 
 
Dit heeft aanleiding gegeven tot een aantal promoties en het was niet meer dan logisch 
dat het vele werk hierbij verricht ook tot deze thesis zou leiden. 
 
Hij is getrouwd met Marion Meijer en heeft vier kinderen, Nanneke, Maartje, Kim en 
Frank.
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Figures Chapter VI: 
 
Figure I: Gastric metaplasia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H&E, x100: Overview: Atrophic duodenal mucosa   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H&E, x200: increased number of intraepithelial lymphocytes and underlying gastric 
glands 
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Figure II: Giardia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H&E; x200; Duodenitis with increased number of intraepithelial lymphocytes, Giardia 
lamblia parasites (arrow) 
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Figures Chapter X 
Figure1: Marsh I  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Marsh II 
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Figure 3: Marsh IIIA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Marsh IIIB 
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Figure 5: Marsh IIIC 
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Picture 6:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 7:  
 
 
 
 
 
 
 
 
 
Picture 8:  
 
 
 
 
 
 
 
CD30 x 400, a single positive CD30-
positive cell in the mucosa 
CD3 x 100, large numbers of intra -
epithelial CD-3 positive lymphocytes 
CD8 x 100, almost total absence of CD8-
positive lymphocytes; some positive CD8 
H&E, x 200, large numbers of 
intraepithelial lymphocytes with focal 
presence of atypical variants (arrow) 
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Figure 9: Small cell type EATL 
Figure 10: CD8 
Figure 11: CD30 
Figure 12 : Large cell type. EATL  
Figure 13: CD8 
Figure 14: CD30 
